Molecular and immunophenotypic features of chronic myeloid leukemia in an era of evolving therapeutic strategies by Janssen, J.J.W.M.
 Jps omslag buiten DEF  19-10-2009  12:29  Pagina 1
MOLECULAR AND IMMUNOPHENOTYPIC 
FEATURES OF CHRONIC MYELOID LEUKEMIA 
IN AN ERA OF EVOLVING THERAPEUTIC
STRATEGIES
Jeroen Johannes Wilhelmus Maria Janssen
Jps t&m Chapter2 DEF  19-10-2009  13:46  Pagina 1
© J.J.W.M. Janssen, Amsterdam 2009-Molecular and immunophenotypic features of chronic myeloid
leukemia in an era of evolving therapeutic strategies
ISBN: 9789086594016
Cover design: Loe Limpens en Bart Nagel
Lay-out: Ed van Eechoud
Printed by: Rikken Print, Gendt
Printing of this thesis was financially supported by: Amgen, Bayer-Schering Pharma, Becton-Dickinson
Biosciences, Bristol-Myers Squibb, Celgene, Eusapharma, Fenwal Nederland, Fresenius-Kabi Nederland
BV, Genzyme, GlaxoSmithKline, Janssen-Cilag, MRC Holland, MSD, Novartis Oncology, Novo-Nordisk,
Pamgene, Pierre Fabre Medicament, Roche, Sanofi-Aventis, Schering-Plough, Shire, Wyeth.
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 2
VRIJE UNIVERSITEIT
MOLECULAR AND IMMUNOPHENOTYPIC 
FEATURES OF CHRONIC MYELOID LEUKEMIA 
IN AN ERA OF EVOLVING THERAPEUTIC
STRATEGIES
ACADEMISCH PROEFSCHRIFT
ter verkrijging van de graad Doctor aan
de Vrije Universiteit Amsterdam,
op gezag van de rector magnificus
prof.dr. L.M. Bouter,
in het openbaar te verdedigen
ten overstaan van de promotiecommissie
van de faculteit der Geneeskunde
op vrijdag 18 december 2009 om 13.45 uur
in de aula van de universiteit,
De Boelelaan 1105
door
Jeroen Johannes Wilhelmus Maria Janssen
geboren te Renkum 
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 3
promotor: prof.dr. G.J. Ossenkoppele
copromotor: dr. G.J. Schuurhuis
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 4
Voor Annelot, Pepijn, Carolien en Ole
Voor Marieke
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 5
CHAPTER 1. General Introduction
Adapted from: Towards cure of CML. Why we need to know more about 
CML stem cells. Janssen JJWM, Schuurhuis GJ, Terwijn M, Ossenkoppele GJ. 
Current Stem Cell Research and Therapy 2009, in press
PART ONE: PRECLINICAL STUDIES
CHAPTER 2. Identification Of Genes Potentially Involved In Disease Transformation Of 
CML
Janssen JJWM, Klaver SM, Waisfisz Q, Pasterkamp G, de Kleijn DPV, 
Schuurhuis GJ, Ossenkoppele GJ. Leukemia 2005;19(6):998–1004
CHAPTER 3. Aberrant IL8 Response In CML Derived Monocytes
Janssen JJWM, Klaver SM, Waisfisz Q, Westers TM, Schuurhuis GJ, 
Ossenkoppele GJ. Submitted
CHAPTER 4. Maintained Immunogenicity Of Chronic Myeloid Leukemia-Derived 
Dendritic Cells In The Presence Of Imatinib Mesylate: Implication For 
Vaccination Regimens
Westers TM, Janssen JJWM, Houtenbos I, Snoijs NC, van de Loosdrecht AA, 
Ossenkoppele GJ. Leukemia 2006;20(1):154-7
CHAPTER 5. A New Flow Cytometry-Based Method To Discriminate Malignant From 
Normal Stem Cells In Chronic Myeloid Leukemia
Janssen JJWM, Deenik W, Smolders KGM, Terwijn M, Kelder A, Cornelissen JJ, 
Schuurhuis GJ, Ossenkoppele GJ. Submitted
CHAPTER 6. CD90 (Thy-1) Is A Unique And Specific Marker For CML Stem Cells 
Janssen JJWM, Smolders KGM, Schuurhuis GJ, Ossenkoppele GJ. Submitted
CHAPTER 7. Methylation Patterns Of Tumor Suppressor Genes In CML Blast Crisis
Adapted from: Janssen JJWM, Denkers F, Valk PJM, Cornelissen JJ, 
Schuurhuis GJ, Ossenkoppele GJ. Haematologica, in press
9
45
59
65
73
93
109
TABLE OF CONTENTS
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 6
PART TWO: CLINICAL STUDIES
Results of prospective clinical trials
CHAPTER 8. Mobilization Of Hematopoietic Progenitors In CML: A Second Course Of 
Intensive Chemotherapy Does Not Improve Ph-Negativity In Stem Cell 
Harvests
Janssen JJWM, van Rijn RS, van der Holt B, Schuurhuis GJ, Vellenga E, 
Verhoef GEG, Ossenkoppele GJ, van den Berg E, Hagemeijer A, Slater R, 
Nieuwint AW, Cornelissen JJ. Bone Marrow Transplantation 2000;25(11):1147-55
CHAPTER 9. Efficacy Of Escalated Imatinib And Cytarabine In Newly Diagnosed 
Patients With Chronic Myeloid Leukemia. Results Of The Dutch Belgian 
HOVON-51 Study
Deenik W, Janssen JJWM, van der Holt B, Verhoef GEG, Smit WM, Kersten MJ, 
Daenen SMGJ, Verdonck LF, Ferrant A, Schattenberg AVMB, Chu IWT, 
Goudswaard CS, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, 
Wijermans PW, Verelst S, Beverloo HB, Löwenberg B, Valk PJM, Ossenkoppele GJ, 
Cornelissen JJ. Submitted
Sudden blast crisis case reports
CHAPTER 10. Secondary Imatinib Resistance Associated With An Aberrant BCR-ABL
Fusion Gene
Janssen JJWM, Hochhaus A, van Oostveen JW, Waisfisz Q, Schuurhuis GJ, 
Ossenkoppele GJ. Leukemia 2004;18(5):1020-1
CHAPTER 11. Isolated Central Nervous System CML Blast Crisis Developing In Major 
Molecular Response During Imatinib Treatment
Janssen JJWM, Berendse HW, Schuurhuis GJ, Merle PA, 
Ossenkoppele GJ. American Journal of Hematology 2009, in press
Short Reflection On The Thesis And Future Perspectives
Samenvatting Voor Medisch Niet-Ingewijden
List of Publications 
Dankwoord
119
135
155
161
169
173
183
187
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 7
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 8
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 9
10
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 10
11
HISTORY
Chronic myeloid leukemia (CML), first described more than 150 years ago, is a rare disease of
the hematopoietic stem cell, affecting approximately 1 in 100.000-150.000 individuals per year.1
The disease leads to a huge accumulation of less and more mature myeloid cells in the bone
marrow, peripheral blood and spleen.2 Splenic irradiation, introduced in 1903, was the only
available palliative treatment during the first half of the twentieth century. The road towards a
rational and targeted approach in current treatment was paved in 1960, when David Hungerford
and Peter Nowell at the University of Pennsylvania, Philadelphia, USA described the presence
of an abnormally small chromosome in the bone marrow of patients with CML.3 It took another
13 years before Janet Rowley at the University of Chicago was able to demonstrate that the so-
called Philadelphia-chromosome was the result of a reciprocal translocation between
chromosomes 9 and 22.4 In the 1980s, scientists in Rotterdam, the Netherlands and Los
Angeles, USA, were able to demonstrate that this translocation resulted in a fusion of the C-ABL
gene derived from the long arm of chromosome 9 and the BCR-gene that is located on the long
arm of chromosome 22.5 Subsequently, it was shown that this fusion led to the production of a
constitutively active tyrosine kinase which was then called BCR-ABL.6 In the late nineties of the
twentieth century Dr Brian Druker at the Oregon Health & Science University Portland, USA,
together with scientists from the pharmaceutical company Novartis, initiated the clinical
development of imatinib mesylate (IM) as a very active BCR-ABL tyrosine kinase inhibitor (TKI),
which heralded a revolution in clinical hematology.
CLINICAL ASPECTS
In half of the CML cases, patients are asymptomatic. The disease may then be diagnosed
accidentally at check-ups or when blood is tested for other reasons. In the other half of the
cases, complaints can be abdominal fullness due to, sometimes massive, splenic enlargement,
fatigue, night sweats, gout and weight loss. Signs of leukostasis, like headaches and visual or
auditory disturbances are infrequently encountered, but may occur in CML with very high white
blood cell counts. Physical examination may reveal a palpable spleen but is often otherwise
normal. In patients who are treated suboptimally or who have an inadequate response to
treatment, an acute phase of the disease eventually develops in which the disease behaves as
an acute leukemia with accumulation of blasts in the blood and bone marrow. In around two
thirds of cases this so-called blast crisis is of myeloid phenotype, the rest being lymphoid or
biphenotypic.7 Because normal hematopoiesis is replaced by these immature cells, bone
marrow failure ensues, leading to fatal infections, bleeding and anemia. Survival in blast crisis
that is unresponsive to treatment is, on the average, less than six months.8-10
LABORATORY FEATURES
The clinical diagnosis can be made by examination of the peripheral blood which shows
hyperleukocytosis with white blood cell counts that may exceed 500x109/l. There is an extreme
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left shift with myeloid cells in all maturation stages, from blasts to segmented neutrophils,
present. The bone marrow is hypercellular due to myeloid proliferation and typically, small,
hypolobulated megakaryocytes are seen. Pseudo-Gaucher cells and sea-blue histiocytes are
also a characteristic of CML. The diagnosis can be confirmed by cytogenetic examination of
metaphase spreads showing a Philadelphia chromosome in 90-95% of cases. In 5-10% of
cases, the Philadelphia chromosome is lacking, but variant or occult translocations exist.11-13 In
these cases, in order to establish the diagnosis of CML, a BCR-ABL translocation, as detected
by reverse-transcriptase polymerase chain reaction (PCR) should always be present.
THE PHILADELPHIA CHROMOSOME
As a result of a reciprocal translocation between the part of the long arm of chromosome 9 that
is telomeric of band q34 and part of the long arm of chromosome 22, telomeric of band q11, the
Philadelphia chromosome is generated. As this t(9;22)(q34;q11.2) translocation leads to a net
loss of a substantial part of chromosome 22, the Philadelphia chromosome is much smaller than
the normal chromosome 22. This facilitates detection by light microscopic examination. The
reciprocal product of this translocation, the der9t(9;22)(q34;q11.2) is less conspicuous than the
Philadelphia chromosome as it is only slightly larger than the normal chromosome 9.
THE BCR-ABL FUSION GENE
On a molecular level, the t(9;22) translocation leads to the juxtaposition of the C-ABL gene,
derived from chromosome 9q and the BCR gene, which is located on 22q. The breakpoint in the
ABL gene is most often located between exons a1 and a2, while in the BCR gene, the most
frequently occurring breakpoint is between exons e13 and e14 or between exons 14 and 15,
giving rise to e13a2 (former name b2a2) and e14a2 (former name b3a2) fusions, respectively. In
rare cases of CML, a break occurs in between BCR exon 19 and 20, leading to an e19a2 fusion.
This fusion product leads to the clinical picture of a CML with predominance of circulating
neutrophils and few immature myeloid progenitors. Previously this was called chronic
neutrophilic leukemia, but the “World Health Organization (WHO) Classification of Tumours of
Haematopoietic and Lymphoid Tissues”14 has designated this name to a BCR-ABL negative
entity resembling classical CML. In 20-30% of adult acute B-lymphoblastic leukemia cases, a
Philadelphia chromosome is also detected. In this case the BCR-ABL fusion is relatively short,
as it consists of only the first BCR exon that is fused to the ABL a2 exon.
THE BCR-ABL TYROSINE KINASE
The BCR-ABL protein that is found in CML has a molecular weight of 210 kiloDalton. This
contrast with 185 kD for the ALL BCR-ABL fusion protein, due to its shorter BCR-sequences that
are involved in the fusion. However, apart from the regular 210 kD protein, in a significant part of
CML patients, the 185kD protein can be also detected in low levels, due to alternative splicing
of the BCR gene.15,16
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The first exon of c-ABL encodes an N-terminal 81 amino acid auto-inhibitory domain that
normally keeps its tyrosine kinase activity in check.17 In the BCR-ABL fusion, the ABL part still
functions as a tyrosine kinase, however, due to the loss of this domain, its tyrosine kinase 
activity is strongly enhanced. This results in a multitude of aberrancies in the intracellular signal
transduction pathways, that ultimately leads to the clinical picture of CML, as will be described
further on. 
TREATMENT
Non-TKI treatment
Allogeneic stem cell transplantation (alloSCT) was, and still is, the only potentially curative
treatment option for CML. At present, its use is restricted to those patients who are 
unresponsive to TKI’s (see below) and to those who present in advanced stages of the disease.
However, due to age limits and donor availability, only a minority of patients is eligible for this
intensive treatment. The recent introduction of non-myeloablative transplantation strategies
definitely increases the applicability of alloSCT to elderly patients and to those with co-
morbidities. Nevertheless the risk of treatment related mortality induced by these transplants
remains substantial.18-20
Autologous stem cell transplantation has been investigated in the pre-IM era as a way to
improve upon the results of conventional treatment in patients who were ineligible for allogeneic
stem cell transplantation.21-23 A report of a Dutch-Belgian study applying dual chemotherapy
courses to reduce tumor cell contamination of autologous stem cell grafts is included in this
thesis (Chapter 8). The results of several other studies applying autologous transplantation are
also discussed in this chapter. As is shown, long term cytogenetic remissions were infrequently
observed after autoSCT and, after the introduction of IM, this procedure has been abandoned.
Before the introduction of IM, interferon-alpha (IFN-alpha) was the standard treatment for CML
patients who were ineligible for allogeneic stem cell transplantation, as it could induce
cytogenetic responses. Patients who attained at least a partial cytogenetic remission (PCyR) had
relatively good survival, which was clearly superior to the results of treatment with cytotoxic
drugs like hydroxyurea and busulfan.24-28 Unfortunately, only a minority of patients did achieve
such a good response, in most studies this was below 20%. Besides, side effects are numerous
and include flu-like symptoms and depression. These led to discontinuation of IFN-alpha in
around 25% of treated patients. Addition of low-dose cytarabine resulted in higher response
rates, but induced even more toxicity.29 IFN-alpha should now be considered as front-line
treatment only in the context of clinical studies (see below).
Hydroxyurea and, to a lesser extent, busulfan are both very effective in reducing leukocyte
counts and have long been used as palliative treatment for patients who could not tolerate, or
were otherwise unable to be treated with, other modalities. However, they almost never induced
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a significant reduction in the percentage of Philadelphia-chromosome positive cells in the bone
marrow and did not prevent progression into blast crisis. Still, hydroxyurea may be used in the
initial phase of disease, to induce rapid reduction of leukocyte counts while awaiting
confirmation of the diagnosis with cytogenetic and molecular studies.
Treatment with tyrosine kinase inhibitors
Nowadays, standard treatment for newly diagnosed patients consists of IM (formerly called
STI571), which is available as an oral drug and should be taken at a dose of 400-800 mg qd.
This leads to a very rapid normalization of the leukocyte count and differential (95% within 4
weeks) and in almost 70% of cases to the disappearance of the Philadelphia chromosome
containing cells within one year. At longer follow-up, this increases to more than 85% and in
80% of these, the BCR-ABL transcript level, as determined by quantitative PCR, decreases
more than 1000-fold (“3 logs”) compared to the level at diagnosis.30 This so-called major
molecular response (MMR) is an important landmark, as patients attaining this level rarely show
transformation into blast crisis. When the reduction in transcript level is more than 4,5 logs,
quantitative PCRs will usually give negative results, referred to as a complete molecular
response. In some of these patients, even no BCR-ABL signal can be detected by nested
conventional PCR which should have a sensitivity of one BCR-ABL positive cell in a background
of one million normal cells. These patients may still have up to one million remaining malignant
cells in their body. Apparently, given the favorable long-term results in patients attaining at least
a MMR, these remaining cells stay quiescent and do not lead to relapse of the disease in the
vast majority of patients as long as IM is continued.
However, there is a substantial fraction of patients, between 10 and 15%, that does not respond
optimally to IM. These patients are at increased risk of developing blast crisis. In most cases,
blast crisis will be preceded by an episode of rising numbers of Philadelphia-chromosome
positive cells or BCR-ABL transcripts, however, CML patients may also develop sudden blast
crisis, without a previous loss of attained molecular response, as will be described in this thesis
(Chapters 10 and 11). Criteria for defining quality of response to IM have recently been 
published by an international collaborative group supported by the European Leukemia Net.31
According to these criteria, a suboptimal response was defined as not attaining a complete
hematological response (CHR) at three months, failure to reach at least a partial cytogenetic
response (PCyR, 1-35% Ph+ metaphases on bone marrow examination) at six months, a lack of
complete cytogenetic response (CCR) at 12 months or less than an MMR at 18 months. IM
failure is concluded if a CHR is not present at six months, if a PCyR is not attained at 12 months
or if Ph+ metaphases are still present at 18 months. Any loss of response also defines IM failure. 
Although patients having a suboptimal response may still have benefit from continuing IM, 
failure implicates that the chance of progression into more advanced disease is high: the IRIS
study (International Randomized Study of Interferon and STI571) showed that 19% of patients
failing to reach a PCyR at 12 months had progressed at 60 months of follow-up.32 In around 50%,
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clinical resistance to IM is related to the development of point mutations in the ABL kinase
domain. Second generation TKI’s, like nilotinib (Tasigna®), dasatinib (Sprycel®) and bosutinib may
in these circumstances induce MCR (<35% Ph positive metaphases) in about 20-50% of
patients.33-36
Nilotinib is an aminopyrimidine derivative of IM with approximately 30 times more potency in
vitro against IM-sensitive BCR-ABL-expressing cell lines. Its kinase inhibition spectrum is more
BCR-ABL specific than IM with PDGFR and c-KIT relatively weakly inhibited, while SRC family
kinases are not inhibited at all.37 Dasatinib is chemically unrelated to IM and is 300 times as
potent in in-vitro models. Apart from BCR-ABL, many SRC kinase family members are inhibited
by dasatinib. Bosutinib, like dasatinib, is a dual ABL/SRC kinase family inhibitor.38 All three
second generation TKI’s have broad activity against most IM resistant mutants, but show
reduced activity against several other ABL mutants in in-vitro sensitivity screens.39 Moreover, all
lack activity against the clinically relevant T315I ABL mutant. Due to their broad kinase 
inhibition, both bosutinib and dasatinib have potentially more adverse effects than nilotinib, but
in clinical practice, all three are generally well tolerated. 
RESIDUAL BCR-ABL POSITIVE CELLS OCCUR UNDER TREATMENT WITH IM
As was stated before, in the vast majority of patients, IM is unable to kill a substantial amount
of residual CML cells, evidenced by persisting BCR-ABL transcripts, even though the level of
this persistence may be very low. In fact, half of the patients who attained a long-lasting
complete molecular response and who stopped IM relapsed within six months.40 This implicates
that even long-term deep suppression of the CML clone does not eradicate the disease, at least
not in part of the patients. Lifelong treatment with IM is therefore probably needed in most of
these patients. 
An important question is how these residual cells are able to survive (albeit suppressed by BCR-
ABL tyrosine kinase inhibition), while the majority apparently is being eradicated by the drug. As
these residual cells are able to rapidly proliferate upon release of tyrosine kinase inhibition, at
least part of these must have stem cell characteristics. As outlined below, specific resistance of
CML stem cells allows these to survive treatment with TKI’s. First, we will introduce the stem cell
concept in CML.
THE STEM CELL CONCEPT IN CML
CML is considered to be a stem cell disease, but, although virtually all cells of myeloid lineage
carry a Ph chromosome, only 50-60% of mature B-cells and few to virtually none of mature T-
cells (and NK-cells) are Ph+.41-43 Several explanations have been proposed for this phenomenon.
It has been suggested that the leukemia initiating translocation between chromosomes 9 and 22
occurs in a more committed progenitor cell that is already restricted to the myeloid and B-cell
lineage, and does not involve the T-cell lineage. Another explanation would be that T- cells, due
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to their long lifetime, developed before the CML-initiating Philadelphia translocation occurs.
There are two arguments against the latter explanation: firstly, even in patients with longstanding
CML T-cells remain Ph- and, secondly, analysis of T- and B-precursor subsets showed that these
were both Ph+. Therefore the most likely explanation would be that BCR-ABL induces a loss of
differentiating potential beyond the T-lymphoid progenitor stage, while retaining the earlier
developed normal Ph- lymphocytes.44 A mechanistic explanation for this interference of
differentiation remains to be found. Differentiation into the myeloid lineage is only slightly
affected in CML as the bactericidal activity of neutrophils is only moderately decreased,
presumably by their relative immaturity.45,46 Morphologically, myeloid cells in CML are normal,
although less mature.
FUNCTIONAL AND IMMUNOPHENOTYPIC CHARACTERISTICS OF NORMAL AND CML
STEM CELLS
Stem cells can be detected by using several functional and immunophenotyping techniques. In
a colony forming unit (CFU) assay, bone marrow cells of normal and leukemic individuals that
are cultured in semi-solid media give colonies of maturating cells along granulocytic,
macrophage or erythroid lineages within one to two weeks. However, the cells that give rise to
these colonies are not stem cells, but committed progenitor cells that are unable to sustain long-
term self renewal and clonogenic capacity. In CML, the numbers of these colonies per number
of plated cells equals those of normal bone marrow samples, but, due to the vast increase in
overall number of cells, the total number of colony forming cells in CML increases several-fold.47
More primitive cells, amongst which are stem cells, can be identified in so-called long-term
culture assays that use stromal feeder layers, where upon cells are cultured. Cells that are still
able to form colonies after five weeks or longer of culture on these stromal layers are called long-
term culture initiating cells (LTCIC’s).48,49 Remarkably, while the vast majority of colonies in the
short term assays are Ph+, LTCIC’s in the bone marrow of many chronic phase CML patients are
predominantly Ph-.50,51 Both Ph- and Ph+ LTCIC frequencies are reduced compared to normal
bone marrow.52 Moreover, CML LTCIC’s have defective self-maintenance ability, although, or
perhaps, because they are more actively cycling.53
These results correlate with flow cytometry assays that use the fluorescent RNA dye Pyronin Y
and the DNA dye Hoechst33342 to identify stem cells.54,55 After incubating CD34+ cells with these
dyes, cycling (G1/S/G2/M) cells show high levels of fluorescence for one or both dyes, whereas
non-cycling G0 cells remain double negative. Several in vivo experiments with irradiated
immunocompromized mice show that cells with long-term repopulating capacity reside
predominantly in the G0 CD34
+ compartment of both normal and leukemic individuals.56-59 In CML
however, this G0 compartment is significantly smaller than that of normal individuals, which
correlates with the reduced self-renewal ability, described above.60,61 Likewise, the number of
CML CD34+ cells that remain in G0 phase after three to four days of stimulation with a cocktail
of growth factors is lower in CML than in normal individuals.62 Functional and immunophenotypic
characteristics of these so-called quiescent cells are compatible with very primitive
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hematopoietic cells, while their non-quiescent counterparts have more mature properties.63 The
accumulation of myeloid cells in chronic phase CML therefore apparently results from the net
effect of increased cycling of relatively few Ph+ stem cells that, at the same time, have
diminished self-renewal capacity, together with an enlarged colony forming compartment of Ph+
progenitor cells that in itself have near-normal CFC frequency.
Low staining of Hoechst33342 and other dyes like Rhodamine-123 can also be used to define
a resting population of cells that possesses both high levels of drug efflux pumps and long-term
repopulating capacity. LTCIC’s in CML show less efflux of Rhodamine-123 than their normal
counterparts which relates to their above-mentioned increased cycling behavior.64 Stem cells
also show high activity of detoxification enzymes like aldehyde dehydrogenase (ALDH),
providing a mechanism that cooperates with their high drug effluxing capacity, together
protecting them from harmful environmental influences.65 In AML, high ALDH activity correlated
with increased engraftment capacity in NOD/SCID mice,66 while in a CML cell line that was
resistant to cyclophosphamide ALDH activity was more than 2000-fold upregulated compared
to its non-resistant counterpart. Although this correlated with BCR-ABL upregulation, IM
sensitivity was unaffected.67 Whether ALDH activity in CML stem cells also correlates with stem
cell activity has not been reported yet.
Leukemic and normal stem cells can also be identified by more complex use of flow cytometry
and seem to share many immunophenotypic properties. While normal and leukemic
CD34+CD38+Lin- cells can only engraft irradiated, severely immunocompromized mice for less
than six weeks, long-term stem cell activity, as defined not only by LTCIC activity, but 
particularly by in-vivo repopulating capacity and retained stem cell capacity upon serial
transplantation, resides in the CD34+CD38- Lin-Thy-1+c-kit- or low population in normal as well as
in CML cells.68,69 Interestingly, as shown in this thesis (Chapter 6), we demonstrate that the level
of Thy-1 (CD90) expression is high for CML CD34+CD38- cells, but clearly lower for the residual
normal CD34+CD38- cells that can be found in untreated chronic phase CML.
Thus, in chronic phase CML, the most primitive stem cell compartment can be defined in 
roughly the same way as in normal bone marrow where long-term stem cell capacity seems to
reside in a population of cells that is CD34+CD38- Lin-Thy-1+c-kit- or low, while CD34+CD38+ cells
only display short term colony forming capacity. It is controversial to use lineage negative cells
as equivalent for CML stem cell activity since in both AML70 and in CML, as we show in this
thesis (Chapter 5), leukemic stem cell activity may reside in the CD34+CD38-Lin+ fraction. The
use of DNA staining agents can substitute for CD38 since CD34+ cells without any DNA
replication over a few days of incubation with a stimulating cytokine cocktail also have stem cell
properties.
Compared to chronic phase CML cells, blast crisis cells show clearly better engraftment in
immunocompromized mice.71 Moreover, as reported by Jamieson et al, it appears that in the
advanced phase of the disease, there is a change in the compartment of cells with stem cell
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Figure 1. Schematic representation of signaling pathways involved in BCR-ABL mediated leukemogenesis. 
In reality, growth factor receptors for IL-3, GM-CSF and G-CSF differ from each other. Dashed arrows represent
translocation of proteins from cytoplasm to nucleus and vice versa. The connection between GSK3b and NFkappaB is
dashed and grey as literature data are inconclusive. Inhibitory pathways are shown as              , activating pathways as
.
capacity: contrary to the situation in chronic phase CML, blast crisis
CD34+CD38+CD123+CD45RA+ granulocyte macrophage progenitor cells had leukemia-initiating
capacity.72 These cells were able to engraft immunodeficient mice and repetitive transplantation
in secondary recipients showed ongoing stem cell activity. Activation of the Wnt-beta-catenin
pathway was found in these cells. Recently, it was shown that this activation was caused by an
inactivating mutation of the beta-catenin degrading glycogen-synthase kinase-3-beta (GSK3b)-
enzyme (see below).73
PERTURBATIONS OF SIGNAL TRANSDUCTION PATHWAYS IN CML (STEM) CELLS 
The signaling pathways affected by BCR-ABL have extensive cross connections, so that
alterations in the properties of the key proteins of one pathway may affect other pathways as
well. Single signal transduction pathways may thereby have an effect on all of these functions at
the same time. Features of CML cells that are essential for the pathogenesis of CML relate to
proliferation, survival, differentiation and motility. Several of these will be reviewed and the
extensive cross-talk between signaling cascades will be highlighted. Figure 1 shows a graphical
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overview of the signaling pathways that will be discussed in the next paragraphs.
Most signal transduction pathways that are involved in the pathogenesis of CML converge at the
level of transcription factors, like STAT proteins and C-MYC, and of the BCL-2 family. These
proteins all act synergistically to induce proliferation, while at the same time promoting cell
survival. 
The JAK-STAT pathway
In normal cells, binding of cytokine receptors by their ligands leads to phosphorylation of JAK2,
which indirectly activates STAT proteins.74 Subsequently, these activated STAT proteins migrate
into the nucleus where they regulate transcription of genes that are involved in cell proliferation
and survival, like cyclin D1, cyclin D2 and BCL-XL.75-77 Erythropoietin, thrombopoietin and many
interleukins, like IL-3, signal through this pathway.78,79 Deprivation of growth factors in normal cell
types will lead to growth arrest and loss of viability. However, transduction of cell lines with BCR-
ABL completely abrogates this growth factor dependence.80-85 This relates, at least in part, to
constitutive activation of the JAK/STAT signal transduction pathway that can be demonstrated
in these cells and also in primary CML cells.86-94 Here, binding and phosphorylation of JAK2
(among several others) by BCR-ABL was demonstrated.95,96 STAT proteins can also directly be
activated by BCR-ABL, hereby bypassing JAK2 activation, as shown in two separate studies.97,98
JAK2 phosphorylation seems relevant for the oncogenic properties of BCR-ABL, as K562 cells
possessing a kinase defective JAK2 mutant were unable to induce tumors in nude mice.95 In
these cells, STAT5 activation was unaffected, indeed pointing at direct BCR-ABL mediated
activation of STAT proteins, but also suggesting that other signaling pathways where JAK2 is
involved may play an important role in CML (see below). 
STAT activation may also result from IL3-mediated signaling. In several studies BCR-ABL was
shown to induce autocrine IL3, G-CSF and GM-CSF production in primary, primitive CML cells
concomitant with STAT5 phosphorylation.99-102 Conflicting data however exist about the relevance
of IL3 for leukemogenesis of CML. Blocking of IL3-mediated signaling by anti-IL3 antibodies did
not prevent STAT activation in CML cell lines and lethally irradiated IL3/IL3-receptor-/- recipient
mice that were transplanted with BCR-ABL transduced IL3/IL3-receptor-/- cells still rapidly
developed a fatal myeloproliferative disease.103-105 In contrast, in another study, it was
demonstrated that primitive IL3-/- BCR-ABL transduced cells had strongly reduced long-term
leukemia initiating and maintaining activity after transplantation in recipient mice and this did
correlate with reduced STAT5 activity.106 Possibly, different model systems may explain these
diverging results.
Pathways leading to C-MYC upregulation
Another important aspect of perturbed signaling in CML is the upregulation of C-MYC
expression. C-MYC activity sensitizes cells towards apoptosis induction, but also stimulates
proliferation by induction of several cell cycle activation enzymes. BCR-ABL tyrosine kinase
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increases C-MYC expression in several ways. Firstly, BCR-ABL binds to adaptor proteins like
GRB2, SHC, CRKL and CBL after which this complex recruits the nucleotide exchange factor
SOS.107-113 SOS then activates RAS into its active GTP bound form.114 Activated RAS further
signals through RAF, MEK and MAPK (ERK) and eventually to C-MYC.115,116
Secondly, BCR-ABL was shown to form a complex with JAK2 and AKT, thereby 
phosphorylating both proteins. Subsequently, this activated BCR-ABL/JAK2/AKT complex
downregulated the kinase activity of GSK3b. Reduction of GSK3b activity eventually caused
increased NFkappaB activation, in its turn increasing C-MYC expression.95,96 Notably, in other,
non-CML cell systems, GSK3b increased NFkappaB activity instead.117-120
Thirdly, an important role of the Wnt-beta-catenin signaling cascade is gaining increasing
interest as BCR-ABL phosphorylates beta-catenin on tyrosine residues which renders the
protein more stable by preventing its binding to the GSK3b-axin destruction complex.121,122
Phosphorylated beta-catenin may then enter the nucleus where it binds to the TCF4
transcription factor, resulting in, amongst others, induction of C-MYC expression.123,124 This
mechanism may be amplified by the reduced GSK3b activity already described in the previous
paragraph.
At last, concomitant STAT5 and C-MYC downregulation was demonstrated in K562 cells upon
treatment with a BCR-ABL tyrosine kinase inhibitor, indicating that C-MYC is a potential target
gene for STAT5. Activation of STAT proteins by BCR-ABL may therefore increase C-MYC
transcription.77
Pathways leading to apoptosis resistance
Decreased sensitivity towards apoptosis induction is also a major consequence of the
constitutive kinase activity of BCR-ABL. The PI3K/AKT pathway, shown above to be involved in
increasing C-MYC expression, plays a central role herein. Next to activating RAS, the already
described multimeric complex consisting of BCR-ABL, CBL, CRK and CRKL phosphorylates
PI3-kinase.125-127 The AKT protein (see above) is a substrate of this complex and hereby plays a
role in stimulating anti-apoptotic signaling. For example, after phosphorylation of the
proapoptotic BCL-2 family member BAD by p-AKT, BAD is bound to the 14-3-3 protein leaving
less free BAD available for heterodimer formation with the antiapoptotic protein BCL-XL.128
Consequently, more anti-apoptotic BCL-XL remains in the cytoplasm, preventing cytochrome-c
efflux from the mitochondria and subsequent apoptosis induction. In addition, BCR-ABL
mediated STAT5 activation resulting in increased transcription of the BCL- XL gene may result in
an additional rise in the BCL-XL level.129
The anti-apoptotic BCL-2 protein is also upregulated in CML cells, possibly through the
downregulation by BCR-ABL tyrosine kinase activity of the BCL-2 interacting mediator (BIM).
This reduction in BIM expression is a post-transcriptional event that is dependent upon signaling
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via the mitogen activated protein (MAPK) pathway.130,131 This pathway is also involved in the
increased expression of C-MYC as described earlier. Besides, upregulation of the anti-
apoptotic protein MCL-1 also results from activation of this signal transduction pathway.132
Although the above-described increased C-MYC levels may sensitize cells for induction of
apoptosis, the concurrent upregulation of several anti-apoptotic BCL-2 family proteins prevents
its execution, so that the net effect of C-MYC induction is stimulation of proliferation by
upregulation of several cell cycle activation enzymes.133
Adhesion related pathways
Next to its effect on proliferation and survival pathways, BCR-ABL reduces adhesion of
progenitors to stromal cells.134,135 In contrast to C-ABL, which localizes both in nucleus and
cytoplasm, BCR-ABL is exclusively localized to the cytoplasm.136,137 There, the above described
multimeric complex of BCR-ABL and adaptor proteins also interacts with several key proteins
involved in beta1-integrin signaling, like focal adhesion kinase, Pyk-2, vinculin, talin and
paxillin.138-143 As a result, these proteins become unavailable for normal beta1-integrin mediated
signaling transduction. As signaling through beta1-integrin is an essential step in the
reorganisation of F-actin fibers in the cytoskeleton and their linkage to the extracellular matrix,
disruption of the signaling cascade leads to diminished adhesion of CML cells to the bone
marrow microenvironment, which may explain part of the clinical picture of CML.144 Perturbation
of this process may also be important for another reason: normal beta1-integrin signaling
upregulates the cyclin-dependent kinase inhibitor P27kip-1, which in turn inhibits cyclin-dependent
kinase-2 (CDK-2), preventing cells from entering the cell cycle.145 Disrupted beta1-integrin
signaling thereby provides an additional mechanism by which BCR-ABL stimulates entry into the
cell cycle.
Stem cell maintenance related signal transduction pathways
Most of the above-described results of perturbations in signal transduction have been gathered
in blast crisis derived cell lines and it is unsure what relevance these perturbations in signaling
routes have for primary CML chronic phase stem cells. Signaling through the Wnt-beta-catenin
pathway was however found to play an important role. Zhao et al, using (repetitive)
transplantation experiments in mice, found that both normal and CML chronic phase stem cells
that were deficient in beta-catenin showed diminished self renewal compared to their beta-
catenin expressing counterparts.146 Remarkably, beta-catenin knock-out stem cells especially
showed reduced ability in inducing CML-like disease, while ALL could still be initiated. The
authors hypothesized that for CML induction, beta-catenin expression in a primitive stem cell is
essential, while ALL arises from a slightly more differentiated progenitor subset that does not
need beta-catenin expression. 
As described, beta-catenin levels are regulated by GSK3b activity. Notably, inhibition of GSK3b,
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leading to an increase in active beta-catenin, had differential effects on normal stem cells and
K562 cells. Whereas hematopoietic stem cell maintenance was improved, apoptosis was
induced in K562 cells, as well in other leukemic (non-CML) cell lines.147 It was suggested that this
related to inhibition of NFkappaB signaling, where upon normal stem cells would be less
dependent than leukemic stem cells.119 This would be in contrast with the above-described
report of Samanta et al, where BCR-ABL induced GSK3b inhibition resulted in increased
NFkappaB signaling. Again, different cell systems may explain discordant results. Moreover, as
K562 is a CML blast crisis cell line, it is questionable whether the reported differential effect can
be extrapolated to chronic phase CML stem cells.
Furthermore, CML stem cell maintenance was very recently demonstrated to be dependent on
activation of Smo-1, a critical intermediate of Hedgehog pathway signaling. Smo-1 activation
leads to increased transcription of, amongst others, Bcl-2 and Cyclin D1 through induction of
Gli-transcription factors and was shown to be BCR-ABL induced. Murine fetal hematopoietic
stem cells derived from embryonic livers that were BCR-ABL+ but Smo-1-/- were unable to
maintain stem cell capacity in serial transplantation experiments. It was suggested that Smo-1
might be an interesting target for therapy, as Smo-1 inhibitors in combination with nilotinib, a
second generation TKI, were synergistically and relatively specifically active against primary
CML LTCIC’s.148 Hedgehog signaling is regulated by GSK3b, which may be important in view of
recent data on this enzyme in advanced phase CML (see below under Molecular and cellular
events involved in transformation of CML).149,150
Activation of Notch and BMI-1, genes that are also involved in stem cell maintenance, has been
described in human acute leukemia’s.151-155 Like Hedgehog, Notch is regulated by GSK3b,156,157
but it is unclear whether deregulation of Notch is relevant for the pathogenesis of chronic phase
CML. BMI-1 is a repressor of the p16INK4a/p14ARF tumor suppressor complex. In murine BCR-ABL
induced leukemia models, no upregulation of BMI-1 in leukemic stem cells was found.158
However, in human CML CD34+ cells, BMI-1 seems to play a role as the level of its expression
was found to correlate with prognosis.159 Clearly, further research is needed to establish the role
of these genes in CML.
At last, very recently, an important role of the promyelocytic leukemia tumor suppressor protein
(PML) in CML was demonstrated by Ito et al.160 PML was found to be highly expressed in
hematopoietic stem cells. Unexpectedly, patients with low PML expression in CD34+ cells had
clearly better complete molecular and cytogenetic response rates than patients with high PML
expression. Further investigations revealed that PML keeps leukemic and normal stem cells in a
quiescent state by inhibiting the mammalian target of rapamycin (mTOR), thereby maintaining
their stem cell capacity. Degradation of PML by arsenic trioxide (As2O3) induced cell cycle
entrance of both normal and primary chronic phase CML stem cells, however, this effect was
much more profound in the leukemic cells and correlated with increased leukemic stem cell
exhaustion in murine serial bone marrow transplantation experiments. Combining As2O3 with
cytarabine resulted in very effective leukemic stem cell kill.
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HOW DO CML STEM CELLS DEFY ANTILEUKEMIC TREATMENT?
Hematopoietic stem cells in general make use of various mechanisms that protect them from
being damaged by environmental influences. They show increased expression and activity of
efflux pumps that can pump out toxic substances, like chemotherapeutic drugs, which can be
accompanied by reduced influx.161 Because stem cells show less cycling than more committed
progenitors, they are less sensitive to cell cycle specific drugs like cytarabine.162-164 These
characteristics apply to CML stem cells as well: CD34+CD38+ progenitors are clearly more
sensitive to IM than the primitive CD34+CD38- stem cells, especially under conditions of 
reduced growth factor availability.165 This may be explained by several mechanisms. Firstly, a
strong increase in BCR-ABL mRNA- and protein expression (up to 100 fold and 3-10 fold,
respectively) was found in the most primitive stem cell compartment compared to more
committed progenitor cells.166-168 This may lead to insufficient inhibition of its kinase activity by IM
and thereby to reduced cell killing by the drug. In more advanced CML, there is an increase in
the average expression of BCR-ABL, with maintenance of the large difference between the most
primitive stem cells and the more committed progenitor cells. This high BCR-ABL expression
parallels the autocrine production of IL3 and GMCSF which is only present in the most primitive
stem cells.169 Possibly, this autocrine loop offers additional protection of stem cells against IM.
Secondly, imatinib influx into the most primitive stem cells is hampered by their very low
expression of Oct-1, which pumps imatinib into the cell.170,171 Levels of Oct-1 transcripts in more
mature progenitor cells were more than 100 fold higher.172 Thirdly, the mRNA levels of the ABCB1
(syn: P-glycoprotein) and ABCG2 (or BCRP) efflux pumps for which imatinib is a substrate, were
two fold higher in the most primitive cells compared to progenitors.173,174 It remains to be
established whether this would be enough to explain low sensitivity of primitive stem cells to
imatinib and the reduced sensitivity to conventional chemotherapeutic drugs.
In addition, K562 cells that were cultured in an in-vitro bone marrow stroma model were
protected from apoptosis induction by IM.175 This phenomenon seemed to be based on secreted
humoral factors, as culture in stroma conditioned medium was also protective. Protected cells
showed STAT3 activation and upregulation of the anti-apoptotic STAT3 targets BCL-XL, MCL-1
and survivin. Possibly, this mechanism contributes to resistance of leukemic stem cells as
described in the previous paragraph. 
Apart from the presence of the BCR-ABL protein and its consequences for signaling pathways,
chronic phase CML stem cells thus share many properties with normal stem cells, which would
make specific treatment difficult.
MOLECULAR AND CELLULAR EVENTS INVOLVED IN TRANSFORMATION OF CML 
As described above, patients that do not respond optimally to TKI’s are at increased risk of
developing blast crisis. The processes responsible for this transformation are still not fully
understood. However, many genetic abnormalities can be found in blast crisis cells. These
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include doubling of the Philadelphia-chromosome, loss of 17p and several additional
chromosomal abnormalities, like trisomy 8.176 Furthermore, progressive shortening of telomeres
occurs during disease evolution, which probably relates to a higher number of past cell divisions
and to reduced telomerase activity in CML CD34+ cells compared to normal.177-180 Of note,
patients who developed transformation to accelerated or blast phase within two years had
significantly shorter telomeres than those who transformed later than two years after
assessment.181
On a molecular level, upregulation of BCR-ABL transcripts, p53 deletion (correlating with the
loss of 17p), loss of expression of INK4a/ARF (in lymphoid crises), upregulation of MDM2 (a
negative regulator of p53), increased expression of C-MYC (sometimes related to trisomy 8),
EVI-1 and HoxA9, downregulation of the C/EBP-alpha gene and deletion or mutation of the
retinoblastoma (Rb) gene can be seen.176,182-189 Furthermore, epigenetic changes, like increased
methylation of several (tumor-suppressor) genes, have been reported.190-197 In this thesis,
additional data will be presented concerning aberrant methylation of a large number of tumor
suppressor genes in a set of CML blast crisis samples (Chapter 7). 
Apparently, genomic instability is also a feature of the transformation process, which may be
related to the increased production of reactive oxygen species that was found in BCR-ABL
positive cells.198-200 This phenomenon is tyrosine kinase mediated as it is abrogated by imatinib.
Besides this, DNA repair mechanisms in CML are abnormal and the response to DNA damage
is inappropriate.201,202 While normal cells go into apoptosis when DNA breaks cannot be repaired,
CML cells take more time to repair the damage, even if this repair is unreliable and thereby may
develop gross mutations. Eventually these may give rise to genetic abnormalities that cause
cells to behave increasingly aberrant and ultimately block differentiation, thus causing blast
crisis. Reduced telomerase activity itself may also be implicated in genomic instability as was
evidenced by experiments with telomerase knock-out mice: spontaneous tumor formation was
seen in later generations of these mice.203
Whether the described genetic changes are the cause or the result of the blast crisis and
whether they are relevant for CML stem cells is still a matter of debate. Relevant data 
concerning stem cells in transformation of CML comes from a study by Jamieson et al.204 They
demonstrated that in CML blast crisis, the CD34+CD38+CD45RA+CD123+ granulocyte-
macrophage progenitor compartment expands and gains stem cell activity. This correlated with
increased nuclear beta-catenin levels and upregulation of beta-catenin target gene expression.
Moreover, in-vitro assays showed these cells to have serial replating capacity. Their additional
work in immunocompromized mice demonstrated leukemogenicity of the GMP cells which was
sustained upon serial retransplantations. Inactivating mutations in the GSK3b protein were
reported to be responsible for the increased beta-catenin levels.73 If these GSK3b mutations
relate to the increased genomic instability of BCR-ABL+ cells is an interesting question. Thus, as
outlined before for chronic phase CML, perturbations in the Wnt-beta-catenin signaling cascade
seem to play a significant role in acute phase CML as well. 
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SUGGESTED WAYS TO ATTACK LEUKEMIC STEM CELLS
If we aim at curing CML, we should look for strategies that will kill quiescent, and thereby
resistant primitive leukemic stem cells, while at the same time sparing normal stem cells. Of the
second generation TKI’s dasatinib and nilotinib, only the former targets more immature
CD34+CD38- cells than IM, but the quiescent CD34+CD38- cells remain unaffected by all
available TKI’s.205 Improved elimination of non-dividing CD34+ CML cells by TKI’s could indeed
be achieved by intermittent addition of G-CSF which caused increased cycling, thereby
sensitizing CML stem cells to IM. However, elimination of leukemic stem cells was still not
attained.206,207 It therefore seems unlikely that treatment with single, even newer TKI’s, will be able
to kill stem cells. Intelligent alternative stem cell targeting strategies should therefore be
explored.
In this respect, the combination of IM with As2O3 is interesting. Several in-vitro studies suggest
synergy between IM and As2O3,208,209 and, in view of the above-described important the role of
PML in stem cell maintenance, this seems a rational approach. Cardiotoxicity of the combination
may however limit its clinical applicability.210
Combining TKI’s with farnesyltransferase inhibitors (FTIs) may also be a valuable approach. Two
FTIs, lonafarnib and BMS-214662, alone or in combination with IM, showed anti-proliferative
and apoptosis inducing activity against quiescent CML CD34+ cells and decreased long-term in
vitro stem cell capacity, as measured by the LTCIC assay.211,212 Normal quiescent stem cells were
less sensitive to these combinations. Remarkably, expansion of the quiescent leukemic cells
remained suppressed, even after removal of lonafarnib. This contrasted with the effects of the
other drugs that were also tested in combination with IM, namely cytarabine, the heat-shock
protein (HSP)-90 antagonist 17-AAG and the phosphatidylinositol-30 kinase (PI-3K) inhibitor
LY294002. Clinical studies with TKI-FTI combinations have been initiated.213,214
Although cytarabine is a cell cycle specific agent, which did not lead to increased elimination of
quiescent stem cells in the experiment described above, the drug is being tested in combination
with IM for newly diagnosed CML patients in the Dutch HOVON-78 study. The results of its
predecessor, the dose finding HOVON-51 study, that combined IM with different doses of
cytarabine, will be presented in this thesis (Chapter 9).
Furthermore, as Wnt signaling apparently plays a major role in chronic as well as acute phase CML,
targeting this cascade may be a valuable option to pursue. Wnt-1 and -2 inhibiting monoclonal
antibodies and small molecule inhibitors of beta-catenin are being developed and have already
shown in-vitro activity for example in colon cancer cells, but have not yet been tested in leukemic
cells.215,216 Topoisomerase II inhibitors like merbarone and etoposide, also inhibit Wnt-beta-catenin
signaling by suppressing the beta-catenin-mediated TCF/lymphoid enhancer factor transcriptional
activity.217 Because effective drug concentrations of these compounds are rather high and because
of their mutagenicity they are however unsuitable for clinical practice in chronic phase CML. 
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Paradoxically, the GSK3b inhibitor 6-bromoindirubin 3’-oxime, which increased beta-catenin
levels both in normal stem cells and in the K562 CML blast crisis cell line, seems to have rather
specific activity against the latter, possibly through NFkappaB downregulation, as already
described.147 Another non-ATP competitive inhibitor of GSK3b, 4-benzyl,2-methyl,1,2,4-thiadia-
zolidine,3,5-dione, also specifically inhibited viability of primary blast crisis CD34+CD38- cells,
but presumably this effect was achieved by concomitant inhibition of other kinases and by its
oxidative properties.218 It may be worthwhile to investigate the activity of these compounds
against chronic phase CML stem cells, possibly in combination with IM. Interestingly,
antileukemic strategy might thus be paralleled either by up- or downregulation of beta-catenin. 
Several other compounds have shown synergistic activity in combination with IM. Among these
are demethylating agents and inhibitors against NFkappaB and COX-2.219-229 None of them
seems to have specific anti-stem cell activity. However, highly specific activity against AML and
CML blast crisis CD34+CD38- cells was demonstrated for the plant-derived agent parthenolide
and its orally bio-available derivative dimethylaminoparthenolide by induction of oxidative stress
responses, inhibition of NFkappaB and activation of p53.230,231 It is presently unknown whether
the latter compounds have specific activity against chronic phase stem cells.
Finally, immunotherapeutic strategies may be very effective partners of TKI’s. Non-dividing cells
in relatively low numbers should be perfect candidates for attack by cytotoxic T-cells as is
evidenced by the high activity of donor lymphocyte infusions in molecular or cytogenetic
relapses of CML after allogeneic stem cell transplants. Besides, complete cytogenetic
responses to IFN-alpha are presumably based on cytotoxic T-cell responses against BCR-ABL
positive cells. BCR-ABL derived peptides and tumor associated antigens, like the proteinase-3
associated PR1 peptide are expressed on the cell surface by HLA molecules and can elicit
cytotoxic T-cell responses.232-234 On the other hand, cytokine secretion by effector T-cells,235 T-cell
activation and proliferation to T-cell receptor binding was inhibited by IM,236,237 which provoked
doubts on the feasibility of combined IM-immunotherapy approaches. Moreover, it was
questioned whether BCR-ABL positive monocyte derived dendritic cells would be able to
present antigens to T-cells in the presence of IM. In this thesis (Chapter 4), the latter question
will be dealt with. In the meantime, several preclinical reports have however suggested that IM
may successfully be combined with immunotherapeutic approaches probably because the
drugs reduces the number of immunosuppressive regulatory T-cells.238,239
Clinical strategies, combining IM or IFN-alpha and vaccination strategies with bare antigens or
antigen loaded dendritic cells have been developed, some of which have shown activity in early
studies. For example, in a small group of patients who had suboptimal responses to IM or IFN-
alpha, addition of a peptide vaccine derived from the b3a2 (e14a2) fusion clearly improved
responses with half of IM-treated and one-third of IFN-alpha-treated patients attaining CCyR.240
Randomized trials comparing IM with immunotherapy-supported IM are awaited for with
interest.
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As is described above, apart from BCR-ABL itself and a few related proteins, no CML specific
targets have been identified. To improve treatment efficacy while at the same time reducing
damage to normal (stem) cells, new strategies that are truly stem cell specific are definitely
needed. Our group recently demonstrated that stem cells in acute myeloid leukemia (AML) carry
a highly specific leukemia marker, C-type lectin-like-1 (CLL-1).241 This is a promising finding as it
could make primitive stem cell targeted immunotherapy feasible. However, as will be shown in
Chapter 5 in this thesis, CLL-1 is absent on CML stem cells. Improvement in the therapeutic
efficacy of CML treatment will be facilitated by knowledge of CML stem cell specific targets.
These may be targets that are suitable for signal transduction inhibitors or those that are
candidates for immunotherapeutic strategies. This thesis (Chapter 5 and 6) will describe efforts
that we, as a first but essential step, have undertaken to identify leukemic and normal stem cells,
which should ultimately lead to detection of these specific targets.
CONCLUSIONS AND PERSPECTIVES
Although IM is very active and well-tolerated in the majority of patients with CML, cure cannot
be attained with this or second generation tyrosine kinase inhibitors, necessitating lifelong
treatment. Moreover, a substantial number of patients demonstrates insufficient response to
these drugs. Quiescence and multiple other mechanisms are responsible for the drug resistance
of CML stem cells. Wnt-beta-catenin signaling possibly plays a crucial role in the
pathophysiology of CML chronic phase as well in transformation to blast crisis. New drugs
targeting Wnt-beta-catenin signaling and specifically active in leukemic stem cells are being
developed, hopefully leading to further optimization of treatment results in CML. It is likely that
the optimal strategy for eliminating leukemic stem cells will involve targeting multiple pathways,
which asks for combination of several agents and possibly also immunotherapeutic approaches.
Effective use of potential new targets for CML as found in literature and described in this thesis
(Chapter 2), should be evaluated for their importance in stem cells. At the same time, direct
target finding in CML stem cells is warranted, presuming that CML stem cells can be specifically
identified. The latter will be also dealt with in this thesis (Chapter 5). In view of the quiescence of
stem cells, it can already be anticipated that the sequence of administration of new and old stem
cell directed drugs may be of crucial importance for optimizing therapeutic results.
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This thesis is divided in two parts. In Part One, several preclinical studies are described. In our
search for genetic events contributing to disease transformation, we performed suppressive
subtractive hybridization on samples collected in a large number of patients throughout the
course of their disease. The results of the analysis of the differential expression of genes at
separate disease stages are reported in Chapter 2. Next, in Chapter 3, we focus on a single
gene, IL8, that we identified in Chapter 2 as being differentially expressed. The effect of imatinib
on the properties of CML derived dendritic cells is the topic of Chapter 4. In Chapter 5, we
describe the discovery of a new flow cytometric strategy that enables to distinguish benign from
malignant stem cells in CML, whereas in Chapter 6 the remarkable finding of specific CD90
expression on the malignant stem cells is presented. Chapter 7 reports on our analysis of
methylation of tumor suppressor genes in CML CD34+ cells in chronic as well as blast crisis.
In Part Two of this thesis, results of clinical studies that we performed in CML patients are
reported. Chapter 8 describes the results of stem cell mobilization and autologous stem cell
transplantation in the pre-imatinib era, a procedure that can nowadays be considered obsolete,
due to the advent of imatinib and other tyrosine kinase inhibitors. However, as treatment with
this new class of drugs is still partly unsatisfactory, we performed the HOVON-51 study that
combined imatinib with cytarabine. Efficacy data are reported in Chapter 9.
In Chapter 10 and 11, two case reports, describing the sudden occurrence of blast crisis,
illustrate the need for an ongoing search for improving treatment results of CML.
Finally, a short general overview is given and future perspectives are discussed.
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ABSTRACT
In patients with chronic myeloid leukemia who do not reach a (near) complete cytogenetic
response the disease progresses over several years from an indolent, chronic phase into a
rapidly fatal blast crisis. Events that are responsible for this transformation process are largely
unknown. To identify changes in gene expression that occurred during the course of the disease,
we performed cDNA subtraction on sequentially stored peripheral blood mononuclear cell
pellets, collected throughout the course of disease of a single CML patient. Thirty-two
differentially expressed sequences were identified, of which 27 corresponded to known genes.
On quantitative PCR, eight of these genes, YWHAZ, GAS2, IL8, IL6, PBEF1, CCL4, SAT and
MMRN showed comparable differential expression in additional CML patient samples. This set
of genes can be considered as a starting point for further research on causes of disease
transformation in CML and may lead to new targets in the treatment of resistant CML.
Jps t&m Chapter2 DEF  19-10-2009  13:47  Pagina 46
47
INTRODUCTION
CML is a malignant disorder of the hemopoietic stem cell that is characterized cytogenetically
by the presence of the Philadelphia chromosome, which represents fusion of the BCR-gene
derived from chromosome 22 with the ABL-gene from chromosome 9. The protein product of
this fusion, BCR-ABL, has leukemogenic properties and is pivotal in the development of CML.
Typically, after several years the chronic phase of the disease transforms into a rapidly fatal blast
crisis. In patients that obtain a (near-) complete cytogenetic response on interferon and/or
imatinib, development of blast crisis is delayed and may even be prevented. Although the
response percentage to imatinib is high, especially in patients with high Sokal or Euro-risk
scores primary and secondary resistance to the drug is seen. Moreover, a small number of
patients present with disease in accelerated or even blastic phase, in which imatinib is clearly
less effective.1
The molecular mechanisms that underlie BCR-ABL-mediated transformation are poorly
understood, however several events have been described to coincide with development of blast
crisis. Mutations or deletions of P53 and its related gene TP73L (in around 25% of myeloid blast
crises), doubling of the Philadelphia-chromosome, trisomy 8, upregulation of C-MYC and RB
expression have been found.2-6 Changes in proliferation, differentiation, apoptosis sensitivity,
DNA repair function, as well as loss of imprinting and genomic instability have also been
observed upon disease transformation.7 In a small minority of cases of advanced stage CML, N-
and K-RAS mutations have been reported.8 The question which of these changes occurred as a
cause or as a result of the transformation itself has not been solved yet.
To identify events responsible for disease progression, we performed PCR subtraction on
samples from a CML patient of whom peripheral blood mononuclear cells had been collected
throughout the course of the disease. Thirty-two differentially expressed sequences were
identified of which eight potentially relevant genes showed similar differential expression in an
additional set of CML patients.
MATERIALS AND METHODS
Patients
Suppression subtractive hybridization was performed on peripheral blood mononuclear cell
pellets isolated at diagnosis, two years after diagnosis and at blast crisis of a single CML patient.
This was a 51-year old man who was diagnosed with CML in 1995. Sokal score at diagnosis was
1.22, Euro score 2065. Cytogenetics revealed the standard translocation t(9;22)(q34;q11), RT-
PCR showed a b3a2 fusion. He had no HLA-identical siblings and was given intensive treatment
with induction chemotherapy as part of a clinical research protocol in August 1995.9 Next,
interferon alpha 3-6 x 106 U s.c. q.d. was started, but because of lack of any response and
intolerance to this drug, he switched to hydroxyurea after 1.5 years. Three-and-a-half years after
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diagnosis, the disease transformed into a blast crisis and he died of progressive bone marrow
failure shortly thereafter. Blast cells at blast crisis were Sudan black positive and were positive
on immunophenotyping for CD34, CD13, CD117 and CD45 (dim), but negative for CD41, CD5,
CD2, CD19 and CD20, compatible with myeloid blast crisis.
Characteristics of the index patient at the time points when samples for suppression subtractive
hybridization were taken are shown in Table 1. Peripheral blood mononuclear cell pellets of an
additional group of CML patients were used to validate the differential expression of genes as
found in the index patient. None of these patients ever reached any cytogenetic response.
Treatment consisted of interferon-alpha and/or hydroxyurea. Samples were collected throughout
the course of the disease. Late chronic phase was defined as a time point at least two years
after diagnosis and not fulfilling common criteria of blast crisis. Of several patients, sequential
samples from diagnosis throughout blast crisis were available; in others a more limited part of
the disease course was represented, e.g. from diagnosis to late chronic phase, or from late
chronic phase to blast crisis.
Isolation of peripheral blood mononuclear cells
Peripheral blood was collected by venipuncture into lithium heparin coated glass containers.
Peripheral blood mononuclear cells were isolated using density gradient centrifugation with
Ficoll-Paque (1.077 g/ml). Cells were pelleted, snap-frozen in liquid nitrogen and then stored at
-80oC until use.
Suppression subtractive hybridization and library screening
Total RNA was extracted using the Qiagen RNeasy kit (Qiagen, Westburg BV, The Netherlands)
Table 1. Clinical characteristics of index patient.
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according to the manufacturer’s protocol. CDNA synthesis, subtraction PCR, library screening,
and sequence analysis were performed as described previously.10 Briefly, cDNA was prepared
by using the SMART PCR cDNA synthesis kit (Clontech, Beckton Dickinson Biosciences BV,
Woerden, The Netherlands) and samples were mixed for the PCR-Select cDNA subtraction kit
according to the manufacturer’s protocol. Subtracted cDNA products were subsequently ligated
into pGEM-T-Easy cloning vectors (Promega Benelux BV Leiden, The Netherlands) and
transformed into supercompetent XL1Blue cells (Stratagene Europe, Amsterdam, The
Netherlands). Plasmid DNA was spotted in an identical manner onto four separate nylon
membranes (Hybond-N, Amersham Pharmacia) for every subtraction procedure. This was
performed with libraries derived from the subtraction of I) chronic phase minus diagnosis and
reverse, II) late chronic phase minus blast crisis and reverse and III) blast crisis minus late
chronic phase and reverse. After baking the membranes at 80oC for 2 h, each blot was
hybridized with a different radioactively labeled cDNA probe: for the subtraction procedure of 
chronic phase minus diagnosis blot 1 was hybridized with unsubtracted cDNA of the late 
chronic phase sample, blot 2 with unsubtracted cDNA of the diagnosis sample, blot 3 with
subtracted DNA of chronic phase minus diagnosis and blot 4 with subtracted cDNA of 
diagnosis minus chronic phase. Likewise, hybridizations were performed for all subtraction
procedures. Only clones that showed a clear difference between the two subtracted probes and
no or a low signal for the unsubtracted probes were selected for sequence analysis.
P53 sequence analysis
For P53 sequence analysis, DNA from mononuclear cell pellets was isolated with the QIAamp
DNA Blood Mini Kit (Qiagen) according to the manufacturer’s protocol. P53 exons 5-9 were
amplified using PCR (primer sequences: see Table 2a) and directly sequenced thereafter on the
ABI Prism 310 Genetic Analyzer (Applied Biosystems-Perkin Elmer, Foster City, California, USA).
Table 2a. Primer sequences p53.
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Quantitative PCR (Q-PCR)
PCR amplification was performed with a LightCycler real-time PCR machine (Roche
Diagnostics, Almere, The Netherlands). Reaction volumes were 20 ul, consisting of 2 ul cDNA, 2
ul of LightCycler Fast Start DNA SYBR Green Mastermix (Roche), and 0.5 mM reverse and
forward primers each. MgCl2 was added to a final concentration of 4 mM in all reactions except
for GAPDH amplification to which 1.5 mM was added. In all PCR reactions, conditions were an
initial denaturation step at 95oC for 10 minutes, followed by 45 cycles, each for 15 s at 95oC, 10
s at 59oC and 10 s at 72oC. For quantification, comparisons were made with standard curves of
PCR products cloned into PGEM-T-easy vectors (Promega). GAPDH signals were used for
normalization of expression for highly expressed genes, Beta-glucuronidase (GUS) signals for
normalization of genes with a relative low expression. For primer design the GeneFisher
program, accessible at http://bibiserv.techfak.uni-bielefeld.de/genefisher/ was used.11 Primers
were purchased from Isogen (Maarssen, the Netherlands). Primer sequences are shown in Table
2b.
Statistical analysis
Gene expression levels as expressed relative to GUS or GAPDH copy numbers were loge-
transformed. Median values of the additional groups of patients at the three different disease
stages were compared using the Mann-Whitney U-test for non-parametric variables. A p-value
of less than 0.05 was considered to indicate a statistically significant difference. 
RESULTS AND DISCUSSION
Differential expression of the identified genes was validated in the index patient samples by
quantitative PCR. The results from subtractive hybridization and Q-PCR correlated for all tested
genes, except for MEN1, which showed only weak differences on the library screening blots.
Table 3 gives the extent of differential expression for all tested genes. Four genes showed less
than twofold difference, which was considered too low for reliable determination of differential
expression. The differences in expression between time points for the remaining genes varied
from 2- to 106-fold (linear values). Although possibly interesting, expressed sequence tags and
genes that were only predicted were not validated by quantitative PCR.
Some of the identified differentially expressed genes presumably represent differences in
maturation stages between undifferentiated blasts at blast crisis and more mature myeloid
progenitors at diagnosis and late chronic phase. Their identification demonstrates the power of
the suppression subtractive hybridization technique; however, these genes are probably
irrelevant to the disease transformation process. These genes include: MPO, LYZ, encoding the
cytoplasmic enzymes myeloperoxidase and lysozyme respectively; PRG1, encoding a
proteoglycan which is stored in more mature myeloid cells;12 FPR1, a neutrophil G-protein
coupled receptor;13 S100A8, encoding calgranulin A which is abundantly expressed in neutrophil
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cytoplasm.14 The upregulation of LARS (leucyl tRNA synthetase)15 was interpreted as reflecting
increased transcriptional activity in blast crisis cells.
The differential expression of the other genes was verified by Q-PCR in an additional group of
CML patients. At least 6 (range 6 - 47) individual patient samples were analyzed for every time
Table 2b. Primer sequences Q-PCR.
Table 3. List of differentially expressed genes in
index patient and level of differential expression.
* Between brackets: loge -transformed difference
** Genes hypothetically encoding proteins
*** Reverse to subtraction result 
**** Orf: open reading frame
ND: not done, NS: non-significant, D: diagnosis,
LCP: late chronic phase, BC: blast crisis
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point of the disease for each gene. For 14 genes, subtraction results could not be confirmed in
this additional group of patients. However, YWHAZ, GAS2, IL8, IL6, PBEF1, CCL4, SAT and
MMRN showed a similar pattern of expression in the additional patient samples as was found in
the index patient. Figure 1 A-H shows the median relative expression levels of these genes in
this set of patient samples as observed in samples taken at diagnosis, late chronic phase or
blast crisis. These consistently differentially expressed genes will be discussed in more detail
below.
Apoptosis related genes 
Delayed apoptosis is a feature of early phase CML,16 but even more so of advanced disease
stages in which upregulation of BCR-ABL is a common event.17 YWHAZ (tyrosine 3-monooxyge-
nase/tryptophan 5-monooxygenase;14-3-3 zeta protein) is involved in the regulation of
apoptosis. Subtractive hybridization revealed higher expression in late chronic phase than at
diagnosis. Q-PCR results in the group of CML patients at three disease stages show that
YWHAZ expression peaks at late chronic phase (Figure 1A). YWHAZ has a central role in the
regulation of apoptosis, cell growth and cycling by modulating the functional activities of 
several key signaling proteins.18 For instance, the pro-apoptotic protein BAX can bind to the
YWHAZ protein, which leads to increased levels of homo-dimerized BCL2 and hence to
decreased apoptosis. A YWHAZ family member, BAP-1, shows 80% homology with YWHAZ
and is essential for the transforming properties of BCR-ABL.19 Although this association has not
been described for the YWHAZ protein, it may similarly be involved in the BCR-ABL induced
apoptosis resistance.
Figures 1A-H. Median relative expression levels of consistently differentially expressed genes as observed in
samples taken at diagnosis, late chronic phase or blast crisis. 
Expression levels have been loge-transformed and are relative to the expression of GUS (Beta-glucuronidase) or 
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase). Abbreviations: YWHAZ=tyrosine 3-monooxygenase/tryptophan
5-monooxygenase; GAS2=growth arrest specific-2; IL8=Interleukin-8; IL6=Interleukin-6; PBEF1=Pre-B-cell colony-
enhancing factor precursor; CCL4=small inducible cytokine A4; SAT=spermidine/spermine-N-acetyltransferase;
MMRN=multimerin. NS=not significant. D=diagnosis; LCP=late chronic phase; BC=blast crisis.
Figure 2. Median expression levels of GAS2 in myeloid
versus lymphoid or biphenotypic blast crisis.
Expression levels have been loge-transformed and are
relative to the expression of GUS.
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The protein product of the GAS2 (growth arrest specific-2) gene, whose expression has not
previously been reported in hematopoietic cells, is a caspase-3 substrate. It plays a role in the
regulation of microfilament and cell shape changes during apoptosis.20 Overexpression of the
protein stabilizes P53 and thereby increases cell susceptibility to apoptosis following DNA
damaging agents.21 Therefore, the upregulation of GAS2 in blast crisis compared to diagnosis
seems to be contradictory to its known physiological role. Q-PCR in a large group of patients
shows a remarkable difference in expression between diagnosis and blast crisis, as was found
by subtractive hybridization, but even more between late chronic phase and blast crisis (see
Figure 1B). Separating blast crises into myeloid versus lymphoid or biphenotypic reveals higher,
though non-significant GAS2 expression in myeloid crises (Figure 2). As P53 mutations mainly
occur in myeloid blast crisis, we hypothesized that high GAS2 expression might represent P53
abnormalities. Therefore, exons 5-9 of the P53 gene (the hotspot region for mutations) were
sequenced in the blast crisis sample of the index patient, but no mutations were found (result
not shown).
Cytokines
Some genes encoding proliferation-inducing cytokines and interleukins were also identified as
being higher expressed in late chronic phase than at both diagnosis and blast crisis, such as IL8.
Consistent results were found with Q-PCR in other CML patients (see Figure 1C). IL8 has
mitogenic, motogenic and angiogenic properties.22 A high level of expression has been related
to disease progression in CLL23 and it was strongly linked to refractory disease in T-ALL.24 If high
expression in late chronic phase CML has relevance for CML transformation as well is unknown
but warrants further study.
A second cytokine gene, IL6, was much higher expressed in late chronic phase compared to
both diagnosis and blast crisis in the index patient, as well as in the additional group of patients
(see Figure 1D). In agreement with this, it has previously been shown that IL6 levels were higher
in cultures of CML monocytes of treated CML than those obtained at diagnosis and at blast
crisis.25 At blast crisis, levels were very low, although the difference with late chronic phase was
not significant. Constitutively active IL6 induces continuous JAK/STAT activation in AML.26 This,
in turn, induces cell cycle transition through upregulation of cyclins D2, D3, A, and cdc25A and
the concomitant down-regulation of p21 and p27.27 It may be hypothesized that constant IL6
stimulation in chronic phase CML induces increased proliferation, which could predispose to
secondary abnormalities that can culminate in blast crisis. Otherwise, low IL6 levels at 
diagnosis and at blast crisis may be considered to reflect inadequate monocyte function.25
PBEF1 (Pre-B-cell colony-enhancing factor precursor) is, like IL6 and IL8, highest expressed in
late chronic phase (Figure 1E). Previous reports showed the gene to be expressed in bone
marrow stromal cells and in activated lymphocytes. PBEF1 stimulates the growth of pre-B-cell
colonies but no effect was seen on myeloid or erythroid colonies.28 Using a comparable
suppression subtractive hybridization as ours, it was found to be upregulated in colonic
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carcinoma samples as compared to normal mucosa.29 What role it may play in CML cells remains
speculative, but if PBEF1 also increases proliferation of myeloid progenitors, this might, as
already stated for IL6, facilitate the occurrence of secondary genetic events.
Remarkably, also the CC chemokine gene CCL4 (“small inducible cytokine A4”; SCYA4; MIP-1
beta) showed highest expression at late chronic phase, while expression at both diagnosis and
blast crisis were clearly lower (see Figure 1F). CCL4 is an antagonist of the proliferation-inhibiting
effect of MIP-1 alpha30 and induces cytotoxic T- and NK-cell proliferation and cytolytic capacity.31
Other genes
Higher expression of the growth- and cell cycle-associated gene SAT (spermidine/spermine 
N-acetyltransferase) in late chronic phase compared to diagnosis was found at subtractive
hybridization. Q-PCR in additional patient samples reveals that expression at diagnosis is lowest
compared to the other two disease stages (see Figure 1G). SAT encodes a rate limiting enzyme
in the catabolism of polyamines, substances involved in many cellular processes, including
chromatin condensation, maintenance of DNA structure, RNA processing, translation and
protein activation. Upregulation of SAT leads to apoptosis in melanoma cells.32 Its role in CML
remains speculative.
The gene for MMRN (multimerin), encoding a specific factor V/Va binding protein, was
upregulated at blast crisis compared to late chronic phase according to the subtractive
hybridization and this was confirmed by Q-PCR in the additional patient samples (Figure 1H).
The expression levels at diagnosis were comparable with those at late chronic phase. Multimerin
is a constituent of platelet alpha granules33 and thus elevated expression of this gene in blast
cells may reflect differentiation into the megakaryocytic lineage.33 However, immunophenotyping
showed negativity for the megakaryocytic marker CD41 on the blasts of all five patients where
it was tested. 
Previous approaches to elucidate mechanisms of disease transformation with similar techniques
as described by us found downregulation of, among others, PIASy, a potential inhibitor of the
STAT proteins with apoptosis-promoting and growth suppressive properties34 and upregulation
of PRAME35 in blast crisis progenitor cells derived from the bone marrow. In another, probably
less appropriate experiment, overexpression of ribosomal proteins, of a C-MYC related protein
and of a cellular adhesion molecule was found in K562 cells, serving as a model of CML blast
crisis, compared to primary CML spleen cells. This comparison may have revealed many
aspecific differences in gene expression that are unrelated to disease progression, but are due
to secondary clonal aberrations that may occur during long term culture of the cell line or to
specific individual properties of the cells that constitute the K562 cell line. None of these studies
showed overlapping results with each other or with our findings; further data on the role of these
genes in CML is lacking.
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We are aware that the gene expression profiling as performed by us potentially harbours 
several pitfalls. Firstly, we used peripheral blood samples from only one patient for the
subtraction procedure. This may have led to patient-specific changes in gene expression.
However, a significant number of highly interesting genes showed a comparable expression pat-
tern in a larger set of patients.
Secondly, differences in the cellular composition of mononuclear cell fractions between the
separate phases existed and may have caused irrelevant differential expression results. At
diagnosis of CML, more myelocytes and fewer monocytes compared to late chronic phase are
present and these were part of the mononuclear cell fractions studied by us. This is also true for
the subtraction analyses comparing late chronic phase with blast crisis or diagnosis and blast
crisis since the blast crisis samples typically have high blast counts. However, differential
expression of blasts at blast crisis versus more mature myeloid cells at diagnosis or late 
chronic phase may actually reveal genes that are in fact responsible for the maturation block;
therefore we feel that our approach is at least complementary to others where progenitor cells
are used to perform gene expression comparisons.
Thirdly, differences in expression levels may also result from treatment. For most of the 
identified genes no literature data exist on the potential effect of hydroxyurea or interferon alpha
on their expression. Only for IL8 it has been described that treatment with interferon alpha of
CML cells and with hydroxyurea for sickle cell anemia decreases its expression,36,37 which is
contradictory to what we found by subtractive hybridization and Q-PCR. As patients cannot be
left untreated when a diagnosis of CML is made, drug-induced changes are an inherent problem
of investigations into the causes of disease transformation using patient samples. Moreover,
genetic events that are responsible for disease transformation occur while patients are on
medication.
We used peripheral blood samples for the subtraction procedure. Although the use of bone
marrow samples may also appear appropriate in these experiments, a draw-back of bone
marrow aspirates is the unquantifiable contamination with peripheral blood cells. These may
have different properties compared to bone marrow derived cells, and as immature cells are only
present in the peripheral blood in large numbers at diagnosis and at blast crisis, comparisons
between bone marrow cell populations taken at different stages of the disease may reveal
differential expression reflecting the nature of the cells rather than specific changes reflecting
stage of disease. Secondly, many CML patients have inaspirable bone marrow due to fibrosis,
leading to selection of patients if only bone marrow cells would be used.
We conclude that several genes involved in apoptosis regulation and cell proliferation, 
processes that are thought to play a role in the transformation process, as well as genes
encoding cytokines, are differentially expressed in subsequent disease stages. This interesting
set of genes can be considered as a starting point for further research on causes of disease
transformation in CML and may lead to new targets in the treatment of resistant CML.
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Recently, Hantschel et al demonstrated BCR-ABL induced upregulation of IL8 and of CD69 in
the CML blast crisis derived K562 cell line.1 In four newly diagnosed CML patients they also
found higher serum IL8 levels compared to four healthy volunteers. After the start of imatinib in
the CML patients, IL8 levels decreased, but rose subsequently in two of the tested patients.
Apart from possibly being implicated in disease progression, the authors suggested that IL8 may
be an early marker for treatment response in CML.
These results seem in contrast to what we previously reported on the differential expression of
IL8 at separate phases of CML.2 In a large number of diagnostic samples, collected in the 
pre-imatinib era, we detected low IL8 mRNA levels in the mononuclear cell (MNC) fraction, while
in chronic phase, when patients were treated with interferon-alpha or hydroxyurea, higher levels
were found. In blast crisis samples, levels were low again. We considered the high IL8 levels in
chronic phase an interesting finding, since IL8 is linked to tumor progression: high levels of IL8
were related to shorter survival in chronic lymphocytic leukemia3 and to refractory disease in
acute T-lymphoblastic leukemia.4 The low levels in blast crisis were however in apparent contrast
with this hypothesis.
To further clarify these observations, we tested IL8 production by measuring mRNA and
intracellular protein levels in cellular subfractions of untreated, newly diagnosed CML chronic
phase patients, of patients in blast crisis and of normal controls. Our results indeed suggest that
IL8 production in CML blast crisis cells is higher than in normal cells, however, contrary to what
is suggested by the Hantschel data, IL8 in chronic phase cells is not increased compared to
normal. Moreover, our results question the relevance of the IL8 levels and their differences in cell
subsets in CML as they seem very low compared to LPS-induced levels. Lastly, they suggest
that BCR-ABL is not implicated in IL8 upregulation. 
After informed consent, we isolated peripheral blood mononuclear cells using density gradient
centrifugation with Ficoll-Paque (1.077 g/ml) from newly diagnosed CML patients, from patients
in CML blast crisis and from healthy controls. CD34+ progenitor cells and CD14+ monocytes
(being the most important source of IL8 in peripheral blood) were subsequently selected after
incubation with anti-CD34 and anti-CD14 micro beads, respectively, using an Automacs device
(Miltenyi Biotech, Germany). The purity of the CD34 and CD14 based isolations as measured by
flow cytometry was always above 95%. All heparin coated blood collection tubes were tested
lipopolysaccharide (LPS) negative in a Limulus amebocyte lysis assay. Quantitative PCR for IL8
was performed as described previously.2 Intracellular IL8 protein detection was performed on a
FACSCalibur flow cytometer (BD Biosciences, Erembodegem, Belgium) after incubation of cells
with Brefeldin A (10 ug/ml), subsequent permeabilization with FACS Permeabilization Solution
(BD Biosciences) and staining with anti-IL8-PE antibodies (Dako Netherlands, Heverlee,
Belgium). Phospho-CRKL was measured by flow cytometry as described previously.5 All cell
subsets were kept on ice and processed directly after blood collection unless otherwise stated.
In agreement with what we expected on the basis of IL8 measurements in the supernatant of the
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K562 blast crisis cell line by Hantschel et al, we found clearly higher IL8 mRNA production in the
CD34+ cell fraction of blast crisis (BC) patients (all myeloid), both compared to normal controls
as well as to newly diagnosed CML chronic phase patients (Figure 1), although the difference
was not statistically significant when the mononuclear fraction of BC (14/18 myeloid; blasts
39%; range 9-85) was compared with that of normal controls. However, and in contrast to what
was suggested by Hantschel et al, neither at the level of CD34+ cells, nor at the level of the
unselected MNC, were IL8 mRNA levels higher in the CML chronic phase cells than in the 
normal controls.
On the other hand, CML CD14+ selected monocytes produced more IL8 than the control
monocytes, both at the mRNA level as well as at the protein level (Figure 2). Imatinib 3 ug/ml,
when applied for four hours, strongly inhibited phospho-CRKL expression (the functional 
read-out of BCR-ABL kinase activity; data not shown), but did neither change IL8 expression in
unstimulated CML CD14+ monocytes nor inmonocytes of normal controls (data not shown).
Serum or supernatant levels of IL8 were not assessed.
For better interpretation of the relevance of the detected IL8 levels and their differences in cell
subsets and disease phases, we then assessed the intrinsic inducibility of IL8 mRNA. To that
Figure 1. IL8 mRNA expression (as measured by 
quantitative PCR and represented as the percentage
of the GAPDH control gene copy number) in
mononuclear cell and CD34+ fractions of controls,
newly diagnosed CML patients and patients in blast
crisis. 
The number of samples tested is given on the X-axis. 
Error bars represent standard error of the mean. P-values
for differences are indicated. Solid hooks: differences
between mononuclear cell (MNC) subsets, dotted hooks:
differences between CD34+ subsets. All statistical
analyses by Mann-Whitney U-test for non-parametric
variables.
Figure 2. IL8 mRNA (as percentage of the number
of GAPDH copies) and protein expression
(arbitrary fluorescence units as measured by FACS
and analyzed using CellQuest Software) in the
CD14+ selected monocyte fraction of controls and
newly diagnosed CML patients.
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end, we used stimulation with LPS. This resulted in very strong IL8 increases in the CD14+
fraction of controls (Table 1). In fact, the steady state levels as we found in the separate
subfractions of cells without LPS induction as described above and the differences between cell
subsets and between CML versus normal controls now appeared almost negligible, or in any
way very low compared to the induced levels. Remarkably however, we detected a pronounced
difference in the inducibility of IL8 mRNA and protein by LPS (Table 1) between the CML 
samples and the normal controls, the latter responding clearly stronger to LPS. We then tested
whether this reduction in LPS induced IL8 upregulation was related to BCR-ABL activity.
Preincubation with imatinib 3 ug/ml for four hours did however not restore decreased LPS
responsiveness in CML CD14+ cells (data not shown). 
In summary, in agreement with the data presented by Hantschel et al, IL8 levels in CD34+ BC
cells are higher than both normal and CML chronic phase CD34+ cells. However, the IL8 levels
and their differences between these and other cell subsets are, also on the protein level, very
low, questioning the relevance for the disease process. Moreover, the differences that were
found seem not to be induced by BCR-ABL kinase activity. However, at diagnosis, CML cells
show reduced responsiveness to LPS compared to normal controls, but, again, BCR-ABL
activity appears unrelated to this phenomenon.
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Chronic myeloid leukemia (CML) is characterized by a reciprocal translocation between
chromosomes 9 and 22 resulting in the BCR-ABL fusion gene. The resulting BCR-ABL fusion
protein has constitutive tyrosine kinase activity and can be targeted by imatinib mesylate (IM).
IM induces complete cytogenetic remission in a majority of patients. However, molecular
remissions are found in 5-15% of IM-treated patients. BCR-ABL is not only a critical oncogene,
but a CML-specific antigen that can evoke immune responses as well. Lack of T cell responses
sufficient to protect against CML may be related to many factors including inadequate Ag
presentation and co-stimulation by CML cells. Dendritic cells (DCs), the most potent antigen
presenting cells, can be generated from CML cells in vitro. CML-derived DCs should be able to
present leukemia-associated antigens to the immune system. Intradermal vaccination with in
vitro generated autologous CML-derived DCs in patients in late chronic phase CML resulted in
an anti-leukemia immune response as demonstrated by a strong delayed type of hypersensitivity
(DTH) response.1 Recently, BCR-ABL-specific peptide vaccination of IM or Interferon-a-treated
patients resulted in the induction of peptide-specific T cell responses and even reduction of
residual cytogenetic disease.2 Both studies underscore that immunotherapy deserves further
exploration to control or eradicate minimal residual disease (MRD) in CML. 
In this study we analyzed in vitro whether continuation of IM treatment during leukemia-derived
DC-based vaccination regimens might affect BCR-ABL positive CML-DCs. Aiming at exploring
CML-DC-based vaccination, we analyzed the effect of IM on the biological function of CML-DCs
rather than the effect of the presence of this compound during the generation of CML-DCs. We
A B
Figure 1. Influence of Imatinib on the immunophenotypic profile of immature and mature CML-derived DCs.
CD40-expression was found to be most constant within the DC population. So, except for CD40, all percentages are
represented as percentage of total DC-population defined as CD40
bright
. Light scatter gating prior to analysis excludes 
interferences of other CD40-expressing populations as activated B cells and monocytes. Results for immature CML-DCs
are depicted in panel A. and mature CML-DCs are depicted in panel B. Y-axes display antibodies, X-axes percentages.
White bars represent immunophenotype in absence of imatinib, gray and black bars depict the immunophenotype of DCs
after 20 h. in the presence of 1 and 5 uM imatinib, respectively. Results are presented as mean±SEM (n=5). Note:
Immature and mature CML-DCs were obtained from a different set of patients.
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focused on properties important in DC-based immunotherapy, i.e. survival, phenotypic
appearance, migration and T cell stimulation. 
Blood and bone marrow samples from 19 patients newly diagnosed with CML (untreated;
positive for the BCR-ABL fusion gene) and bone marrow (n=3) and leukapheresis material from
G-CSF-mobilized healthy donors (n=5) were obtained after informed consent (according to the
protocol approved by the local ethical review board). CML-DCs were generated from CML
samples using GM-CSF, TNF-alpha, and IL-4 as previously described.1 Normal CD34+ cells were
isolated from leukapheresis material or bone marrow aspirates of healthy donors by 
immuno-magnetic column separation using CD34-microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany). CD34+ derived DCs were generated with cytokines used in CML-DC
cultures supplemented with SCF and Flt3L as described previously.3 Maturation of DCs was
induced by additional 48 h. of culture with TNF-alpha, IL-1ß, IL-6 and PGE2.3 Ficoll-separated
CML-samples consisted of 6.1±5.5% lymphocytes (mean±SD; n=19), 3.9±3.2% progenitor
Figure 2. Effect of imatinib on migration of leukemic and normal DCs generated in absence of imatinib.
Migration towards medium, CCL5 (RANTES: 100 ng/ml), formyl-methionyl-leucyl-phenylalanine (fMLP: 10
-8
M), CCL19
(MIP-3beta: 300 ng/ml) and CXCL12 (SDF-1alfa: 100 ng/ml) is depicted for immature CML-DCs (panel A, 0 and 1 uM: n=12,
5 mM: n=5) and normal immature CD34-DCs (n=4, panel C). Migration towards medium, CCL19 and CXCL12 is depicted for
mature CML-DCs (n=5, panel B) and normal mature CD34-DCs (n=4, panel D). White bars represent migration in absence
of imatinib, gray and black bars depict migration in the presence of 1 and 5 mM imatinib, respectively. Y-axis represents
percentage of cells migrated as compared to the initial number of cells. Results are presented as mean±SEM; * p<0.05 as
compared to spontaneous migration in corresponding imatinib concentrations.
A
DC
Bimmature DC mature DC
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cells, 3.2±3.1% monocytes and 83.1±10.1% myeloid cells. After culture 41.5±25.5% viable cells
(mean±SD, n=19) were left as compared to initial cell numbers and this cell population 
contained 66.3±17.0% DCs (n=19). No outgrowth of B or T cells was observed. CML-DCs
displayed morphological characteristics of DCs: a typical veiled appearance, while FISH 
analysis (LSI bcr-abl Dual-Color Fusion Probe, Vysis Inc, Downers Grove, IL) confirmed the
presence of BCR-ABL. Longevity of BCR-ABL positive DCs in the presence of IM is a critical
factor in the magnitude of the T cell response upon vaccination during IM treatment. Since DCs
migrate in approximately one day from the skin to the draining lymph nodes, we chose to expose
the DCs to 0, 1, 5, and 10 uM IM (kind gift of Novartis Pharma, Arnhem, The Netherlands) for the
last 20 h of culture. This resulted in a dose-related decrease in viable cell number (mean
reduction 10% (n=10, p=0.043), 20% (n=5, p=0.043) and 24% (n=5) for 1, 5 and 10 uM IM,
respectively, as compared to cultures without IM), although DC-percentages were not affected.
Thus, total DC-yields decreased in a similar manner (mean reduction 15%, 22% and 42% for 1,
5 and 10 uM IM, respectively, as compared to in absence of IM). It is known that BCR-ABL is
down-regulated at the protein level during differentiation of CML blasts towards DCs.4 Hence,
CML-DCs might be less vulnerable to IM than CML cells. This is evidenced by the survival of a
majority of CML-DCs (approximately 80%) in intermediate concentrations of IM (<5 uM).
DC-culture from CD34+ cells derived concentrations of IM from healthy individuals resulted in an
approximately 2.5-fold increase in total cell numbers, the percentage of DCs was 43±22%
(mean±SD, n=5). Imatinib did not affect the yield of normal CD34+-derived DCs. 
Cultured cells were analyzed by flow cytometry for the expression of CD45, CD34, CD1a, CD14,
CD40, CD80, CD86, HLA-DR, CD83, CD54, CCR7, CXCR4, CD3, CD19 and CD56. After two
weeks of culture in GM-CSF, TNF-alpha and IL-4, most DCs had an immature phenotype: low
CD83, CD86 and CCR7 expression. Short exposure (20 h) of immature CML-DCs to IM did not
affect the expression of co-stimulatory molecules (CD40, CD80, CD86), adhesion molecules
(CD54), HLA-DR, CD83 (Figure 1A), chemokine-receptors CCR5 and CXCR4; CCR7 was not
expressed on immature DCs (data not shown). Exposure of both immature CML-derived and
Figure 3. Effect of Imatinib on proliferation of T cells in 
an allogeneic MLR.
Stimulator and allogeneic responder T cells were cocultured 
in several concentrations of imatinib (depicted on the X axis). 
T-cell proliferation was assessed by incorporation of
[
3
H]thymidine. Percentages on the Y axis depict relative T-cell
proliferation in the presence of imatinib as compared to
proliferation in absence of imatinib (adjusted to 100%).
Stimulation was initiated by ConcavalinA (white bars, n=12),
normal immature CD34-DCs (light gray bars, n=3), immature
CML-DCs (shaded gray bars, n=8), normal mature CD34- DCs
(dark gray bars, n=3) and mature CML-DCs (black bars, n=5), 
all generated in absence of imatinib. Results are presented as
mean ± s.e.m.; *P<0.05 as compared to proliferation in the
absence of imatinib.
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CD34+ derived DCs to a pro-inflammatory cytokine cocktail and PGE2 resulted in significant
upregulation of CD40, CD80, CD86, HLA-DR, CD83 and CXCR4 expression (p=0.043, except for
CD40: p=0.080). Comparing immature and mature DCs from the same set of patients or healthy
donors revealed that maturation induction was more profound in CD34-DCs than in CML-DCs
as reflected by a significant higher surface expression of CD83 and CCR7 (Wilcoxon signed
ranks test, both p=0.025, data not shown). Similar to data for immature CML-DCs, the
immunophenotype of PGE2-matured CML-DCs was not affected by IM (Figure 1B). No
differences were observed regarding the immunophenotype of immature and mature normal
CD34-DCs in presence and absence of IM (data not shown).
DCs can only initiate an immune response after migration to the T cell zones of the lymph node.
The migratory capacity of DCs was analyzed using a transwell system as described previously.3
Analysis was performed in the presence or absence of 1, 5 or 10 uM IM for 16 h; cells were not
treated with IM before entering the migration assay. Migratory capacity of immature CML-DCs
was low (Figure 2A); although, the migration profile of immature CML-DCs did not differ from that
of immature CD34-DCs (Figure 2C). Chemokine-directed migration of CML-DCs increased after
maturation-induction (Figure 2B). CCL19-induced migration significantly correlated to the
expression of chemokine receptor CCR7 (p<0.001). In contrast to mature CD34-DCs, mature
CML-DCs hardly upregulated this receptor (in mature CML-DCs: mean CCR7 expression 11%,
in mature CD34-DCs: mean 37%). As a result, mature CML-DCs showed significantly lower
migratory capacity towards CCL19 as compared to normal mature CD34-DCs (Figure 2D,
p=0.025). No differences were seen regarding CXCL12-induced migration of mature DCs. The
presence of IM did not affect migration of CML-DCs as well as normal CD34-DCs. More
important in view of CML-DC-based immunotherapy, migration of CML-DCs was not impaired
in the presence of IM. The T-cell stimulating capacity of CML-DCs in the presence of IM was
tested in a standard allogeneic mixed leukocyte reaction (MLR). In brief, allogeneic peripheral
blood lymphocytes, isolated from a buffy-coat from a healthy donor, and irradiated DCs (30 Gy),
were co-cultured for five days in continuous presence of 0, 1, 5 or 10 mM IM and subsequently 
pulsed for 18 h with [3H]thymidine (Amersham Pharmacia, Biotech, Buckinghamshire, UK).
[3H]thymidine-incorporation was analyzed in a liquid scintillation counter (Wallac, Turku, Finland).
Exposure of IM-free cultured immature CML-DCs to IM reduced the allo-stimulatory capacity in
a dose-dependent manner (Figure 3, mean reduction 4% (n=15), 49% (n=8, p=0.012) and 78%
(n=8, p=0.012) at 1, 5 and 10 uM IM, respectively, as compared to T cell proliferation in 
absence of IM). Increasing the IM concentration by steps of 0.25 uM showed that T cell
responses towards CML-DCs remained rather stable up to 2.25 uM IM and then rapidly
declined. Mature CML-DCs seemed to be more strongly affected by IM than immature CML-DCs
(Figure 3), but no significant decline in allo-stimulatory capacity could be detected. The T cell
stimulatory capacity of normal CD34+derived DCs declined at a concentration of 5 uM IM,
although significance was not reached. Part of the decrease in the DC-induced T cell
proliferation in the presence of high concentrations of IM might be due to a direct negative effect
of IM on T cell proliferation, since a-specific Concavalin A-induced T cell proliferation was
70
Jps Chapter 3 en 4 DEF  19-10-2009  11:54  Pagina 70
decreased at a concentration of 10 uM IM (mean reduction 25%). These data are supported by
recent reports that showed inhibition of T cell proliferation in vitro and reduction of expansion of
primary cytotoxic T cells in the presence of IM.5,6 T cell responses might be impaired but not
impossible in the presence of IM. Recently, Bocchia et al. showed the feasibility of evoking
immune responses to peptide vaccines in IM-treated patients.2
To summarize, we showed that IM reduced the CML-DC yield in a dose-dependent manner,
although the majority of the CML-DCs survived. IM did not affect the immunophenotype,
migration profile and T cell stimulatory capacity (below 2.5 uM IM) of the CML-derived DCs.
Studies on pharmacokinetics of IM administered in chronic phase revealed a steady state
concentration of approximately 2 uM with peak concentrations of 4.6 uM at a 400 mg standard-
dose level.7 IM concentrations used in cellular assays in vitro correspond more with total than
with free in vivo plasma levels of IM. Moreover, IM concentrations in plasma may not even be a
reliable estimate of intracellular and tissue concentrations. Keeping in mind these limitations, we
conclude that at standard and even at high dose IM the function of CML-derived DCs is only
minimally affected. Our data indicate the feasibility to continue IM treatment during CML-DC-
based vaccination regimens.
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ABSTRACT
Inherent tyrosine kinase inhibitor (TKI) insensitivity of CML hematopoietic stem cells prevents
eradication of the disease by these drugs and is probably involved in development of TKI
resistance. To improve treatment results, more knowledge about CML stem cells is therefore
needed. Previously, these cells could only be identified indirectly by using culture techniques.
We now present a new flowcytometric approach to directly distinguish CML stem cells from their
normal counterparts within single patient samples. In 24 newly diagnosed CML patients CML
CD34+CD38- stem cells could be discriminated from normal stem cells by higher CD34 and
CD45 expression and different forward/sideward light scatter properties. In addition, expression
of CD7, CD11b and CD56 helped to distinguish malignant from benign stem cells. FISH analysis
on FACS sorted cells proved that populations were BCR-ABL positive or negative and long term
liquid culture assays with subsequent CFU assays and FISH analysis proved their stem cell
character. Patients with a large proportion of non-leukemic stem cells had significantly lower
clinical risk scores (Sokal, Euro), than patients with few remaining normal stem cells. This new
technique will expand our possibilities to identify new CML stem cell specific targets and may
improve efficacy assessment of CML treatment.
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INTRODUCTION
Major breakthroughs in chronic myeloid leukemia (CML) research have led to a revolution in
therapy by the introduction of a relatively specific inhibitor of BCR-ABL activity, imatinib (IM) and,
more recently, to even more potent tyrosine kinase inhibitors (TKIs) like nilotinib and dasatinib.
In chronic phase, these drugs induce complete hematologic responses in virtually all patients,
while complete cytogenetic responses are achieved in almost 90% and progression free survival
in 84% of patients.1-3 In a large clinical trial, patients who attained a reduction of the BCR-ABL
transcript level that was more than 1000-fold lower (major molecular response, MMR) than that
at diagnosis had durable responses without any event of progression in a large prospective
clinical trial.1
Unfortunately, not all patients attain such a favorable response. Primary or secondary resistance,
defined at the hematological level, may develop in approximately 4% of chronic phase cases,
while cytogenetic resistance may be observed in up to 10-15% of patients.1,4 Besides, a small
number of patients presents in advanced phases of the disease, where the efficacy of TKIs is
limited. Most important, TKI therapy cannot eradicate the disease, because leukemic stem cells
appear to be inherently resistant against these compounds. This probably relates to several
mechanisms. Firstly, several authors demonstrated a strong increase in BCR-ABL mRNA- and
protein expression (up to 100-fold and 3-10 fold, respectively) in the most primitive stem cell
compartment compared to more committed progenitor cells.5-7 This may lead to insufficient
inhibition of its kinase activity by IM and thereby to reduced cell killing by the drug. The high
BCR-ABL expression parallels the autocrine production of interleukin-3 and GMCSF which is
only present in the most primitive stem cells.7 Possibly, this autocrine loop offers additional
protection of stem cells against IM. Secondly, IM influx into the most primitive stem cells is
hampered by their very low expression of Oct-1, which pumps IM into the cell.8,9 Thirdly, the
mRNA levels of the ABCB1 (also known as P-glycoprotein) and ABCG2 (also called BCRP) efflux
pumps for which IM was shown to be a substrate in several studies,10-12 were two fold higher in
the most primitive cells compared to more mature progenitors.7,13 This may explain low sensitivity
of primitive stem cells to both IM as well as to conventional chemotherapeutic drugs.
For development of more effective strategies that are able to eliminate these CML stem cells,
better insight in their functional properties is needed. In vitro long term culture experiments and
fluorescent in situ hybridization (FISH) analysis or RT-PCR have revealed that both BCR-ABL
positive and negative stem cells co-exist in the CD34+CD38- stem cell compartment in CML,
however, up to now only limited information has become available on how to study these
separately in a direct way in freshly obtained diagnosis samples. 
Recently, we were able to demonstrate that malignant and benign stem cells in AML can be
discriminated in one sample by using flow cytometry.14,15 Using a similar approach, we now show
for the first time that malignant and benign stem cells in CML patients can also be distinguished
on the basis of light scatter properties, CD34 and CD45 expression and hematopoietic lineage
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marker expression. This new finding opens the way to facilitate stem cell specific target
discovery and allows to assess the number of residual malignant stem cells under treatment with
TKIs which may be an important parameter for the evaluation of their therapeutic efficacy.
DESIGN AND METHODS
Samples from patients and healthy volunteers; cell preparation
After informed consent and according to institutional guidelines, peripheral blood and bone
marrow were obtained from newly diagnosed, untreated CML patients. Mononuclear cells were
isolated by density gradient centrifugation using Ficoll-paque (1.077 g/ml; Amersham
Biosciences, Freiburg, Germany) followed by a red cell lysis step with lysis buffer (155 mM
NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.4) for 10 minutes at 4oC, or by direct lysis only.
For control experiments, bone marrow samples from eight healthy volunteers were used. This
study protocol was approved by the Central Medical Ethics Committee, Erasmus University
Rotterdam, The Netherlands.
CD34+ cell selection
CD34+ cells were isolated using CD34 Reagent and the AutoMacs automated selection device
(both from Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s
instructions. Purity as assessed by flow cytometry was always more than 95%. In several cases,
long term clonogenic assays on sorted populations were done on thawed CD34+ cells that had
been cryopreserved in RPMI/20% FCS/10% DMSO.
Fluorescence-activated cell sorting
Freshly isolated mononuclear cells or purified CD34+ cells were incubated with monoclonal
antibodies for 15 minutes at room temperature, washed once in PBS containing 0.1% HSA and
analyzed by flow cytometry. Anti-CD34 phycoerythrin-Cy7 (PE-Cy7), anti-CD45 fluorescein
isothiocyanate (FITC), anti-CD38 allophycocyanin (APC), anti-CD7-phycoerythrin (PE), anti-
CD11b-PE, anti-CD19-PE, anti-CD22-PE, anti-CD56-PE and Via-Probe (7-amino-actinomycin
D, 7AAD) were all from BDBiosciences (Erembodegem, Belgium). Anti-CD2-PE and anti-CD5-PE
were from DAKO (Heverlee, Belgium). Anti–CLL-1-PE and anti-DiNitroPhenol (DNP) were from
Crucell (Leiden, the Netherlands). Every test tube contained anti-CD45-FITC, anti-CD34-PE-
Cy7, anti-CD38-APC, 7-AAD and one of the PE-labeled antibodies. IgG1-PE was used as a
control for PE labeled anti-CD2, -CD5, -CD19, -CD56 and -CD7, IgG2a-PE was used for PE-
labeled anti-CD11b and IgG2b for CD22-PE. For anti-CLL-1, DNP-PE was used as a control.
PBS was used as a control for anti-CD34-PE-Cy7, CD38-APC and -CD45-FITC. 7-AAD was
included to gate out apoptotic/dead cells before stem-cell assessment. Data acquisition was
performed using a three laser FACSCanto II flow cytometer (BD Biosciences). For data analysis
FACSDiva software (BD Biosciences) was used. 
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FACS gating strategy and FACS sorting 
By means of five-color fluorescence-activated cell sorting (FACS) analysis, light scatter
properties and expression of lineage marker (CD2, CD5, CD7, CD11b, CD19, CD22 and CD56)
and CLL-1 were studied. These single markers are absent on normal CD34+CD38- cells.14 The
gating strategy to identify CD34+CD38- stem cells is shown in Figure 1 (next page). Using this
gating strategy, cells were sorted on a FACSAria cell sorter (BD) directly onto glass slides, or into
PBS/0.1% HSA in case further culture experiments were planned. 
Colony forming unit (CFU)- and long term suspension culture assays
For CFU assays, sorted cell populations were cultured in semisolid medium containing alfa-
methylcellulose (Methocult GF H4434; StemCell Technologies, Vancouver, Canada) at 37°C in
5% CO2 in a humidified incubator. The number of colonies was counted after 14 days of 
culture. Colonies of different sizes were plucked using very thin handmade glass pipettes or a
standard laboratory pipette (Rainin, Mettler-Toledo, Tiel, The Netherlands) with 10 ul pipette tips
and spread onto glass slides for FISH analysis (see below). 
Long term stroma-free suspension cultures were performed essentially as has been previously
described.16 The sorted (sub)populations were suspended in CellGro medium (Cellgenix,
Vancouver, Canada) containing 20 ng/ml IL-3, 100 ng/ml Flt-3 ligand and 100 ng/ml SCF (all from
Pepro Tech, Basel, Switzerland) prior to plating in 96 round-bottom- or 24-well plates,
depending on the number of available cells (Greiner, Frickenhausen, Germany). Suspension
cultures were incubated at 37oC in 5% CO2 and received weekly half-medium and -cell changes
(demipopulation). If sufficient cells (>20.000) were available, CFU-assays were performed every
week. This weekly procedure was continued for up to eight weeks or until no CFU output was
present anymore. In cases where the number of cells was very low, we chose to harvest all cells
at one time point only, i.e. five weeks.
Fluorescent in situ hybridization (FISH)
For FISH analysis, slides were dehydrated in ethanol 70, 96 and 100% for 5 min at RT, fixed in
methanol/acetic acid (3:1) and stored at -20oC until use. After thawing, slides were incubated for
90 min at 37oC in 100 mg RNAse A (Boehringer Mannheim, Germany) /ml 2x standard saline
citrate (SSC) and washed three times for 2 min in 2xSSC at 37oC. Next, slides were incubated
for 10 min at 37oC in 0.01% pepsin (Sigma-Aldrich, St Louis, MO, USA) in 10 mM HCl, and
washed twice for 5 min in PBS at room temperature (RT). Afterwards, the slides were incubated
for 10 min in 3.7% formaldehyde in PBS at RT and washed twice for 5 min in PBS. Denaturation
in 70% formamide was performed at 72oC, for 5 min. Next, dehydration was performed twice for
5 min in 70% ethanol at -20oC, 5 min in 96% ethanol at RT and finally 5 min in 100% ethanol at
RT. Slides were air-dried, followed by. hybridization with the Vysis® LSI® BCR/ABL ES Dual Color
Translocation Probe (Abbott BV, Hoofddorp, The Netherlands) overnight under moist conditions
Jps Chapter 5 en 6 DEF  19-10-2009  11:57  Pagina 77
78
at 37oC. Afterwards, slides were washed in 50% formamide/2xSSC at 42oC three times for 10
min. Next, slides were washed at 42oC, for 10 min in 2xSSC, washed in 2xSSC/0.05% Tween at
42oC for 5 min and finally washed in 1xPBS at RT for 4 min. Slides were incubated for 9 min in
DAPI (Sigma-Aldrich) /PBS (0.125 ug/ml) at RT, then dehydrated in ethanol 70, 96 and 100% for
1 min at RT and air-dried. Vectashield (Vector Laboratories, Brunschwig Chemie, Amsterdam,
The Netherlands) was applied to the slides before analysis on a Zeiss fluorescence microscope.
Colonies had to consist of at least ten cells and were scored BCR-ABL positive or negative if at
least 90% of all cells from that colony were either BCR-ABL positive or –negative. The
background level of false positives for this probe-set is around 10%. Scoring was performed in
a blinded fashion to prevent bias.
Statistical analysis
Expression of lineage markers is given in arbitrary fluorescence units as generated by the FACS
Diva software. As FACS Diva software may generate mean fluorescence values of marker-
Table 1. Patient characteristics.
Group I: patient numbers 1-9; group II: 10-19; group III: 20-24. 
BCM: below costal margin
nd: not done
na: not available
1) Sokal and Euro-scores cannot be calculated, because spleen size could not be assessed 
2) assessed by FISH only
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negative populations that can have a value near or below zero, fluorescence ratios were
calculated by dividing the median fluorescence of the positive population by the fluorescence of
the negative control at the level that excludes the upper 2.5% of events. Typical values for
negative populations are below 0.35. Fluorescence ratios were compared using the Mann-
Whitney U-test for non-parametric variables (SPSS 17.0 software package, SPSS, Chicago, IL).
Sokal and Euro-scores were calculated according to Hehlmann et al17 and also compared using
the Mann-Whitney U-test for non-parametric variables. P values less than 0.05 were considered
to indicate a statistically significant difference.
RESULTS
We set out to investigate whether the previously demonstrated marker and light scatter
differences between leukemic and normal stem cells in AML14,15 could also be applied to CML.
To this end, we examined fresh bone marrow and/or peripheral blood samples of 24 newly
diagnosed CML patients by flow cytometry. Patient characteristics are shown in Table 1. Using
the gating strategy as shown in Figure 1, we could distinguish different flowcytometric patterns
on the basis of which we, for reasons of clarity, divided our patients into three arbitrarily defined
groups (indicated as I, II, III). These patterns, that were very similar between peripheral blood and
bone marrow samples, ultimately differed in the degree to which CML and normal stem cells
could be discriminated.
Group I
• Patterns of FSC/SSC and CD34/CD45 expression
Figure 1 shows an example of this group (patient number 1 in Table 1). Two clearly different
populations could be identified using the gating strategy shown in Figure 1B and C: of all events
with high CD34 and CD45 expression, 95% were also high in FSC and SSC. In contrast, 99%
of the cells with lower CD34/CD45 expression were FSClow/SSClow.
We found similar and very clear CD34/CD45 and FSC/SSC patterns in eight other cases (patient
numbers 2-9), arbitrarily defined by at least 90% of CD34high/CD45high events being FSChigh/SSChigh,
while at least 90% of CD34low/CD45low events were FSClow/SSClow. For the whole group of nine
patients in this group, the number of CD34low/CD45low cells as percentage of the total number of
viable CD34+ cells (see Table 2) was almost twice that of the CD34high/CD45high cells. Accordingly,
FSClow/SSClow cells outnumbered FSChigh/SSClow cells in this group twofold.
• Lineage marker expression
An example of lineage marker expression is shown in Figure 1D: 96% of the CD34high/CD45high
cells were CD56 positive, while the CD34low/CD45low cells were marker negative for 96%. In
agreement with this, lineage marker (CD7, CD11b and CD56) expression in an additional group
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Figure 1. Gating strategy to identify CD34
+
CD38
-
stem cells in all CML patients and FSC/SSC characteristics
and expression patterns of CD34, CD45 and lineage marker in a representative patient sample. 
A. A gate was set around all mononuclear cells, subsequently around the 7-AAD
-
(viable) cells. Next, the CD34
+
population of the CD45
dim
blast population was identified, followed by a second check for viability by backgating
into the 7-AAD/FSC plot. With the use of a PBS control, the CD34
+
CD38
-
compartment was determined. The
CD34
+
CD38
-
compartment is only around 1% of the total CD34
+
population. B. CD34
+
CD38
-
events were
backgated into a CD34/CD45 plot, (C.) a FSC/SSC plot and (D.) a CD45/CD56 and a FSC/CD56 plot. The
horizontal lines in the CD56/CD45 and CD56/FSC plots indicate the maximum level of the isotype control. Total
number of analyzed cells (P1) in this case was 8x10
5
.
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of eight patients was always negative in the CD34low/CD45low population, but (partially) positive in
the CD34high/CD45high population. Figure 2A summarizes marker expression for all nine patients.
Overall, CD56 was the marker that most clearly differed in expression between CD34low/CD45low
and CD34high/CD45high cells. In these CML samples, no aberrant expression at all was seen for a
set of markers that is important for AML stem cell identification i.e. CD2, CD5, CD19, CD22 or
CLL-1,14,18 neither in CD34high/CD45high, nor in CD34low/CD45low cells (data not shown). 
• FISH analysis
FSChigh/SSChigh and FSClow/SSClow or CD34high/CD45high and CD34low/CD45low cells were sorted for
FISH analysis in four samples. This proved that, similar to AML, the described parameters
segregate normal from leukemic long term culture initiating cells (see first part of Table 3). 
• Long term liquid cultures of CD34/CD45 and FSC/SSC defined populations
Sorted CD34high/CD45high or FSChigh/SSChigh cells were plated in long term cultures and clonogenic
capacity was measured every week for at least five consecutive weeks as far as allowed by cell
numbers. Quantitative analyses of the clonogenic capacity of the separate sorted populations
are presented in Figure 3A, which shows that in most cases the subpopulations sorted on these
characteristics have long-term clonogenic ability. Results of FISH analysis on plucked colonies
are shown in Table 4 and prove that the colonies from the cultured sorted subpopulations
represent leukemic and normal long term clonogenic cells, respectively.
Summarizing, CML and normal candidate stem cells can be clearly discriminated based on
FSC/SSC characteristics and CD34/CD45 expression patterns and in some cases by aberrant
lineage marker expression. 
Table 2. CML stem cell populations defined by CD34 and CD45 expression. 
CD34
high
/CD45
high
and CD34
low
/CD45
low
cells are presented as a percentage of total number of viable 
CD34
+
cells in group I (n=9), group II (n=10) and group III (n=5).
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A
C
B
Table 3. BCR-ABL status in sorted presumed normal 
and CML stem cells. 
Cells were sorted directly onto glass slides and subjected to
FISH as described in Patients, Materials and Methods.
a)
sorted on FSC/SSC
b)
sorted on CD34/45
c)
sorted on CD34
low
/CD45
low
/FSC
low
/SSC
low
Figure 2. Mean lineage marker expression in 
CD34
low
/CD45
low
versus CD34
high
/CD45
high
in CML patients. 
Black bars: CD34
low
/CD45
low
, white bars: CD34
high
/CD45
high
.
Typical values of negative populations are below 0.35, as
defined in “Patients, materials and methods” section. Error
bars represent SEM.
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The described subcompartments in the remaining 15 patient samples were less well defined,
mostly due to larger differences in frequency between these. In the most extreme cases, one of
the populations was virtually absent, which not only hindered the separate identification of both
populations, but sometimes even prevented assignment of the quality “normal” or “leukemic” to
the high frequency population. In order to still enable separate recognition and qualification, we
investigated whether lymphocytes might serve as an internal control for light scatter properties
and CD45 levels of CD34+CD38- cells. In addition, as external controls, we compared light
scatter properties of CD34+CD38- cells of normal bone marrow samples with lymphocytes
present in the same samples. 
In the group I CML samples, the FSClow/SSClow cell population turned out to have consistently
higher FSC than the corresponding lymphocytes in the same sample. The ratio of both (“FSC
ratio”) was 1.09 (mean, range 1.00-1.21). In contrast, the mean FSC ratio of the FSChigh/SSChigh
population was 1.58 (range 1.40-1.72) and thus showed no overlap with the FSClow/SSClow
population. Although in control bone marrow the normal CD34+CD38- cell population had a
slightly higher FSC ratio than the presumed normal FSClow/SSClow stem cell population in the
CML samples, it was still lower than that of the FSChigh/SSChigh population in 17 of 23 tested CML
samples. For CD45, the ratio between the CD34low/CD45low and the lymphocytes population in
the CML samples was 0.17 (range 0.13-0.23) and 0.34 (range 0.29-0.52) for the CD34high/CD45high
population, again showing no overlap between both populations. By using these light scatter
and CD45 expression ratio’s, the identity of the individual cell populations could now much
better be determined in any sample, especially in those cases where only one population could
be discerned. The remaining 15 patient samples were now analyzed accordingly and were
divided in two groups depending on the extent of discrepancy between CD34/CD45 expression
and FSC/SSC properties. 
A B
Figure 3. Clonogenic capacity after long term culture of presumed leukemic (CD34
high
/CD45
high
or FSChigh/SSC
high
)
and normal (CD34
low
/CD45
low
or FSC
low
/SSC
low
) stem cells.
On the x-axis, the number of weeks that cells had been in culture before plating in CFU-assay is given. Results of bone
marrow and peripheral blood were averaged within patients. Open data points: CD34
high
/CD45
high
or FSC
high
/SSC
high
cells,
filled data points: CD34
low
/CD45
low
or FSC
low
/SSC
low
cells. 
A: Group I. Circles: patient no. 1, diamonds: patient no. 2, triangles: patient no. 5, squares: patient no. 7.
B: Group II. Circles: patient no. 11, diamonds: patient no. 12.
Jps Chapter 5 en 6 DEF  19-10-2009  11:57  Pagina 83
84
Group II
• Patterns of FSC/SSC and CD34/CD45 expression
This group contains ten patients (patient numbers 10-19, see Table 1) in whom the
CD34high/CD45high population was still clearly identifiable, but in whom the CD34low/CD45low
population was less well defined compared to group I patients. This seemed partly due to their
much lower frequencies compared to the CD34high/CD45high cells (see Table 2). For all ten patients
in this group, CD34low/CD45low cells as percentage of the total number of viable CD34+ cells was
a factor three to four lower than that of the CD34high/CD45high cells (the mean and ranges are
shown in Table 2). In contrast to group I, in which at least 90% of CD34low/CD45low were
FSClow/SSClow, group II was arbitrarily defined to have between 10% and 50% FSChigh/SSChigh
cells in the CD34low/CD45low compartment. A representative example of this group is shown in
Figure 4A.
•  Lineage marker expression
Lineage marker expression in the CD34low/CD45low population in this group was virtually absent
for CD11b and CD56, but low expression of CD7 was seen (fluorescence ratio 0.39, see Figure
2B). Compared to group I, for CD11b and CD56 the differences with the CD34high/CD45high
population were smaller compared to group I, but more significant, apparently due to less
variability between patients. When we subdivide lineage marker expression in the three
CD34/CD45 and FSC/SSC defined subpopulations (CD34low/CD45low/FSClow/SSClow,
Table 4. FISH results of long term liquid culture
derived colonies. 
Colonies were scored BCR-ABL positive if at least 10
cells were evaluable and at least 90% was positive.
Patients 1, 2, 5 and 7 belong to group I, patients 12 and
13 to group II. n= number of colonies tested.
a)
sorted on FSC/SSC
b)
sorted on CD34/CD45
c)
no growth at 5 weeks, data derived from 4 weeks colonies
d)
sort of FSC
high
/SSC
high
failed 
e)
sort of CD34
low
/CD45
low
failed
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CD34low/CD45low/FSChigh/SSChigh and CD34high/CD45high/FSChigh/SSChigh), only the two FSChigh/SSChigh
populations had aberrant marker expression, together with FISH analysis (see next paragraph)
strongly suggesting CML character (see Figure 5). Similar to group I patients there was no
aberrant expression of CD2, CD5, CD19, CD22 or CLL-1 in any of the ten patient samples (data
not shown).
• FISH analysis
In three patients of this group, CD34high/CD45high cells were sorted, which revealed on average
96% (range 89-100%) BCR-ABL positive interphases, while in two cases, sufficient
CD34low/CD45low cells were available for FISH analysis. In concordance with marker expression
and FSC/SSC distribution, these were partly BCR-ABL positive: 48 and 34%, respectively (Table
3, second part). An additional patient sample was sorted on FSChigh/SSChigh and FSClow/SSClow
expression. FSChigh/SSChigh cells were 96% BCR-ABL positive, FSClow/SSClow cells were 35%
BCR-ABL positive (see Table 3, second part). In retrospect, and after re-analysis of all cases, in
this sample the upper limit of the FSClow/SSClow sorting gate turned out to include a small 
number of FSChigh/SSChigh events. 
• Stem cell cultures of CD34/CD45 and FSC/SSC defined populations
Long term cultures in this group were done in two patients, based on CD34/CD45 expression.
Both CD34high/CD45high and CD34low/CD45low cells showed long term clonogenic activity. In line
with the direct sort experiments, the CD34low/CD45low compartment of patient no. 12 (Table 4) that
consisted for a relatively high percentage of FSChigh/SSChigh cells, contained a mixed population
Figure 4. FSC/SSC characteristics of CD34/CD45 defined subpopulations in patient groups II (4A) and III (4B).
Gating as performed in Figure 1. Note the presence of both FSC
low
/SSC
low
cells and FSC
high
/SSC
high
cells within the
CD34
low
/CD45
low
compartment in group II, but also the almost complete absence of FSC
low
/SSC
low
cells within the
CD34
low
/CD45
low
compartment in group III.
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of BCR-ABL positive and BCR-ABL negative colonies, while all CD34high/CD45high cells generated
BCR-ABL positive colonies. In the second patient (no. 13) technical failure prevented long term
culture of the CD34low/CD45low cells. CD34high/CD45high cells generated, in contrast to what was
expected, colonies that were only 62% BCR-ABL positive. In retrospect, and after re-analysis of
all cases, the gate for CD34high/CD45high was set slightly too wide, resulting in admixture with
some CD34low/CD45low cells.
Thus, similar to, although less clear than the situation in group I, the results suggest that BCR-
ABL negative long term clonogenic cells are CD34low/CD45low, FSClow/SSClow and lineage marker
negative. However, in contrast with group I, BCR-ABL positive cells, may be both
CD34high/CD45high and CD34low/CD45low. Irrespective of this, BCR-ABL positive cells were always
FSChigh/SSChigh and may carry lineage markers. Whereas in group I the presumed normal cells
outnumbered those of the presumed leukemic cells, in group II the inverse was found. The
FSC/SSC and, when present, the lineage marker properties thus offer the best discrimination
between CML and normal long term clonogenic cells.
Group III
• Patterns of FSC/SSC and CD34/CD45 expression
This group of five patients (patient numbers 20-24, see Table 1) was arbitrarily defined by 50-
100% of CD34low/CD45low cells being FSChigh/SSChigh. The CD34low/CD45low population was poorly
circumscribed and twenty-fold smaller than the CD34high/CD45high population (see Table 2). A
representative example of this group is shown in Figure 4B.
• Lineage marker expression
Similar to groups I and II, lineage marker expression was lower in the CD34low/CD45low cells than
in the CD34high/CD45high cells, but differences were not statistically significant (see Figure 2C).
Also similar to group II, within the CD34low/CD45low population, FSChigh/SSChigh cells had higher
Figure 5. Lineage marker expression in CD34/CD45 and 
FSC/SSC defined subpopulations in patient group II.
White bars: CD34
low
/CD45
low
/FSC
low
/SSC
low
; black bars:
CD34
low
/CD45
low
/FSC
high
/SSC
high
; grey bars:
CD34
high
/CD45
high
/FSC
high
/SSC
high
. Differences between the 
latter two groups (CD34
low
/CD45
low
/FSC
high
/SSC
high
and
CD34
high
/CD45
high
/FSC
high
/SSC
high
) are all NS.
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expression of CD7, CD11b and CD56 than the few available FSClow/SSClow cells (not shown),
although these differences were non-significant. Expression of CD2, CD5, CD19, CD22 or CLL-
1 was lacking in all samples (data not shown).
• FISH analysis
Sorting of CD34high/CD45high cells of three patient samples revealed 98% (range 95-100%) BCR-
ABL positivity, but now CD34low/CD45low cells in two patients were for the vast majority BCR-ABL
positive: 81% and 96%, respectively (see Table 3). In agreement with the results for group II, in
these cases the CD34low/CD45low contained in majority FSChigh/SSChigh: 66% and 86%,
respectively. In one patient (no. 20), CD34low/CD45low cells were subsequently sorted on low
FSC/SSC: although sorting these very few cells is difficult, still the resulting cells now were for
the largest part (71%) BCR-ABL negative, again demonstrating that sorting on CD34/CD45 and
FSC/SSC more reliably identifies CML and normal long term clonogenic cells than sorting on
CD34/CD45 only. No long term liquid culture assays were performed in this group as insufficient
numbers of CD34low/CD45low cells could be sorted for this purpose.
Thus, in agreement with the results of group II, BCR-ABL positive long term clonogenic cells are
present, not only in the CD34high/CD45high compartment, but also in the CD34low/CD45low
compartment where they make up the majority of this compartment. These cells, which may be
lineage marker positive, are however all found in the FSChigh/SSChigh compartment, together with
all CD34high/CD45high cells. In contrast, normal long term clonogenic cells segregate into
CD34low/CD45low/FSClow/SSClow compartment.
A B
Figure 6. A. Sokal scores and B. Euro scores in groups I, II and III. 
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Correlations with clinical risk scores and major molecular responses
The very large differences in CML long term clonogenic cell frequencies as well as the ratio with
normal long term clonogenic cells, might suggest underlying biological differences between
patients in the total stem cell compartment, possibly related to the stage of disease. We therefore
made an inventory of the Sokal and Euro risk scores (Figure 6). Although the number of patients
in each group was rather small, the risk scores differed significantly in the three groups,
especially between group I and III. Group I patients had lowest risk scores, while group III
patients had highest. 
For assessment of response, only patients treated with imatinib 400 mg o.d. were analyzed.
Thus, in group I, all six evaluable patients attained an MMR after a median follow-up of 374 days
(range 184-547), in group II only four of seven (57%) evaluable patients attained an MMR
(median follow-up 451 days, range 354-847) and in group III, after a median follow-up of 755
days (range 525-815), two of four patients (50%) achieved an MMR, while one patient showed
primary hematologic resistance to imatinib and the other patient did not reach MMR at 525 days
of follow-up.
DISCUSSION
Previously, identification of malignant versus residual benign stem cells in CML was done by
performing FISH analysis or RT-PCR on colonies that had grown out of remaining viable cells
after at least five weeks of culture.19,20 Next to that indirect technique, it was shown that the lack
of HLA-DR expression on CD34+/lineage marker- cells identified a population of cells in the bone
marrow, that was mostly Philadelphia negative and had long term clonogenic capacity, while
CD34+HLA-DR+ cells were for the largest part malignant.21,22 However, additional studies showed
less clear separation between leukemic and normal cells by HLA-DR based sorting.23 In this
report, we demonstrate that additional characteristics, as defined by advanced multiparameter
flow cytometry, enable improved discrimination between CML long term clonogenic cells
(“candidate stem cells”) and their normal counterparts in a direct way.
Using forward and sideward scatter properties, CD34/CD45 and lineage marker expression we
could clearly identify in nine of 24 tested patient samples a CD34low/45low population that was also
FSClow/SSClow and highly enriched for BCR-ABL negative cells, while CD34high/CD45high cells were
also FSChigh/SSChigh and highly enriched for BCR-ABL positive cells. In the other patients there
was increasing contamination of the CD34low/CD45low compartment with BCR-ABL positive cells.
These cells were nonetheless, and similar to CD34high/CD45high cells, high in FSC and SSC and,
importantly, similar to FSChigh/SSChigh cells, but in contrast to CD34low/CD45low cells, also partially
marker positive. Accordingly, the BCR-ABL negative normal compartment, i.e.
CD34low/CD45low/FSClow/SSClow, dramatically decreased in size. In all patients, the population that
was both CD34high/CD45high and FSChigh/SSChigh was always BCR-ABL positive, showing that the
malignant part of the candidate stem cell compartment in CML bone marrow can always be
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identified. Moreover, this study shows that malignant cells with long term clonogenic capacity
may aberrantly express lineage markers.
The data presented here is relevant in view of several issues. Firstly, the ability to reliably
discriminate malignant from benign stem cells within a single patient will make molecular and
functional characterization of the CML stem cell compartment, e.g. by gene expression array
studies, much more informative. This is especially important when normal stem cells make up
the majority of the total stem cell compartment as was the case in patient group I. Background
“noise” due to mixing of leukemic and non-leukemic stem cells as well as to interindividual
differences in non-relevant gene expression can now be reduced by accurate FACS sorting of
separate populations. This may improve development of treatments with an optimal therapeutic
window as now the absence of putative targets in or on the simultaneously present normal stem
cells can be taken into account. 
Secondly, quantitation of the malignant and benign stem cells in CML may have clinical value in
addition to the already used prognostic indices like the Sokal- and Euro-scores. In clinical trials,
lower Sokal or Euro-risk scores were associated with higher response rates to both conventional
treatment and to tyrosine kinase inhibition.1,17 Remarkably, we found significantly lower Sokal
and Euro risk scores in patients with a large normal stem cell population as defined by the
CD34/CD45 and FSC/SSC characteristics (low for both) as compared to those with a large
malignant stem cell population (FSChigh/SSChigh). Moreover, although based on limited data, our
results suggest that the chance of attaining an MMR is higher in the former patient group.
Residual leukemic stem cell enumeration may also serve as a relevant surrogate end point in
clinical studies with new (stem cell targeting) drugs. Furthermore, clinical CML management
might in future be guided by detection of normal and residual leukemic stem cells in patients
under TKI-treatment. As approximately 50% of IM treated patients with long-lasting complete
molecular responses maintained their response after stopping IM,24 it would be highly relevant
to see whether persistent remission could be predicted by flowcytometric analysis of the
primitive stem cell compartment. In view of this question, a Dutch-Belgian HOVON study has
been initiated in patients with long lasting complete molecular responses. After interruption of
IM, regular evaluation of the CD34+CD38- stem cell compartment using our flow cytometric
strategy, together with quantitative PCR on BCR-ABL, will be performed to guide re-initiation of
IM in these patients. We have also just started clinical studies in TKI-treated patients, to assess
the role of this flow cytometric technique.
The third relevant issue is that, although CD56 expression was reported on short term
clonogenic CD34+ CML cells in a small fraction of CML patients,25 in most studies, CML stem
cells are defined by their lineage negativity.6,26,27 We now show that expression of CD56 (and CD7
and CD11b) is also a property almost exclusively characterizing FSChigh/SSChigh BCR-ABL
positive cells that had clonogenic capacity in long term liquid culture, thereby resembling the
AML stem cell compartment.14 Lineage marker negative CML stem cells therefore only constitute
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a subpopulation of the leukemic stem cells. Possibly, these cells differ in more characteristics (in
gene or protein expression, biological behavior) from their marker positive counterparts. Using
only marker negative leukemic cells for in vitro or in vivo experiments would thereby potentially
bias results.
In conclusion, flow cytometric discrimination of leukemic and normal candidate stem cells is an
exclusive tool for defining new therapeutic targets and applied diagnostics in CML. We are now
exploring this technique for the analysis of differentially expressed genes in malignant versus
benign candidate stem cells and are planning in-vivo experiments with leukemic candidate stem
cells that have been identified by flow cytometry. 
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ABSTRACT
CML stem cells are highly resistant against all tyrosine kinase inhibitors (TKI’s), which prevents
eradication of the disease by these drugs and necessitates life-long treatment. Resistant stem
cells may also give rise to clinical resistance and transformation into blast crisis. For treatment
that aims at curing the disease, stem cell specific target identification is crucial. Here we
describe the new finding of strong CD90 (Thy-1) expression on CML stem cells in 22 newly
diagnosed CML patients, which enabled us to discriminate leukemic from normal stem cells with
high fidelity. CD34+CD38-CD90+ cells were BCR-ABL positive and generated BCR-ABL positive
colonies in long term culture assays, while CD34+CD38-CD90- cells were BCR-ABL negative and
produced BCR-ABL negative colonies. This finding is highly relevant as it offers the possibility
to properly identify leukemic stem cells, to develop new CML specific targets and to improve
therapeutic assessment of current and new treatments in CML.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a clonal disease that originates from a transformed
hematopoietic stem cell or multipotent progenitor cell and is characterized by the presence of
the reciprocal t(9;22) translocation encoding for a new fusion gene (BCR-ABL) with constitutive
tyrosine kinase activity.1,2 Inadequately treated, the disease transforms into a rapidly fatal blast
crisis. Fortunately, the availability of the BCR-ABL tyrosine kinase inhibitor imatinib (IM) has
changed the outcome of treatment of CML dramatically. Almost all patients will attain a 
complete hematological response and, more importantly, up to 90% even achieve a complete
cytogenetic response. Patients who achieve such a favorable response are protected from
disease progression as was shown in a large prospective clinical trial.3 However, TKI treatment
for CML is not perfect: TKI’s do not lead to eradication of the disease, necessitating life-long
treatment with these costly drugs. Besides, a significant number of patients are intolerant to TKI
treatment or proved to be clinically resistant.3,4 The inability of TKI’s to cure CML is most likely
due to the inherent resistance of leukemic stem cells to these drugs. Although several
mechanisms that explain this resistance are identified, up to now this has not led to more
effective stem cell specific treatment.5-11
For development of effective CML stem cell directed treatment strategies, knowledge of stem
cell specific targets is thus crucial. In the first place, this asks for improved ways of identification
of CML stem cells. We previously showed that the malignant stem cells in newly diagnosed CML
samples can be identified as a CD34+/CD38- population that is relatively high in CD34 and CD45
expression with concomitant high forward scatter (FSC, reflecting cell size) and sideward light
scatter properties (SSC, reflecting cell granularity). This contrasts with the BCR-ABL negative
stem cells, that have lower CD34 and CD45 expression, together with low FSC/SSC. In a
number of patients, BCR-ABL positive cells can however also be detected in the CD34low/CD45low
population, but in contrast to normal stem cells, these cells are FSChigh/SSChigh. We also
described that lineage marker expression, especially CD56, may be found in the, as malignant
characterized, CD34high/CD45high population, but this is rather heterogeneous and 
non-consistent between CML samples.
In acute myeloid leukemia, normal and malignant stem cells can also be distinguished by flow
cytometry, on the basis of lineage marker expression and light scatter properties as we 
recently showed.12-14 Moreover, we demonstrated a lack of CD90 expression on CD34+ blasts in
the majority of AML patients that were younger than 60 years of age.15 As CD90 expression was
higher in the residual normal CD34+ cells, this difference even enabled purging of stem cell grafts
by CD90+ selection. The remaining part of the AML patients, mainly representing elderly patients
and patients with secondary AML and AML with MDS history, had CD90+ CD34+ cells.
With the purpose of expanding our ability to discriminate malignant from normal stem cells in
CML, we now investigated whether in this disease differences in CD90 expression between
normal and leukemic stem cells could also be detected. In this paper we demonstrate consistent
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expression of CD90 on CML stem cells, that contrasted with clearly lower CD90 expression on
the co-existing normal stem cells. The findings will be discussed in the context of stem cell
identification, therapy design and assessment of efficacy and specificity of current and new
treatments in CML.
PATIENTS, MATERIALS AND METHODS
Patient samples and cell preparation
After informed consent, peripheral blood and bone marrow were obtained from newly
diagnosed, untreated CML patients. Mononuclear cells were isolated by density gradient
centrifugation using Ficoll-paque (1.077 g/ml; Amersham Biosciences, Freiburg, Germany)
followed by a red cell lysis step with lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM
Na2EDTA, pH 7.4) for 10 minutes at 4oC, or by direct lysis only. 
CD34+ cell selection
Ficoll-separated or directly lysed mononuclear cells were incubated in PBS containing 5 mM
EDTA and 0.5% human serum albumin (HSA) for 30 minutes at room temperature with CD34
Reagent (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer’s
instructions. Cells were washed twice in PBS/5mM EDTA/0.5% HSA and then selected using the
AutoMacs automated selection device (Miltenyi Biotec). Purity was checked using flow
cytometry and was always more than 95% CD34+. In several cases, long term clonogenic
assays on sorted populations were done on thawed CD34+ cells that had been cryopreserved in
RPMI/20% FCS/10% DMSO.
Fluorescence-activated cell sorting
Fresh isolated mononuclear cells or purified CD34+ cells were incubated with monoclonal
antibodies for 15 minutes at room temperature, washed once in PBS containing 0.1% HSA and
analyzed by flow cytometry. Anti-CD34 phycoerythrin-Cy7 (PE-Cy7), anti-CD45 fluorescein
isothiocyanate (FITC), anti-CD38 allophycocyanin (APC), anti-CD90-phycoerythrin (PE) and Via-
Probe (7-amino-actinomycin D, 7AAD) were all from BDBiosciences (Erembodegem, Belgium).
Every test tube contained anti-CD45-FITC, anti-CD34-PE-Cy7, anti-CD38-APC, 7-AAD and anti-
CD90-PE or IgG1-PE as a negative control antibody. PBS was used as a control for anti-CD34-
PE, CD38-APC and -CD45-FITC. 7-AAD was always included to gate out apoptotic/dead cells
before stem-cell assessment. Data acquisition was performed using a 3-laser FACSCanto II flow
cytometer (BD Biosciences) and analysis was performed using FACSDiva software (BD
Biosciences).
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FACS gating strategy and FACS sorting 
Using five-color fluorescence-activated cell sorting (FACS) analysis, scatter properties and
expression of CD90 were studied. CD34+ blasts were identified in a population characterized by
dim expression of CD45, low sideward scatter (SSC) and 7-AAD negativity. Within this
CD34+CD45dimSSClow7AAD- population, the CD34+CD38- compartment was defined with the use
of a PBS control (see Figure 1). Next, these CD34+CD38- cells were backgated into a
CD34/CD45, FSC/SSC, CD90/CD45 and CD90/FSC plot.
Using the above-mentioned gating strategy, cells were either directly sorted onto glass slides by
a FACSAria cell sorter (BD Biosciences) or sorted into PBS/0.5% HAS, subsequently applied to
the slides and used for further culture experiments. 
Colony forming unit (CFU)- and long term suspension culture assays
For CFU assays, cells obtained after CD34 isolation and FACS sorting of CD34+ subpopulations,
were cultured in semisolid medium containing alpha-methylcellulose (Methocult GF H4434;
Table 1. Patient characteristics.
1)
Sokal and Euro-scores cannot be calculated, because spleen size could not be assessed 
2)
FISH only
nd: not done
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Figure 1. A. Examples of gating strategy. 
A-F. A gate was set around all mononuclear cells (A), subsequently in B. around the 7-AAD
-
(viable) cells. Next, the
CD34
+
population of the CD45
dim
blast population was identified (C and D), followed by a second check for viability
by backgating into the 7-AAD/FSC plot (E). With the use of a PBS control, the CD34
+
CD38
-
compartment was
determined (F). Total number of analyzed cells (P1) in this case was 1.5x10
6
. The CD34
+
CD38
-
compartment is only
around 1% of the total CD34
+
population. 
G-J. In this part of the figure the blue and red colours refer to the same respective populations. CD34
+
CD38
-
events
were backgated into a CD34/CD45 plot (G), a FSC/SSC plot (H), a CD45/CD90 (I) and a FSC/CD90 plot (J). The
horizontal lines in the CD90/CD45 and CD90/FSC plots indicate the maximum level of the isotype control. 
K, L. CD90 expression of this patient in the CD34
+
CD38
dim
(K) and CD34
+
CD38
+
(L) compartment. Note the decrease
in CD90 expression with increasing maturation (compare Figure 1I, 1K and 1L).
M-P. In this part of the figure the blue and red colours refer to the same respective populations. Example of less
distinctive flowcytometric patterns in the CD34/45 (M) and FSC/SSC (N) plot in another patient, where CD90 only
clearly segregates cells into a CD90
low
and CD90
high
population (O,P). Note that the CD90
low
population is CD45
low
(compare 1O and 1M), but its FSC/SSC coincides with that of the CD90
high
CD45
high
population (N).
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StemCell Technologies, Vancouver, Canada) at 37oC in 5% CO2 in a humidified incubator. The
number of colonies was counted after 14 days of culture. Colonies of different sizes were picked
using very thin hand made glass pipettes or a standard laboratory pipette (Rainin, Mettler-
Toledo, Tiel, The Netherlands) with 10 ul pipette tips and spread onto glass slides for FISH
analysis (see below). 
Long term suspension cultures were performed essentially as has been previously described.16
The sorted (sub)populations were suspended in CellGro medium (Cellgenix, Vancouver, Canada)
containing 20 ng/ml IL-3, 100 ng/ml Flt-3 ligand and 100 ng/ml SCF (all from Pepro Tech, Basel,
Switzerland) prior to plating in 96 round-bottom- or 24-well plates, depending on the number of
available cells (Greiner, Frickenhausen, Germany). Suspension cultures were incubated at 37oC
in 5% CO2 and received weekly half-medium and -cells changes (demipopulation). 
If sufficient cells (>20.000) were available, CFU-assays were performed every week up to a
maximum of eight weeks. In cases where the number of cells was very low, we chose to harvest
all cells at one time point only, i.e. five weeks. Subsequently, all cells present were cultured in a
CFU assay. 
Fluorescent in situ hybridization (FISH)
For FISH analysis, slides were dehydrated in ethanol 70, 96 and 100% for 5 min at RT and stored
at -20oC until use. After thawing, slides were incubated for 90 min at 37oC in 100 mg RNAse A
(Boehringer Mannheim, Germany)/ml 2x standard saline citrate (SSC) and washed three times
for 2 min in 2xSSC at 37oC. Next, slides were incubated for 10 min at 37oC in 0.01% pepsin
(Sigma-Aldrich, St Louis, MO, USA) in 10 mM HCl, and washed twice for 5 min in PBS at room
temperature (RT). Afterwards, the slides were incubated for 10 min in 3.7% formaldehyde in PBS
at RT and washed twice for 5 min in PBS. Denaturation in 70% formamide was performed at
72oC, for 5 min. Next, dehydration was performed twice for 5 min in 70% ethanol at -20oC, 5 min
in 96% ethanol at RT and finally 5 min in 100% ethanol at RT. Slides were air-dried. Hybridization
with the Vysis® LSI® BCR/ABL ES Dual Color Translocation Probe (Abbott BV, Hoofddorp, The
Netherlands) took place overnight under moist conditions at 37oC. Afterwards, slides were
washed in 50% formamide/2xSSC at 42oC three times for 10 min. Next, slides were washed at
42oC, for 10 min in 2xSSC, washed in 2xSSC/0.05% Tween at 42oC for 5 min and finally washed
in 1xPBS at RT for 4 min. Slides were incubated for 9 min in DAPI (Sigma-Aldrich) /PBS (0.125
ug/ml) at RT. After this, slides were dehydrated in ethanol 70, 96 and 100% for 1 min at RT and
air-dried. Vectashield (Vector Laboratories, Brunschwig Chemie, Amsterdam, The Netherlands)
was applied to the slides before analysis on a Zeiss fluorescence microscope. Colonies had to
consist of at least ten cells and were scored BCR-ABL positive or negative if at least 90% of all
cells from that colony were either BCR-ABL positive or -negative. The background level of false
positives for this probe-set is around 10%. To prevent bias, scoring was performed in a blinded
fashion.
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Statistical analysis
Expression of CD90 is given in arbitrary fluorescence units as generated by the FACS Diva
software. As FACS Diva software may generate median fluorescence values of CD90-
populations that can have a value near or below zero, we chose to calculate fluorescence ratio’s
by dividing the median fluorescence of the positive population by the fluorescence of the
negative control at the level that excludes the upper 2.5% of events. These ratio’s were also
compared using the Mann-Whitney U-test for non-parametric variables. P values less than 0.05
were considered to indicate a statistically significant difference.
RESULTS
CD90 expression in the CD34+CD38- compartment
We examined fresh bone marrow and/or peripheral blood samples of 22 newly diagnosed CML
patients using the above described gating strategy. Patient characteristics are shown in Table 1.
Figure 1 shows the results of backgating of the CD34+/CD38- populations into the CD34/CD45,
FSC/SSC, CD45/CD90 and FSC/CD90 plots. As we have previously shown, two populations
can be separated on the basis of their CD34/CD45 expression and FSC/SSC properties. In
addition to this finding, high CD90 expression is only seen in the subset of cells that is high in
CD34/CD45 and in FSC/SSC. Hereby, as is shown in the next section, CD90 clearly segregates
the CD34+/CD38- population into two CD90 defined populations that in retrospect also differ in
CD34 and CD45 expression (compare Figure 1G-J). Thus, two main populations are identified:
a CD90highCD34highCD45high FSChigh population and a CD90lowCD34lowCD45lowFSClow population.
Figure 1 K and L illustrates that high expression of CD90 is a characteristic of the most 
primitive CML compartment: CD90 expression decreases upon maturation and ultimately is very
low in the CD34+CD38+ compartment (compare Figure 1I, K, and L). Moreover, it improves
separation in those cases where CD34/CD45 and FSC/SSC show less distinctive patterns, as
was the case in 14 of the 22 cases (example in Figure 1M-P).
CD90high long term clonogenic cells are BCR-ABL positive
High CD90 expression was exclusively present on the CD34highCD45high population, which had
also high FSC/SSC. They represented 0.59% (median, range 0.04-2.62%) of all viable CD34+
cells. Their level of CD90 expression was variable, but it was higher than in the CD90low
population in every tested patient (see Figure 2). FISH analysis of these cells, sorted onto glass
slides at diagnosis in four patients, showed that they were all leukemic (see Table 2, column 2).
CD90high cells were also plated in long term cultures and clonogenic capacity was measured
weekly for at least five consecutive weeks. Colonies were picked and subjected to FISH
analysis. In accordance with the results of the direct sorts, colonies that were derived from long
term cultures of CD90high populations were BCR-ABL positive (Table 2, columns 4 and 5).
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Quantitative data on the number of colonies in long term cultures are presented in Figure 3
(closed data points). As can be seen, long term (> five weeks) clonogenic output of these BCR-
ABL positive CD90high cells could continue until eight weeks. 
CD90low long term clonogenic cells are BCR-ABL negative
CD90low cells, that were all CD34lowCD45low and amounted to 0.09% (median, range 0.01-1.48%)
of all gated viable CD34+ cells. As we know from the previous chapter, CD34lowCD45low cells not
only consist of FSClowSSClow cells, which are BCR-ABL negative, but also, in variable
percentages, of FSChighSSChigh cells, which, however, are BCR-ABL positive. In the analyzed
patient samples, we now found that these CD34lowCD45lowFSChighSSChigh BCR-ABL positive cells were
all CD90low. Figure 4 shows CD90 expression in these three CD90/CD34/CD45/SSC/SSC defined
populations. Sorting experiments were done on the total CD90lowCD34lowCD45low population,
including both FSClowSSClow, BCR-ABL negative and FSChighSSChigh BCR-ABL positive cells. FISH
analysis of directly sorted cells in three patient samples showed that they were in majority BCR-
ABL negative, but, in agreement with the presence of the above described FSChighSSChigh BCR-
ABL positive population, a variable number of BCR-ABL positive cells was present (see Table 2,
column 3). However, in long term cultures originating from the total CD90lowCD34lowCD45low
compartment in four patient samples, there were no BCR-ABL positive colonies beyond five
weeks culture (see Table 2, column 6 and 7). The stem cells present in the CD90low population
are thus all non-malignant.
Quantitative long term culture data of this CD90low population is presented in Figure 3 (open data
points), showing that clonogenic capacity of the normal stem cells was maintained up to eight weeks.
Figure 2. CD90 expression in putative CML and normal
stem cells.
CD90 expression levels in all tested samples using the
fluorescence index as described in the “Patients, materials
and methods-statistical analysis” section in CD45
low
CD90
low
and CD45
high
CD90
high
CD34
+
CD38
-
cells. The Y-axis is a
logaritmic scale to improve visual separation of individual
samples in the CD45
low
CD90
low
population. A fluorescence
index below 0.35 corresponds with absence of expression.
Error bars represent standard errors of the mean (SEM).
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DISCUSSION
Thy-1 or CD90 expression marks a subset of CD34+ cells that is capable of full hematopoietic
reconstitution after stem cell transplantation.17-19 In AML, CD90 expression is correlated with
factors that represent adverse clinical risk factors, like secondary AML, higher age and poor risk
cytogenetics.20 In these patients, the whole AML blast population, including the stem cell
compartment (Terwijn et al, unpublished) is positive. In younger AML patients (<60 yr), CD90 was
absent in more than 75% of patients.15 These results show that in AML the CD34+/CD38- stem
cell compartment may be either positive or negative, which refines the former conclusion of Blair
et al. that the AML stem cell is CD90 negative.21
To investigate whether in CML differences in CD90 expression between malignant and normal
stem cells exist, that could be exploited for clinical and diagnostic purposes, we performed
multiparameter flow cytometric analysis of 22 de novo CML samples followed by FISH analysis
and assessment of clonogenic ability. The results show that the CD34+CD38- stem cell
compartment can be split into two major populations: a CD90high population that turned out to
be BCR-ABL positive, and a CD90low population that contained BCR-ABL negative stem cells.
Table 2. FISH results of directly sorted populations and of
long term culture generated colonies.
Columns 2-3 : FISH results of sorted populations. Freshly isolated
cells were sorted directly onto glass slides or sorted into medium
and subsequently applied to glass slides. FISH was performed as
described in the “Patients, materials and methods” section.
Columns 4-7: FISH results of long term (≥ 5 weeks) liquid culture
derived colonies. Colonies were considered positive if at least 10
cells were evaluable and at least 90% was positive. N indicates the
number of scored colonies.
nd : not done
a
: 3 out of 5 tested colonies at week 5 scored BCR-ABL positive, in
later weeks no BCR-ABL positive colonies detected
b
: of 4 tested colonies, 3 contained >90% BCR-ABL positive cells
and 1 contained 75% BCR-ABL positive cells (although BCR-ABL
positive, it does not meet the >90% positivity limit).
c
: of 19 tested colonies, 14 contained ≥ 90% BCR-ABL negative
cells and 5 contained 75-89% BCR-ABL negative cells.
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The cells from both normal as well as leukemic CD34+CD38- cell compartments were clonogenic
in long term culture assays, strongly suggesting that they represent true stem cells. In the
previous chapter, we have shown that leukemic stem cells show concomitant high CD34/CD45
expression and high FSC/SSC, while normal stem cells have low CD34/CD45 expression and
low FSC/SSC. Together with CD90 expression, proper identification of both leukemic and
normal stem cells is now possible in almost all CML cases at diagnosis. In several cases there
is also a concealed population which is CD34lowCD45lowFSChighSSChighCD90low, but BCR-ABL
positive. This population coincided with our previously defined CD34highCD45highFSChighSSChigh
marker positive population (see previous chapter) and did not have long-term clonogenic ability.
Most likely, this population emerges by inclusion of CD38dim progenitors which are leukemic, but
have decreased CD34/CD45 and CD90 expression, while high in FSC/SSC at the same time. As
a result, we now know that the CML stem cells reside in a population which is FSChighSSChigh and
CD90high, while concomitantly present normal stem cells reside in the FSClowSSClowCD90low
compartment.
It thus seems that high CD90 expression is a specific and consistent feature of CML stem cells.
To our knowledge, this has not been reported previously, although some studies have assessed
CD90 expression in several subsets of CML bone marrow or peripheral blood samples. For
example, Petzer et al. found that malignant long-term culture initiating cells could be found in
the CD90+ as well in the CD90- fraction, which did not seem to differ with the normal LTCIC’s.22
In another study, both CD34+CD90+ and CD34+CD90- cells were shown to be, for the largest
part, BCR-ABL positive, but only two CML samples were analyzed at diagnosis, while the
remainder was harvested at a more advanced disease stage.23 In a third study, CD90 expression
was demonstrated in only two out of eight CML blast crisis CD34+ samples.24 It was suggested
that the CD90 expression in these two CML BC cases represented the development of blast
crisis in a very primitive stem cell. The lack of CD90 in the majority of AML cases that were also
tested would point at development of that disease in a more committed progenitor cell. These
studies were however all reported several years ago, when multiparameter flow cytometry was
still unavailable and specific analysis of CD90 expression in the CD34+CD38- compartment
could not easily be performed. Therefore, the malignant character of CD90low CML cells in the
above-mentioned studies most probably reflects the fact that CD90 expression strongly
Figure 3. Clonogenic capacity after long term culture
for CD90low and CD90high cells.
Only results derived from CFU-assays that were plated
after sorted cells had been in culture for at least 4 weeks
are shown in the graph. Open data points: CD90
high
cells,
filled data points: CD90
low
cells. Triangles: patient no. 4,
diamonds: patient no. 6, circles: patient no. 10, squares:
patient no. 14. After 8 weeks further culturing was
stopped.
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decreases with increasing CD38 expression (see Figure 1C).
These results are relevant in view of several issues. Firstly, the high expression of CD90 on the
leukemic stem cells may be a therapeutic target. CD90 expression in the normal stem cells is
not absent, but was quite lower than on the leukemic stem cells. As shown in other
hematological malignancies, like non-Hodgkin’s lymphoma, addition of monoclonal antibodies,
i.c. rituximab, to multi-agent chemotherapy can significantly improve treatment outcome by
inducing direct or indirect cytotoxicity.25 Anti-CD90 antibodies also have cytotoxic activity as was
shown in an in vitro model with a murine T-cell lymphoma cell line.26 It would be very interesting
to investigate the role of antibodies to CD90 or other anti-CD90 directed immunotherapeutic
strategies in the eradication of residual CML stem cells, that remain under imatinib treatment.
The fact that CD90 knock-out mice are viable and have only very subtle phenotypic
abnormalities might suggest that anti-CD90 treatment would be a safe strategy that is worth
exploring in CML.34 However, CD90 antibodies induced kidney mesangial cell death and
glomerulonephritis in an in vivo rat model, which may limit clinical applicability of such
antibodies in humans.27,28 Possibly, these renal abnormalities relate to the expression of CD90 on
rat kidney stem cells.29 If human kidney stem cells also express CD90 is still unknown. 
A second issue is the question as to why CML stem cells have such a high CD90 expression
compared to their normal counterparts. In fact, very little is known about the function of this
glycosylphosphatidylinositol-anchored protein. As stated above, CD90 expression correlated
with poor risk characteristics in AML. In T-ALL cell lines, the subpopulations that had highest
CD90 expression had the strongest engraftment potential in murine transplantation models.20,30
Comparably, in the setting of human autologous stem cell transplantation, the number of
CD90+CD34+ cells correlated best with long term engraftment.17 CD90 is expressed on activated
endothelial cells and acts as a ligand for the neutrophil integrin Mac-1, mediating neutrophil and
monocyte adhesion and subsequent transendothelial migration.31,32 Accordingly, the importance
Figure 4. Average CD90 expression of
CD45/FSC/CD90 defined populations.
All CD45
high
CD90
high
cells are FSC
high
SSC
high
. Error bars
represent SEM.
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of CD90 for engraftment of hematopoietic and malignant cells might therefore relate to
facilitation of their migration over the bone marrow endothelial barrier. Further information on the
role of CD90 in normal and malignant hematopoiesis is however lacking.
Thirdly, to enable development of specific leukemic stem cell directed therapy, comparison of
gene and protein expression between normal and leukemic stem cells is an essential step.
Previously, we and several groups that analyzed gene expression differences between CML and
normal cells used total mononuclear fractions or the total CD34+ population and often, materials
from several patients were pooled.33-39 This may have generated substantial “background noise”,
as non-relevant cell populations or different cell types may have been compared and the co-
existence of normal and malignant stem cells in CML has not been appreciated. Our flow
cytometric strategy will now allow for sorting of highly purified normal and leukemic stem cell
populations within single patients, which undoubtedly will lead to more reliable results of gene
expression arrays and thereby to better leukemia stem cell specific target identification.
Finally, our finding may have clinical value in improving the assessment of therapeutic efficacy
of TKI’s in CML. A major molecular response to IM as determined by quantitative PCR on the
total mononuclear cell fraction in blood or bone marrow reliably predicts for sustained
progression free survival in CML patients. Possibly, the number of residual malignant stem cells
under treatment will have additional prognostic value. Moreover, it will be very interesting to
investigate whether patients in a complete molecular response have any remaining malignant
stem cells and whether this will predict for relapse in case treatment is interrupted as is being
studied in a current HOVON study.
CONCLUSION
CD90 expression is highly and specifically expressed on CML stem cells, which enables
discrimination with normal stem cells by flow cytometry. This finding may facilitate identification
of CML stem cell specific targets and ultimately have important therapeutic consequences.
Moreover, it may improve assessment of efficacy of new and current treatments of CML.
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Imatinib (IM) or second generation tyrosine kinase inhibitors (TKI’s) induce satisfactory
responses in a large majority of patients with chronic myeloid leukemia (CML). However, TKI’s
do not eradicate the disease, necessitating life-long treatment. In addition, a significant number
of patients shows less than optimal responses to these drugs. In these patients, the disease may
transform into an aggressive phase, called blast crisis (BC), which may be either of the myeloid
or the lymphoid lineage. In a small subset of the patients, CML presents already in BC, without
any apparent chronic pre-phase. In BC, the activity of IM or newer, second generation TKI’s is
limited. Although long term survival is sometimes seen in TKI treated BC, most patients show a
transient response only. Therefore, patients that develop BC should preferably be treated with
AML- or ALL-like induction regimens, followed by an allogeneic stem cell transplant. Induction
failures and relapses are however very common and cure is relatively rare. 
Mechanisms that are related to the transformation process include loss of activity of tumor
suppressor genes (TSGs) like P53 (in 25-30% of myeloid BC), CDKN2A/INK4a/ARF (in 50% of
lymphoid BC) and RB1 (in 18% of lymphoid BC).1 Next to genetic alterations in TSGs,
hypermethylation of the promoter regions of these genes may be responsible for their loss of
expression. Relatively recently, the demethylating drugs decitabine and 5-azacytidine have
become available for clinical purposes. These drugs may act by reversing abnormal methylation
of TSGs. To estimate their potential value in the treatment of CML BC, we set out to establish
the methylation status of the promoters of a large number of TSGs in clinical samples. We used
a relatively new multiplex assay that enables assessment of methylation status in multiple TSGs
and that has been demonstrated to give reliable results, comparable to classical sodium
bisulphite sequencing based assays or methylation specific PCR.2-4
After informed consent, CD34+ cells from peripheral blood and bone marrow of 19 BC patients
and, as controls, from 15 newly diagnosed, untreated CML patients were isolated using an
AutoMacs device (Miltenyi Biotec, Bergisch Gladbach, Germany). Patient characteristics are
shown in Table 1. Methylation specific multiplex ligation-dependent probe amplification (MS-
MLPA) was subsequently performed as described previously using MS-MLPA probe mixes
ME001-Tumor suppressor-1 and ME002-Tumor suppressor-2.4 Probes were targeted to the CpG
islands within the promoter regions of 35 candidate TSGs and contained a recognition site for
the methylation-sensitive restriction enzyme HhaI. Eighteen genes (ATM, BRCA, BRCA2, CD44,
CDH13, CDKN2A, CHFR, ESR1, GSTP1, IGSF4, MGMT, MLH1, PTEN, RARB, RASSF1A, RB1,
TP73 and VHL) were represented by two probes that each recognized a different HhaI 
restriction site. Each probe mix contained control probes that lacked a HhaI restriction site and
were used for quantification purposes. Probe recognition sequences are shown in Table 2. MS-
MLPA products were analyzed by capillary electrophoresis (CE). The level of methylation was
determined by calculating the ratio of the relative peak area of each target probe from the
digested sample and from the undigested sample as previously described.2 A ratio of >10% was
considered to indicate a significant level of methylation. This ratio was set at >20% for CDH13,
ESR1 and MGMT of the ME002-Tumor suppressor-2 kit (according to the manufacturer’s
instructions). Ratio’s below this threshold were regarded as background. In case two probe sets
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Table 2. Recognition sequences for MS-MLPA.
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for a single gene promoter were used, the gene was scored positive when at least one probe set
showed methylation.
Using this MS-MLPA technique, we found methylation of at least one TSG promoter CpG island
in all 19 BC samples. In two of these, a single TSG was methylated, in the other 17 cases at least
two TSGs were methylated, up to a maximum of 14 genes. CDH13 was the most commonly
methylated gene (15 cases), followed by ESR1 in eight, IGSF4 (also known as TSLC1 or CADM1)
in seven, MGMT in six and CDKN2B in five cases. TP73, RARB, CD44, FHIT, GATA5, PAX6 and
TIMP3 were methylated in two to five patient samples, BRCA1, CDKN2A, MSH6, PAX5, STK11,
THBS1 in single patients only. Several of the genes for which two different probe sets were used
showed methylation of only one of the targeted sites. Adding up all methylated genes of these
19 individual samples, we observed 69 methylated genes. See Table 1 for an overview of these
data. As controls, 15 samples from newly diagnosed CML chronic phase (CP) patients were
assayed. Here, only three individual patients had a single methylated gene, CDH13, MGMT (both
probe set 2 only) and MSH6, respectively. All other tested genes were non-methylated.
Thus, aberrant methylation of TSGs is a common event in CML-BC, occurring in all patients and
contrasting with CP samples in only few patients showed evidence for methylation. Importantly,
as we used progenitor cells in all samples (BC as well as CP), methylation appears to be an
acquired event during or preceding transformation of the disease and not just the result of
increasing numbers of progenitor cells that had methylated genes from the start in CP, but that
were obscured by the admixture of more differentiated cells with non-methylated promoters. As
we did not have to our disposal samples from diagnosis and blast crisis of the same patients,
this cannot be proven, however.
Methylation of several individual TSGs in CML-BC has been reported before, however, to our
knowledge, this is the first report of a simultaneous assessment of multiple TSG methylation in
CML-BC. CDH13, ESR1, IGSF4, MGMT and CDKN2B were the genes that were most frequently
methylated. Except for IGSF4 and MGMT, methylation of these genes in CML has been
described in previous reports that investigated single TSGs only.5-7 In contrast to our findings,
CDH13 methylation was reported as a common event in CML CP, occurring in up to 55% of
cases and leading to complete abrogation of CDH13 mRNA expression. In later disease stages
CDH13 methylation did not increase. However, in higher Sokal risk score patients, CDH13
expression was more often absent, correlating with shorter progression-free survival and lower
response to interferon-alpha.5 We detected ESR1 methylation in more than half of the BC
samples but not in the CP samples. In a previous small patient series half of CP samples showed
ESR1 promoter methylation, while in BC, ESR1 methylation was found in every tested sample.6
CDKN2B methylation, as was observed in three of the BC samples, has also been described to
occur more extensively in advanced than in CP CML, although the difference in methylation
extent was limited. Nevertheless, in some BC samples, a rapid and strong increase was
demonstrated in sequentially analyzed samples.7
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This report is also the first to describe methylation of promoter regions of CD44, GATA5, MSH6,
PAX5, RARB, STK11, THBS1, TP73 and WT1 in CML. BRCA1, FHIT and PAX6 methylation were
however previously reported, particularly in CML cell lines, that are all derived from BC patients,
but also in clinical samples, where methylation was unrelated to disease progression. In view of
our data, with the exception of MGMT, methylation of these genes seems to be an uncommon
event.
As the total number of potentially methylated genes is quite high, this suggests that aberrant
methylation is a non-specific, global process that is a feature of advanced phase CML. Possibly,
this hypermethylation process may be related to increased expression of dimethyltransferases,
as was demonstrated for DNMT1, 3A and 3B in CML BC samples, when comparing with normal
bone marrow.8 In the mononuclear cell fraction of CML CP samples, no increase in DNMT levels
was observed. The mechanism behind the upregulation of these enzymes is unknown.
Restoring TSG expression by demethylating treatment may be a rational therapeutic strategy. A
few clinical studies that assessed the efficacy of demethylating treatment in CML have been
published. Kantarjian et al investigated treatment of CML patients with decitabine in different
phases of the disease.9 Responses were superior in early phase CML compared to more
advanced phases, while myelosuppression was the most important adverse effect. The
combination of decitabine with IM seemed to have only modest activity in a second, phase II
study.10 In patients who responded to the combination there was a lesser decrease of global
DNA methylation than in the non-responders. The results of both studies call into question
whether the observed clinical effect relates to reduction of methylation. Further studies are
warranted to determine if hypomethylating activity indeed is their main mechanism of action.
In conclusion, the progenitor cell fraction in CML BC shows clearly more extensive methylation
of putative TSGs than in CP, where methylation is almost absent. Aberrant methylation of several
of the TSGs that we detected has not been previously reported. Our results suggest that
hypermethylation of TSGs may be a therapeutic target, however, more extensive preclinical and
clinical studies incorporating demethylating agents are needed to assess their therapeutic role
in CML BC.
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ABSTRACT
We collected peripheral blood stem cells (PBSC) in 19 early chronic phase CML patients
following each of two consecutive cycles of intensive chemotherapy (CT) to evaluate whether an
additional cycle of CT would increase Ph-negativity of the PBSC harvest. Autologous SCT
(autoSCT) was performed if a major cytogenetic response (MCR) of the PBSC harvest was
obtained. CT consisted of cytarabine 200 mg/m2/day (d1-7)/idarubicin 12 mg/m2/day (d1-2)
(cycle 1) and cytarabine 2000 mg/m2/day (d1-6)/amsacrine 120 mg/m2/day (d1-3) (cycle 2). One
patient died of fungal pneumonia after the first cycle. Stem cells were harvested in 18 patients
after cycle 1 and in 16 patients after cycle 2. After the first cycle, all patients showed a
cytogenetic response of their graft (MCR in eight patients: three complete, five partial), after
cycle 2 seven patients obtained an MCR (one complete, six partial). Seven patients became
eligible for autoSCT. All patients proceeded with IFN-alpha maintenance. Currently, 16 patients
are alive. At the latest cytogenetic examination of bone marrow, four patients showed an MCR,
four a minor response. In conclusion, although a second cycle of CT may contribute to
elimination of leukemia residing in the patient, it appeared not effective in improving Ph-
negativity of the PBSC graft.
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INTRODUCTION 
Chronic myelogenous leukemia (CML) is a malignant disorder arising from the pluripotent
hemopoietic stem cell.1 The hallmark of the disease is the presence of the Philadelphia
chromosome which is the result of a reciprocal translocation between chromosomes 9 and 22.
This leads to a juxtaposition of the BCR gene derived from chromosome 22 and the ABL gene,
derived from chromosome 9. The gene product is a tyrosine kinase, which has increased activity
compared to the normal ABL tyrosine kinase and which plays a central role in leukemogenesis.2
Characteristically, the disease takes an indolent course for three-five years before inevitably
blastic transformation occurs, which is usually fatal within three to six months. Allogeneic stem
cell transplantation (alloSCT) offers the only prospect of cure, but is applicable in only 15-30%
of patients as a result of donor availability and age criteria.3 Patients not eligible for alloSCT are
currently treated with IFN-alpha-based therapies. IFN-alpha has been shown to prolong survival
when compared with conventional chemotherapies, like busulfan or hydroxyurea.4-6
Recently, autologous stem cell transplantation (autoSCT) has received considerable attention in
the treatment of CML. In several uncontrolled studies, it has been suggested that autoSCT may
prolong the chronic phase of CML, but its value is unproven at present.7,8 Benign haematopoietic
stem cells have been observed to coexist with their malignant counterparts in the bone marrow
of patients with chronic phase CML. It is possible to harvest these normal Ph-negative
progenitors from the peripheral blood following mobilization with growth factors in order to be
reinfused after myeloablative therapy. A substantial portion of patients treated in this way revert,
at least temporarily, to Ph-negative hematopoiesis.9-19 The probability of reaching a major
cytogenetic response after autoSCT may be related to the number of negative progenitors in the
stem cell graft.20 Generally, hemopoietic stem cells have been harvested in the early recovery
phase after a single cycle of conventional intensive chemotherapy followed by G-CSF. We
investigated whether an additional cycle of intensive chemotherapy would increase the number
of Ph-negative progenitors in the harvest. Therefore we treated CML patients with two cycles of
intensive chemotherapy, harvested peripheral blood stem cells after both cycles and performed
autoSCT if one of these harvests showed a major cytogenetic response.
PATIENTS AND METHODS
Patients
Patients with newly diagnosed Ph- or BCR-ABL positivity CML were eligible for the study
according to the following criteria: (1) first chronic phase ≤6 months after diagnosis (2) age
between 16 and 65 years; (3) not eligible for HLA-matched allogeneic (sibling) donor
transplantation; (4) WHO performance score 0 or 1. CML patients in accelerated or blastic phase
were excluded, as well as patients with severe hepatic, renal, cardiac, pulmonary or neurological
dysfunctions. Informed consent was obtained in all cases.
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Chemotherapy and mobilization procedures
A back-up stem cell collection was performed shortly after diagnosis. Patients were stabilized
on hydroxyurea prior to start of the chemotherapy regimen. Induction therapy consisted of two
courses of chemotherapy. Cycle one: cytarabine 200 mg/m2/day, days 1-7 (24 h continuous
infusion); idarubicin 12 mg/m2/day, days 1-2 (bolus infusion). Cycle two was started as soon as
there was evidence of hematopoietic regeneration after cycle one, with platelets >100 x 109/l and
polymorphonuclear cells (PMN) >1.5 x 109/l, and consisted of cytarabine 1000 mg/m2 every 12
h, days 1-6 (2 h infusion) and amsacrine 120 mg/m2/day, days 1-3 (1 h infusion). Granulocyte
colony stimulating factor (G-CSF, filgrastim, Neupogen®, Amgen, Breda, The Netherlands) 10
ug/kg/day s.c. was administered after each cycle as soon as leukocytes started to recover >0.5
x 109/l until the last day of leukapheresis. 
Leukapheresis was performed as soon as leukocytes regenerated to ≥2 x 109/l and significant
numbers of CD34+ cells (>10 x 106/l) had appeared in the peripheral blood. Peripheral blood
stem cells (PBSC) were collected by leukapheresis using an automated blood cell separator
(either Baxter CS 3000 Plus or Cobe BCT Spectra). Mononuclear and progenitor cell content
was assessed by conventional counting and flow cytometric analysis of CD34+ cells. CFU-GM
content was evaluated using standard short term clonogenic assays of mononuclear cells in
methylcellulose. Leukapheresis was continued until the collection contained at least 2 x 106
CD34+ cells/kg or 2 x 108 mononuclear cells (MNC)/kg. Cells were then processed,
cryopreserved and stored in liquid nitrogen until use. Toxicity of the chemotherapy was graded
according to the standard Common Toxicity Criteria.
Autologous PBSC transplantation
Patients were considered eligible for autologous PBSC transplantation (PBSCT) if they reached
a major cytogenetic response in at least one of the PBSC harvests obtained after each cycle of
chemotherapy. The conditioning regimen consisted of busulphan 4 mg/kg/day (per os), days –6
to –3 and melphalan 140 mg/m2 (15 minutes infusion) on day –2 followed by reinfusion of
cryopreserved stem cells on day 0. The harvest that showed the lowest number of Ph+ cells after
the first or the second chemotherapy cycle was reinfused. All patients received antibiotic
prophylaxis, consisting of ciprofloxacin for gram negative coverage, azithromycin or penicillin to
prevent streptococcal septicemia and fluconazole as an anti-fungal agent. Cytogenetic
response was evaluated 1-3 months post-transplantation, before start of IFN-alpha
maintenance therapy.
IFN-alpha maintenance therapy
After PBSCT, IFN-alpha was given as soon as hematopoietic recovery was achieved. Patients
ineligible for PBSCT received IFN-alpha following hematopoietic recovery of the last cycle of
intensive chemotherapy. The starting dose was 3 x 106 units three times weekly for 2 weeks.
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Thereafter, a dosage of 6 x 106 units daily was aimed for, with dose adjustments in order to keep
the leukocytes between 2 and 5 x109/l and platelets >75 x 109/l. Bone marrow of the patients
was evaluated cytogenetically every 6 months during treatment with IFN-alpha as long as there
was a complete hematological remission. Patients remained on IFN-alpha as long as
cytogenetic response was maintained and side-effects were tolerated.
Cytogenetics
Samples of the leukapheresis harvest and bone marrow were cultured for 2 days in RPMI/10%
FCS in the presence of 10 mM colcemid. Cells were fixed in methanol/acetic acid until use.
Metaphase spreads were stained using standard G-banding techniques.
Interphase fluorescence in situ hybridisation (FISH)
This procedure has been described by us in detail.21 Briefly, cytospin slides were prepared and
subsequently dried, fixed in ethanol 70% and stored in -30°C until use. After RNAse treatment
and digestion with pepsin, the slides were fixed in 1% formaldehyde in PBS. Denaturation at
72°C was followed by overnight hybridization with BCR and ABL cosmid probes, that were
labeled by nick translation with digoxigenin-11-dUTP and biotin-14-dATP, respectively. After
washing with standard saline citrate, the biotin labeled probe was detected by fluorescein-avidin
DN, followed by biotinylated anti-avidin and fluorescein avidin. The digoxigenin labeled probe
was detected by anti-digoxigenin-rhodamine, followed by Texas red-conjugated donkey anti-
sheep. Samples were scored under an Axioscop 50 microscope (Carl Zeiss Jena, Jena,
Germany). Nuclei were scored positive for the BCR-ABL gene when a green and a red spot were
less than one spot diameter apart.
Response assessment
Response to each cycle of chemotherapy was assessed by cytogenetic examination of a 
freshly obtained sample from a leukapheresis procedure, preferably the procedure which yielded
the highest number of CD34+ cells. A bone marrow aspirate was simultaneously examined for
comparative studies. At least 20 metaphases were analysed when available. Cytogenetic
response was defined as follows: (1) complete: 0% Ph-positive metaphases; (2) partial: 1-34%
Ph-positive metaphases; (3) minimal: 35-99% Ph-positive metaphases; (4) absent: 100% 
Ph-positive metaphases. A major response was defined as either complete or partial (<35% 
Ph-positive cells), and a minor response as either minimal or absent (≥35% Ph-positive cells).
Statistical analysis
Survival was calculated from the date of registration until death or last contact. Hematological
recovery was determined from the first day blood counts were below the specified level. The
Kaplan-Meier method was used to calculate actuarial recovery percentages. Results of
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cytogenetic and FISH analysis are presented as percentages of Ph- or BCR-ABL positivity
respectively in the leukapheresis samples or bone marrow.
RESULTS
Patient characteristics
From April 1995 to December 1997, 19 patients with CML in early chronic phase entered the
study. Patients were recruited from four centers in The Netherlands and from one centre in
Belgium. Patient characteristics are listed in Table 1. Median age was 47 years (range 21-59).
Median Sokal score was 0.94 (range 0.60-1.83, <0.8: n=6; 0.8-1.2: n=8; >1.2: n=5). All patients
showed a t(9;22) by cytogenetic analysis of bone marrow samples and the BCR-ABL
rearrangement by RT-PCR analysis. Two patients had additional cytogenetic abnormalities: one
patient had a constitutional t(4;13) in all cells and trisomy 8 was found in two out of 30 cells of
another patient. All patients except one received hydroxyurea as prior treatment before start of
the first cycle of chemotherapy. None of the patients had received prior IFN-alpha. Median time
from diagnosis to cycle one was 3.6 months (range 0.2-7.4).
PBSC mobilization and harvesting
All 19 patients completed the first cycle of chemotherapy and 16 patients completed the
second. Three patients did not receive cycle two: one patient died of a fungal pneumonia before
leukocyte recovery after cycle one, two other patients went off protocol treatment following
leukapheresis. Reasons for going off protocol treatment were the availability of a matched
related donor for allogeneic BMT in one patient and for the other patient the combination of
Table 1. Patient characteristics.
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severe side effects and an insufficient amount of progenitor cells collected. G-CSF was
administered for a median of four days (range 2-16) after start of chemotherapy cycle one and
for a median of five days (range 2-15) after cycle two. Stem cells were collected in 18 patients
after cycle one and in 16 patients after cycle two. Sufficient numbers of progenitor cells for
autologous transplantation were obtained in 17 patients, with a median number of two
collections per patient for both cycles (range 1-5 for cycle one and 1-3 for cycle two). Details are
listed in Table 2.
Tolerability and toxicity of induction chemotherapy regimen
Following both cycles no severe toxicities other than infections and mucositis were
documented. The median number of days with neutrophil counts below 0.5 x 109/l was 19 (3-26)
after the first and 18 (14-36) days after the second cycle of induction chemotherapy. Platelet
counts were below 20 x 109/l for 13 (median, range 8-28) and 16 (11-27) days respectively and
below 50 x 109/l for 17 (11-30) and 21 (14-37) days respectively. Median numbers of platelet
transfusions were three (1-16) and five (1-17) respectively and that of red blood cell transfusions
were six (range 2-17) after the first cycle and ten (4-16) after the second. 
Infections occurred in 53% (10/19) of the patients after cycle one and in 50% (8/16) of the
patients after cycle two. Eight patients (six after cycle one, two after cycle two) showed positive
blood cultures during periods of fever and were treated with antibiotics with a favorable
response. Micro-organisms isolated were Staphylococcus epidermidis and Streptococcus mitis.
Three patients developed a pneumonia. One patient (no. 5) died of a fungal pneumonia after the
first cycle. Two other cases of pneumonia (one probably fungal and one probably bacterial)
responded well to treatment. Two episodes of fever of unknown origin (FUO) were successfully
treated with broad spectrum i.v. antibiotics. 
a
complete: 0% Philadelphia-positive metaphases; 
partial: 1-34% Philadelphia-positive metaphases; 
minimal: 35-99% Philadelphia-positive metaphases;
absent: 100% Philadelphia-positive metaphases
b
values between brackets indicate number of samples
analyzed by FISH
Table 3. Response in PBSC harvests and bone marrow
samples.
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Cytogenetic analysis
Table 2 also lists the cytogenetic responses achieved in the PBSC collections and in the bone
marrow of the patients at follow-up. When cytogenetic analysis of the harvest failed, as occurred
for some patients, response was evaluated by means of FISH analysis. Preferably, the same
procedure was used for comparison of the response after cycle one vs. that after cycle two.
Evaluation of the harvests showed a cytogenetic (or in situ hybridization) response in all patients
after cycle one. Nine patients (47%) obtained a major (three complete, six partial) cytogenetic
response (MCR). In no patient except one (patient 6) were results of cytogenetic or FISH analysis
after cycle two superior to those after cycle one. In this patient however, there was a large
discrepancy between the results of FISH analysis of the harvest compared with the cytogenetic
analysis of the bone marrow after cycle two (18 vs. 100% BCR-ABL/Ph-positivity, respectively).
Only a partial cytogenetic response could be observed after cycle two, in the harvest of eight
patients (42%). No complete responses were observed. Evaluation of bone marrow samples
showed no significant difference between cycle one and cycle two (see also Table 3). 
PBSC transplantation
Nine patients qualified for autologous PBSCT. Of these nine patients with an MCR in the harvest
obtained after cycle one, two patients went off protocol treatment. The other patients with an
MCR in the harvest obtained after cycle one, also achieved a MCR in the harvest obtained after
cycle two, and they all proceeded with autologous PBSCT. Two additional patients who did not
qualify for autologous PBSCT were, however, transplanted.
The myeloablative regimen was relatively well tolerated. No severe toxicities occurred. In one
patient liver enzyme abnormalities developed, which were ascribed to fluconazole treatment.
These responded well to dose adjustment. No transplantation-related mortality ensued.
Infections occurred in six out of nine (67%) patients. FUO occurred in three patients. Two other
patients had bacteraemia due to Staphylococcus epidermidis during periods of fever and were
treated with antibiotics until defervescence. Intravenous antibiotics or anti-fungals were required
for a median of 11 days (range 5-21). One patient developed a Guillain-Barré syndrome of
unknown cause several weeks post transplantation. There were no graft failures.
Neutrophil recovery to over 0.5 x 109/l took a median of nine (7-14) days, platelets were <20 x
106/l for ten (0-66) days. Patients stayed in a protected environment for a median of 21 days
(range 17-27) and required hospitalization for a median of 29 days (range 26-33). Bone marrow
samples of the patients were evaluated two-four months post-transplantation. Three patients
had an MCR (one complete and two partial), and five patients had a minor response. In one
patient response was absent. All proceeded with IFN-alpha.
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Follow-up
As shown in Table 2, in the group of transplanted patients, median follow-up of the eight patients
still alive is 33 months (range 25-44 months). Only one patient was in a complete cytogenetic
remission after transplantation. He lost his response after a period of two years. Two others
attained a complete cytogenetic response after more than one year of therapy with IFN-alpha
and were 100% Ph-negative at 17 and 21 months after transplantation. The other patients
reverted to predominantly Ph-positive hematopoiesis.
In the eight non-autoSCT patients who are still alive, median follow-up is 39 months (range 19-
44 months). None of these patients attained a major cytogenetic response, although they were
all treated with IFN-alpha after autoSCT. Two patients underwent alloSCT. Current disease 
status and causes of death during follow-up (if applicable) are also shown in Table 2.
DISCUSSION
The use of autologous stem cells for SCT in CML is supported by the observation that, in 
chronic phase CML, Ph-negative progenitors co-exist with malignant progenitors.22 In this study,
we were able to obtain preferentially Ph-negative harvests in almost 50% of early chronic phase
CML patients treated with AML-based intensive chemotherapy. In AML, leukapheresis for
autologous transplantation is generally performed after two, instead of one, cycles of
chemotherapy,23 assuming that tumor contamination of the harvest will be less after two cycles
of chemotherapy. In our group of 19 early chronic phase CML patients, an additional cycle of
high-dose chemotherapy for stem cell mobilization did not improve the yield of BCR-ABL
negative progenitors. It is not likely that differences in the level of myelosuppression after the
successive cycles of chemotherapy account for this phenomenon, because the pancytopenic
period was longer and mean CFU-GM counts were lower after the second course than after the
first in both patient groups (transplanted and non-transplanted). In the transplanted patients,
mean CD34+ counts were also lower after cycle 2.
It is possible that responses after the second cycle of chemotherapy could be impaired by
removal of a substantial portion of Ph-negative progenitors by leukapheresis after the first cycle,
leading to a rather unfavorable starting point for the second cycle of chemotherapy. That
explanation remains hypothetical since we do not know how many normal progenitors exist in
early chronic phase CML and what proportion of them can be removed by leukapheresis. An
alternative explanation could be that CML progenitor cells, as compared to their normal
counterparts, are more apt to survive chemotherapy by their resistance to apoptosis induction
caused by the BCR-ABL gene,24-33 which could result in the selection of Ph+-progenitors at the
cost of normal progenitors.
Several methods have been used to mobilize Ph-negative progenitors with variable success
rates. An overview of published mobilization studies with ≥15 CML patients is given in Table 4.
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Table 4. Overview of published trials (n ≥ 15 patients).
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Abbreviations: 
G-CSF: granulocyte-colony stimulating factor; ICE: idarubicin 8mg/m
2
, d1-5; cytarabine 800mg/m
2
, d1-5; etoposide
150mg/m
2
, d1-3; mini-ICE: idarubicin 8mg/m
2
; d1-3, cytarabine 800mg/m
2
, d1-3; etoposide 150mg/m
2
, d1-3; DA3+7:
daunorubicin 50mg/m
2
, d1-3; cytarabine 200mg/m
2
, d1-7; IC: 2d ida 10mg/m
2
, d1-2; cytarabine 200mg/m
2
, d1-5; IDAC 2+5:
idarubicin 8 (or 10, or 20) mg/m
2
, d1-2; cytarabine 1000mg/m
2
, d1-5; IDLDA: idarubicin 12 mg/m
2
, d1-2, cytarabine
100mg/m
2
, d1-5; IDIDA: daunorubicin 50 mg/m
2
, d1-3, cytarabine 200mg/m
2
, d1-7; Cy 1: cyclophosphamide 5-7 g/m
2
, 
d1; DAUNO-HDAC: daunorubicin 120mg/m
2
, d1; cytarabine 1500mg/m
2
,d1-4; methylprednisolone 100 mg, d1-? (not fully
clear in paper); FAM: fludarabine 30mg/m
2
, d1-3; cytarabine 1000mg/m
2
, d1-3; mitoxantrone 10mg/m
2
, d1-3; DVAP:
daunorubicin 100mg/m
2
, d1; vincristine 2mg, d1; cytarabine 200mg/m
2
, d1-7; prednisolone 100mg, d1-5, followed by
hydroxyurea 3500mg/m
2
, d8-14; HU: Hydroxyurea 3,5g/m
2
, d1-7; Cy 2: Cyclophosphamide 4g/m
2
, d1; ICE-adapted:
idarubicin 12mg/m
2
, d1-3; cytarabine 100mg/m
2
, d1-7; etoposide 75mg/m
2
, d1-7; IFN: interferon-alpha; MVAC:
mitoxantrone 12mg/m
2
, d1-4; etoposide 100mg/m
2
, d1-4; cytarabine 1000mg/m
2
, d1-4; amsa-AraC: amsacrine 75mg/m
2
,
d1-4; cytarabine 1000mg/m
2
, d1-4; CAM: Cy 2; cytarabine 1000mg/m
2
b.i.d., d1-4; mitoxantrone 4mg/m
2
, d1-2; modified
ICE: idarubicin 8mg/m
2
, d1-3; cytarabine 400mg/m
2
, d1-3; etoposide 150mg/m
2
, d1-4.
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As is evident from the data presented herein, results of mobilization in terms of Ph-negativity are
improved in early chronic phase compared to later stages of the disease. Even within the first
year, very early mobilization may be advantageous considering the superior results that several
investigators attained when mobilizing patients within a few months after the diagnosis was
made.12,34-36 Also, “ICE” or “mini-ICE” seems to be more effective chemotherapy in mobilizing Ph-
negative progenitors in more advanced stages of the disease than conventional “3 + 7” or “5 + 2”
daunorubicin and cytarabine chemotherapy. 
In only one study, more than one cycle of intensive chemotherapy was given before harvesting
of (bone marrow) stem cells.37 A positive effect on the elimination of malignant progenitors was
suggested. Ph-negativity increased after consecutive cycles of intensive chemotherapy. In
particular, the first two cycles were effective in decreasing the number of Ph-negative
progenitors, while the third cycle had only a minor effect. If Ph-negativity occurred after one to
three cycles, bone marrow was harvested and patients were autotransplanted, yielding post-
transplant cytogenetic remissions of various duration and an overall survival that seemed to be
better than that of a group of age-matched historical controls. These favorable results may
suggest that intensive chemotherapy also effectively reduces the leukemic burden in the patient,
apart from a graft-purging effect.
Thus, according to the data listed in Table 4, at least 50% major cytogenetic responses may be
achieved with current mobilization regimens, primarily depending on disease stage. This figure
is comparable with our results after the first cycle of chemotherapy in early chronic phase CML.
Probably, the earlier the mobilization takes place, the better the results may be.
It is still unclear whether autologous stem cell transplantation improves survival in CML. Several
uncontrolled studies might suggest it does,38 but no randomized controlled trials have been
published yet. Studies reported so far suggest that intensive chemotherapy and autoSCT
followed by IFN-alpha may improve results as compared to IFN-alpha alone.39 In addition, it has
been shown that patients who do not respond cytogenetically to IFN-alpha, may revert to IFN-
alpha responsiveness after intensive chemotherapy and autoSCT.40,41 All these studies suggest
an additive effect of intensive chemotherapy to an already impressive anti-leukemic activity of
IFN-alpha alone.
A potential disadvantage of autografting is the reinfusion of malignant progenitors especially
when patients do not show a major cytogenetic response of the PBSC harvest. Findings by
Talpaz et al20 have suggested that the probability of achieving a cytogenetic response after
autoSCT may depend on the percentage of normal progenitors in the PBSC graft. These findings
do not argue against intensive chemotherapy, but they question the applicability of autoSCT. In
order to avoid such a potential problem, the Dutch-Belgian HOVON group has set out to
prospectively compare standard treatment (IFN-alpha and low-dose cytarabine) vs. intensive
chemotherapy including high-dose cytarabine followed by IFN-alpha, but without autoSCT.
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We conclude that Ph-negative peripheral blood progenitor cells are preferentially harvested after
a single course of intensive chemotherapy. For autografting purposes, a second cycle of
chemotherapy does not improve Ph-negativity in the graft. Whether intensive chemotherapy
with or without autoSCT has a role in delaying transformation in CML is the issue of several
randomized trials that are now underway. The role of the newly introduced tyrosine kinase
inhibitor STI-571 still has to be fully investigated but it certainly is to be expected that this drug
will change our treatment of CML in view of the very promising results recently reported.42 Future
studies will have to address the question if addition of STI-571 to existing mobilization schemes
will lead to better results of autografting procedures.
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ABSTRACT
While most patients with first chronic phase CML obtain a complete cytogenetic response (CCR)
upon treatment with a standard-dose of imatinib, complete molecular responses (CMR),
however, are rare. Having reported feasibility previously, we hereby report efficacy of escalated
imatinib in combination with two cycles of intravenous cytarabine as received by 162 CML
patients included in the HOVON-51 study. With a median follow-up of 55 months, the five year
cumulative incidences of a CCR, major molecular response (MMR), and CMR were 89%, 71%,
and 53%, respectively. A higher Sokal risk score was inversely associated with CCR (HR=0.63;
95% CI, 0.50-0.79, p<.001). A higher dose of imatinib and a higher dose of cytarabine were
associated with increased CMR with HRs of 1.60 (95% CI, 0.96-2.68, p=.07) and 1.66 (95% CI,
1.02-2.72, p=.04), respectively. Progression-free survival and overall survival at five years were
92% and 96%, respectively. Achieving an MMR at one year was associated with complete
absence of progression and a probability of achieving a CMR of 89%. It is concluded that the
addition of intravenous cytarabine to imatinib as upfront therapy for CML patients is associated
with a high rate of CMR. 
The study was registered at www.kankerbestrijding.nl as CKTO-2001-03.
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INTRODUCTION
The introduction of imatinib, a specific kinase inhibitor of the BCR-ABL protein, in 1998 and its
approval by the Food and Drug Administration in 2001, has dramatically changed prospects for
patients with chronic myeloid leukemia (CML).1,2 Most patients with newly diagnosed chronic
phase CML nowadays achieve a complete cytogenetic response (CCR), which subsequently
predicts for relatively long survival.3 Moreover, patients achieving a major molecular response
(MMR) do even better, as not a single patient that attained a MMR at 18 months had progressed
at five years.3,4 The recently presented seven year follow-up data of the International
Randomized Study of Interferon and STI571 (IRIS) study confirmed durability of cytogenetic
responses and a low rate of progression.5 However, the estimated five year event-free survival
(EFS) was 83%, and an estimated another 16% of patients discontinued imatinib for various
reasons within the first five years.3 Comparable results were observed in a recent large single
center study, with a five year probability of remaining in stable cytogenetic remission while still
receiving first-line imatinib of 63%.6 Collectively, these results indicate that although the majority
of patients enter a stable cytogenetic remission, still more than one third of patients may be in
need of an alternative therapy. 
Patients needing second-line therapy include patients, who do not tolerate imatinib and patients
acquiring resistance. Primary or acquired resistance against imatinib is currently defined at the
hematologic, cytogenetic, and also molecular level.7 It may be caused by different mechanisms,
including point mutations in the BCR-ABL kinase domain, overexpression of BCR-ABL,
additional chromosomal abnormalities in the Philadelphia (Ph) positive clone, and a relative
insensitivity of quiescent leukemic stem cells to imatinib.8-12 Prevention of resistance and
improving the cytogenetic and molecular response rates may be achieved by different
approaches, including dose escalation of imatinib, second-generation tyrosine kinase inhibitors,
or combination therapy.13-17 Several combinations have been explored in vitro and also in early
clinical studies.14,18-22 Among the combinations of imatinib and cytostatic drugs, the combination
of cytarabine and imatinib was found to result in a synergistic effect, especially at higher
concentrations of either drug.20-22 Based on these findings, the HOVON cooperative study group
set out to clinically explore the feasibility and efficacy of the combination imatinib and cytarabine
applying a step-wise dose-increase of either drug. Recently, feasibility results of that
combination were reported.14 While a higher dose of cytarabine was associated with more
infectious complications; a standard-dose of cytarabine appeared well tolerated. Here, efficacy
of the combination of imatinib and intravenous cytarabine is reported with emphasis on the rate
and duration of molecular responses as well as its major determinants.
METHODS
The HOVON-51 was a multi-center study designed to investigate the feasibility and efficacy of
escalated imatinib in combination with intravenous cytarabine in patients with early chronic
phase CML. Inclusion criteria included: age between 18 and 65 years, presence of the Ph
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chromosome or BCR-ABL rearrangement, adequate organ function, registration within six
months of diagnosis, and no previous treatment except for hydroxyurea. The ethics committees
of all participating centers approved the study and informed consent was obtained from all
patients in accordance with the Declaration of Helsinki. Patients were recruited as from August
2001 to November 2005.
Study design and treatment
The design of the study has been described in detail recently.14 In short, patients were assigned
to one of seven predefined, successive dose levels. Dose levels were open for inclusion, only
when the preceding dose level had met the criteria of acceptable toxicity and safety, until finally
the highest dose level V was evaluated. First, a pre-phase of imatinib (400 mg) monotherapy was
given to all patients, followed by combination therapy of two cycles of intravenous cytarabine
(200 mg/m2 or 1000 mg/m2 days 1 to 7) with imatinib (200 mg, 400 mg, 600 mg or 800 mg qd).
Imatinib (400 mg, 600 mg or 800 mg) maintenance therapy was continued after the second cycle
until disease progression, intolerance of treatment, or eligibility for allogeneic stem cell
transplantation (allo-SCT), whichever occurred first.
Dose adjustments during imatinib maintenance therapy were made in case of nonhematologic
toxicity of common toxicity criteria (CTC) grade 2 or higher. If a patient experienced a CTC grade
2 nonhematologic toxicity that did not resolve despite therapeutic intervention, imatinib was
withheld until the toxicity had resolved to ≤ grade 1. If the toxicity CTC grade 2 recurred, 
imatinib was withheld and after resolution of the toxicity resumed at a reduced dose that was
100-200 mg qd lower than the dose used before the toxicity occurred. If ≥ CTC grade 3 
recurred or if toxicity had been life threatening, treatment with imatinib was discontinued, and
patients were taken off protocol. In case of hematologic toxicity ≥ CTC grade 4 during imatinib
maintenance therapy, imatinib was withheld and resumed at the same or a reduced dose after
resolution of the toxicity to ≤ grade 2. No dose adjustments were made for hematologic toxicity
≤ CTC grade 3.
Definition of endpoints
Hematologic and cytogenetic responses were as detailed before.14 The definition of molecular
response was adapted in order to be compatible with the international scale,23,24 and defined as
complete molecular response (CMR; no residual BCR-ABL transcripts by real-time quantitative
polymerase chain reaction) or MMR (value of ≤0.1% on the international scale). Only BCR-ABL
values resulting from assaying with a level of sensitivity of at least 0.01% were considered
appropriate. If during follow-up cytogenetic results were not available, real-time quantitative
polymerase chain reaction (RQ-PCR) measurement of BCR-ABL was used as a surrogate for
CCR where BCR-ABL values below 1% were considered as achieving CCR.15,25 Molecular
response was centrally assessed at the Erasmus University Medical Center in Rotterdam using
RQ-PCR on peripheral blood and/or bone marrow. Molecular analysis was done at baseline,
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after cycles 1 and 2, at six months, and at least every three to six months thereafter. All patients
who failed to achieve an MMR at one year were evaluated for point mutations in the ABL kinase
domain, which investigation was repeated during follow-up as long as patients failed to achieve
an MMR. Patients, who lost their initial response or progressed during follow-up, were also
evaluated for mutations. BCR-ABL mutation analyses was performed as previously described.26
Cumulative incidences of response are expressed as the time from registration to complete
hematologic response (CHR), major cytogenetic response (MCR), CCR, MMR, and CMR. Loss
of CHR was defined as a white blood cell count (WBC) >20 x 109/l or progression to advanced
phase CML; loss of MCR as an increase of Ph-positive metaphases by at least 30 percentage
points to ≥35% Ph-positive metaphases; loss of CCR by the detection of one or more Ph-
positive metaphases, loss of MMR as a 0.5 log increase of BCR-ABL to a BCR-ABL level >0.1%;
and loss of CMR as renewed detection of BCR-ABL transcript levels. In case of loss of
hematologic, cytogenetic or molecular responses, confirmation by a subsequent evaluation at
least one month apart was required. Progression was defined as development of accelerated
phase or blast crisis CML, whichever came first. Failure on imatinib treatment was defined as
progression (to advanced phase CML), loss of CHR, loss of MCR, or an increasing WBC (defined
as doubling of the WBC to >20 x 109/l on two occasions at least one month apart in a patient
who had never attained a CHR despite receiving maximally tolerated doses of therapy). 
Progression-free survival (PFS) was defined as the time from registration until progression or
death, whichever came first. Failure-free survival (FFS) was defined as the time from registration
until failure on imatinib treatment or death, whichever came first. Event-free survival was defined
as the time from registration until failure on imatinib treatment, discontinuation of imatinib
treatment, going off protocol treatment for any reason, or death, whichever occurred first.
Overall survival (OS) was calculated as the time from registration until death whatever the cause.
Patients still alive at the date of last contact were then censored.
Statistical methods 
The cumulative incidences of CHR, MCR, CCR, MMR and CMR were calculated using
competing risk analysis. Competing risks were disease progression, discontinuation of
treatment before achieving response, or death without previous response. As an allo-SCT was
allowed as off protocol treatment if no cytogenetic response was acquired within 12 months or
according to the physician’s preference, those patients were censored at the date of allo-SCT.
Progression-free survival, EFS, FFS, and OS were estimated by the Kaplan-Meier method, and
95% confidence intervals (CIs) were determined. Patients who received an allo-SCT were
censored at the date of transplantation. Time to response and survival endpoints were illustrated
by Kaplan-Meier curves until five years.27 In our trial, patients had been assigned to receive
standard- or intermediate-dose cytarabine (200 mg/m2 and 1000 mg/m2), as well as
low/standard-dose (200 and 400 mg) or high-dose (600 mg and 800 mg) imatinib. Univariate and
multivariate Cox regression analyses,28 without and with interaction terms, were performed to
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evaluate the effect of higher dose levels and the impact of the Sokal risk score and Euro score
on clinical outcome. Hazard ratios (HRs) with 95% CIs were determined. All reported p values
are two sided, and a significance level α=0.05 was used.
RESULTS
Patient characteristics are presented in Table 1. Median age at diagnosis was 47 years (range:
19-65 years); patients were fairly evenly distributed among the three Sokal risk categories. A flow
diagram of treatment actually received is depicted in Figure 1. One hundred and sixty-two
patients received a first cycle of combination therapy and 140 patients (86%) also received a
second cycle of combination therapy. One hundred fifty-seven patients (97%) started with
imatinib maintenance therapy. The current analysis is based on data collected up to December
18, 2008, resulting in a median follow-up of 55 months (range: 10-84 months). Currently, 112
patients (69%) are still on protocol treatment, and 50 patients went off protocol treatment for
various reasons (Figure 1). Second-line therapy included allo-SCT from either a related or a mat-
ched unrelated donor in 18 patients, nilotinib or dasatinib in 14 patients, chemotherapy in seven
patients, and other treatment modalities in seven patients. 
Table 1. Baseline characteristics of all 
patients.
Percentages may not sum up to 100% due
to rounding.
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Hematologic, cytogenetic and molecular response
Patient responses are presented in Table 2 and Figures 2, 3 and 4. One hundred fifty-four
patients developed a CHR, 146 patients an MCR and 135 patients a CCR. The median time to
a CCR was approximately 4.5 months. In total, 107 patients achieved an MMR and 78 patients
developed a CMR on protocol treatment. The median time to MMR was 11 months and the
median time to CMR was approximately 22 months. With a median follow-up of 55 months, nine
patients lost their CHR, 16 patients lost their previously established MCR and 17 patients lost
Figure 1. Flow diagram of 162 patients entered in the Dutch-Belgian HOVON-51 study. 
Reasons for going off protocol treatment are indicated.
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their CCR. Of all 107 patients with a MMR, six patients lost that response and loss of CMR was
observed in ten patients (Table 2). At five years, cumulative incidences of a CCR, MMR, and
CMR were, respectively, 89%, 71%, and 53% (Figure 2A, B, C). Of note, 89% of the patients
who achieved an MMR at one year subsequently developed a CMR. Furthermore, none of the
107 patients with an MMR subsequently progressed to accelerated phase or blast crisis CML. 
Four out of 135 patients with a CCR progressed to accelerate phase or blast crisis, while five
out of 27 patients who failed to achieve a CCR also progressed to advanced phase CML. Among
the 103 patients with a CCR at one year, 91 (88%) subsequently obtained an MMR and 71
patients (69%) ultimately developed a CMR. In contrast, molecular responses were rare in
patients failing to achieve a CCR at one year. Among 41 patients continuing protocol treatment,
Table 2. Patient responses (n=162).
Abbreviations: CHR, complete hematologic
response; AP/BC, accelerated phase or crisis;
CCR, complete cytogenetic response; MMR, major
molecular response; CMR complete response. 
Note: All responses presented were exclusively
achieved on protocol treatment. Loss of
responses included all losses either during
protocol treatment or off protocol treatment.
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but who failed to achieve a CCR at one year, 27 patients (66%) subsequently developed a CCR
at later time points (Figure 2A), 15 patients (37%) attained MMR and only six patients (15%)
ultimately developed a CMR. 
Different parameters were evaluated for prediction of response, including Sokal risk score, Euro
score, dose of imatinib and dose of cytarabine. There were significant differences in the rates of
MCR and CCR among patients, according to Sokal risk and Euro score in univariate analysis. A
higher Sokal risk score remained adversely associated with MCR and CCR (HR=0.63; 95% CI,
0.50-0.79, p<0.001) (Table 3) in multivariate analysis. At one year the cumulative incidences of a
A
C
B
Figure 2. Cumulative incidences of complete
cytogenetic response (A), major molecular response
(B), and complete molecular response (C).
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Figure 3. Time to complete molecular response by dose of imatinib.
(HR: 1.60(0.96-2.68); P= 0.07).
Figure 4. Time to complete molecular response by dose of cytarabine.
(HR: 1.66(1.02-2.72); P=0.04).
Table 3. Results of the multivariate analyses.
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CCR was 76% in patients with a low Sokal score, 74% in patients with an intermediate Sokal
score and 40% in patients with a high Sokal score. However, at five years these differences in
response rates were less pronounced with 89%, 93%, and 81%, in low, intermediate, and high-
risk patients, respectively. Furthermore, a higher Sokal score was also inversely associated with
MMR (HR=0.74; 95% CI, 0.58-0.96, p=0.02) (Table 3), but not with CMR. In contrast, the dose
of imatinib and the dose of cytarabine were not associated with cytogenetic response, but a
higher dose of imatinib (600 or 800 mg) appeared to be associated with a better MMR and CMR
(HR=1.60; 95% CI, 0.96-2.68, p=0.07) (Table 3, Figure 3). Independently, also the higher dose of
cytarabine was associated with a better CMR. Sixty percent of patients, receiving the higher
dose of cytarabine, developed a CMR at five years as compared to 50% for patients receiving
a standard-dose of cytarabine (HR=1.66; 95% CI, 1.02-2.72, p=0.04) (Table 3, Figure 4).
Progression-free, overall, failure-free and event-free survival
After a median follow-up of 55 months, nine patients have developed accelerated phase or blast
crisis CML and a total of three patients died resulting in a five year PFS of 92% (95% CI, 85%-
95%) (Figure 5). The estimated annual rate of progression was 5.0% in the first year, 0.7% in the
second year, 0.8% in the third year, 2.2% in the fourth year, and 0% in the fifth year. Due to the
limited number of events, prognostic factors were not evaluated for possible association with
PFS. In total, six patients died, resulting in an OS at five years of 96% (95% CI, 92%-98%).
Causes of death of these six patients included blast crisis CML in three patients, excessive
toxicity in two patients and an unrelated cause in one patient. Recipients of allogeneic stem cell
graft were censored at the time of transplant for the latter analysis in concordance with earlier
reports and to facilitate comparison.3,9 Twenty-seven patients ultimately received an allo-SCT in
second or third line, predominantly because of primary or secondary resistance (Table 4). Twelve
out of these 27 patients died due to either non-relapse mortality (n=11) or progressive disease
(n=1). Survival without censoring of allogeneic SCT recipients at the time of transplant estimated
88% at five years.
Figure 5. Event-free survival (EFS), failure-free survival (FFS),
progression-free survival (PFS), and overall survival (OS).
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Failure-free survival was defined as failure on imatinib treatment including progression to
advanced phase CML, loss of CHR, loss of MCR, or an increasing WBC for patients without
CHR, or death. Twenty patients failed imatinib treatment, of which seven patients progressed to
the accelerated phase or blast crisis as first event of treatment failure, two patients had an
increasing WBC, two patients had a loss of CHR and nine patients had a loss of MCR. Another
three patients died without prior failure on imatinib treatment. The estimated five year FFS was
86% (95% CI, 79%-91%) (Figure 5). Neither the dose of cytarabine or imatinib, nor Sokal risk
and Euro score were associated with FFS. However, time dependent analysis showed that early
cytogenetic and molecular responses had a favorable impact on FFS. A landmark analysis of the
103 patients who had achieved a CCR at one year revealed a superior estimated five year FFS
of 97% as compared to 77% in 41 patients without a CCR at one year (p<0.001) (Figure 6A).
Moreover, the five year FFS for 61 patients who rapidly achieved a MMR at 12 months was
superior as compared to the 83 patients who had failed to attain an MMR at one year (100%
versus 86%; p=0.002) (Figure 6B). 
Furthermore, also EFS was assessed, with EFS defined as all failures and including patients
going off protocol for other reasons than progression, including intolerance of treatment and
allo-SCT. A total number of 50 events were noted, resulting in five year EFS of 69% (95% CI,
Table 4. Indications and outcome of patients
after allogeneic hematopoietic stem cell
transplantation.
Abbreviations: CHR, complete hematologic
response; MCR, major cytogenetic response; CCR,
complete cytogenetic response; MMR, major
molecular response; BC, blast crisis; WBC, white
blood cell count; allo-SCT, allogeneic stem cell
transplantation; CML, chronic leukemia.
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61%-76%) (Figure 5). A higher Sokal risk and Euro score were associated with worse EFS in uni-
variate analysis. A higher Sokal risk score remained adversely associated with EFS (HR=1.55;
95% CI, 1.08-2.22, p=0.02), when adjusted for dose of cytarabine and imatinib.
Point mutations in the BCR-ABL kinase domain
Patients failing to achieve an MMR at one year, and at subsequent evaluation time points
thereafter were evaluated for point mutations within the BCR-ABL kinase domain. In addition,
patients with primary or secondary hematologic or cytogenetic resistance and all patients who,
at any time, progressed to accelerated phase or blast crisis were evaluated for mutations. In
total, 153 samples were evaluated for point mutations in the kinase domain. It resulted in a
cumulative incidence of mutations of 10% at five years. In total, 14 different mutations were
A
B
Figure 6. Landmark analysis of failure-free survival (FFS), by complete
cytogenetic response at 1 year (panel A), or by major molecular response at
1 year (panel B).
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detected in 15 patients (Table 5), including two patients with a T315I mutation. Nine out of these
15 patients with a mutation subsequently lost their response and three patients progressed to
advanced phase CML.
Tolerance of protocol treatment
Adverse events and side effects during the phase of combination therapy were reported in detail
before.14 During maintenance, the most frequent adverse events CTC ≤ grade 2 included
constitutional symptoms (34%) and gastrointestinal complaints (33%), however, toxicity CTC
grade 3 or 4 occurred infrequently. Both the incidence and severity of these side effects were
essentially similar to what can be observed in patients receiving monotherapy with imatinib as
reported before.3 Combination therapy and maintenance were well tolerated as illustrated by
only 9% of patients discontinuing treatment because of side effects (n=15), which represent all
discontinuations including the toxic deaths), an EFS of 69%, and a total number of 112 patients
still continuing protocol treatment. 
Abbreviations: CHR, complete hematologic response; HR, hematologic response; MCR,
major cytogenetic response; CCR, complete cytogenetic response; MMR, major
molecular response; MR, molecular response; BC, blast crisis; WBC, white blood cell
count
Table 5. Kinase domain mutations.
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DISCUSSION
Allogeneic hematopoietic SCT is still the only treatment modality that has been proven to cure
patients with CML.29 Although imatinib treatment is associated with high rates of cytogenetic
responses and major molecular responses in patients with first chronic phase CML, complete
molecular responses are rare and the majority of patients continuously harbour minimal 
residual disease, necessitating prolonged treatment with imatinib.3,4,6 With the ultimate aim to
improve the CMR rate, the HOVON study group set out to explore the feasibility and efficacy of
the combination of cytarabine and imatinib. Recently, the feasibility of intravenous cytarabine
and escalated imatinib was reported.14 With a median follow-up of 55 months, long-term 
efficacy of combination therapy is presented here. The most important findings of our study
include a high CMR rate, a relatively low incidence of primary cytogenetic and molecular
resistance, resulting in a high PFS, and a relatively high number of patients still continuing
protocol treatment, while maintaining their remission.
The cumulative incidence of a CMR was 53% at five years. To what extent can that percentage
be explained by the addition of cytarabine? A higher dose of imatinib monotherapy may 
already be associated with a faster and better response, although different results were
observed in distinct risk-categories of patients.13,30-34 In addition, the association between 
plasma trough levels and outcome, as was observed by several investigators,35,36 has suggested
that a threshold of at least 1002 ng/ml should be aimed for, but it is unclear to what extent
responses may be further improved when higher levels of imatinib are achieved. A modest dose
dependent effect of imatinib was also apparent in our study (Table 3, Figure 3), which was of
borderline significance. It seems therefore unlikely that the higher dose of imatinib per se has
resulted in the observed CMR rate. Rather, the earlier observed in vitro synergistic or additive
effect of cytarabine seems to be mirrored here clinically.20-22 An additive effect of cytarabine is
further supported by the significant dose dependent effect of cytarabine as observed in our
study. Moreover, none of the patients receiving the higher dose of cytarabine has shown
progressive disease until the latest follow-up. While our results do suggest at least an additive
effect of cytarabine, however, only a direct comparison in a prospective randomized trial may
exactly answer the question to what extent cytarabine improves the molecular response rate and
prevents disease progression. To that end, the HOVON cooperative group recently started a
prospective randomized study comparing 800 mg imatinib versus the combination of 800 mg
combined with cytarabine at a dose of 200 mg/m2 intravenously. Two other cooperative groups
explored the combination of cytarabine and imatinib. The French cooperative groups
demonstrated the feasibility of imatinib and low-dose cytarabine,18 but long-term results are not
available yet. Furthermore, the Australian cooperative group developed a protocol including
addition of cytarabine for patients failing to obtain a sufficient response three months after dose
escalation of imatinib. Recently, their results were reported and it appeared that only a minority
of patients actually received the combination, which precludes any definite conclusion as
regards the additive value of cytarabine in their study.15
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By inducing a high CMR, combination therapy may prevent primary resistance at the various
levels (hematologic, cytogenetic, molecular), and it may also prevent secondary resistance in
patients relapsing from an earlier established response. To what extent was resistance
prevented? Primary cytogenetic resistance defined as failure to achieve a CCR at 18 months,
was observed in 36 patients (22%) in our study. Nineteen out of the 36 patients (53%), who 
failed to achieve a CCR by 18 months, were Sokal high-risk patients. While a percentage of 22%
may be somewhat better as can be observed following imatinib only (approximately 30% in the
Hammersmith study6), still primary cytogenetic resistance is of concern and combination 
therapy only partially prevented cytogenetic resistance. It indicates that a subset of high-risk
patients is still in need of a more efficient approach. Furthermore, additional parameters apart
from those incorporated in the Sokal and Euro scores may be needed to more accurately 
identify the patients at highest risk of primary cytogenetic resistance. New diagnostic techniques
such as gene expression profiling and single nucleotide polymorphisms may possibly add to the
well established risk scores.37,38 Secondary resistance percentages were rather low and PFS
estimated 92% at five years, as compared to an estimated five year PFS of 83% in the
Hammersmith study.6 As outlined by de Lavallade et al, another important outcome estimate is
the five year probability of achieving and maintaining a MCR, while continuing imatinib. It was
63% for patients with early chronic phase CML receiving a standard-dose of imatinib in the
Hammersmith series of patients.6 For comparison, 69% of the patients in the present study
maintained at least an earlier established MCR and were still on imatinib according to protocol.
Apart from an encouraging efficacy of combination therapy, that high percentage of patients
continuing protocol treatment also illustrates that combination therapy was rather well tolerated. 
Our intention was to improve the molecular response rate. What is the advantage of achieving a
major and/or complete molecular response? Our results, as well as those by several others,
clearly suggest that patients with a more pronounced response, such as a MMR, benefit in terms
of a lower risk of disease progression and prolonged PFS.3,4,39-41 Therefore, aiming for a MMR has
been advocated as an important treatment goal by several investigators.4,39 Is a further
improvement up to the level of a CMR of additional benefit? Recent preliminary reports have
suggested that a subset of patients in continued CMR may potentially be cured, as was
suggested by absence of molecular relapse following cessation of imatinib maintenance.
Rousselot et al. initially described 12 patients who discontinued imatinib with undetectable
residual disease for more than two years.42 Six patients were able to discontinue imatinib without
disease recurrence. A more recent follow-up and inclusion of a total of 50 patients essentially
showed the same picture with approximately 50% of patients maintaining PCR-negativity after
cessation of imatinib.43 A similar observation was done in Australia, with a relatively high failure
free survival, but longer follow-up may be needed to definitely assess to what extent patients
may be cured.44 Collectively, these studies for the first time suggest that apart from allo-SCT,
also “conventional” treatment based on tyrosine kinase inhibition may possibly be associated
with cure. It is therefore, that the HOVON cooperative group has amended the present HOVON-
51 study, by allowing all patients in continued CMR of at least two years to take part in a
prospective study evaluating stopping imatinib maintenance. Thereby, we may be able to more
150
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definitely assess the contributing value of cytarabine in terms of possible cure. It should,
however, be emphasized, that interruption and stopping of tyrosine kinase inhibitor therapy is
experimental and should only be explored within the context of well-monitored prospective
studies. 
In conclusion, following earlier in vitro findings,20-22 our clinical results may mirror the contributing
effect of cytarabine to that of imatinib in patients with first chronic phase CML. The additional
value of cytarabine in first chronic phase CML seems a better eradication of residual disease as
reflected by a relatively high rate of CMR. While cytogenetic resistance may partially be
prevented, a subset of high-risk patients still represents a category of patients for which better
approaches are needed. The ultimate advantage of an increased CMR rate should be assessed
in future studies, including well-monitored studies evaluating cessation of imatinib in patients
with a long-lasting CMR.
REFERENCES
1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL 
tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
2. Cohen MH, Johnson JR, Pazdur R. U.S. Food and drug administration drug approval summary: 
conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full 
approval. Clin Cancer Res 2005;11:12-19.
3. Druker BJ, Guilhot F, O’Brien S, et al. Five-year follow-up of patients receiving imatinib for chronic 
myeloid leukemia. N Engl J Med 2006;355:2408-2417.
4. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or 
interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 
2003;349:1423-1432.
5. O’Brien SG, Guilhot F, Goldman JM, et al. International Randomized study of interferon versus 
STI571 (IRS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of 
major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia 
in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008;112:(abstract 186).
6. De Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with 
chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. 
J Clin Oncol 2008;20:3358-3363.
7. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic 
myeloid leukemia: recommendations from an expert panel on behalf of the Europian LeukemiaNet. 
Blood. 2006;108:1809-1820.
8. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by 
BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
9. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukaemia in chronic phase responding to 
imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. 
Hematologica 2003;88:260-267.
10. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML 
treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the 
ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;9:625-
632.
11. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells 
from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-
325.
12. Holyoake T, Jiang X, Eaves C, et al. Isolation of a highly quiescent subpopulation of primitive 
leukemic cells in chronic myeloid leukemia. Blood 1999;94:2056-2064.
151
Jps Chapter 9 en 10 DEF  19-10-2009  12:13  Pagina 151
13. Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed 
Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103:2873-
2878.
14. Deenik W, van der Holt B, Verhoef GEG, et al. Dose finding study of imatinib in combination with 
intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. 
Blood 2008;111:2581-2588. 
15. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and 
molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial 
therapy. Blood 2008;112:3965-3973.
16. Cortes J, O’Brien S, Jones D, et al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with 
newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic 
myelogenous leukemia in early chronic phase (CML-CP). Blood 2008;112:(abstract 446).
17. O’Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping 
resistance in check. Expert Opin Investig Drugs 2008;17:865-878.
18. Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining 
imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic 
myelogenous leukemia in chronic phase. Blood 2003;102:4298-4305.
19. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant 
interferon-a2b in early chronic-phase chronic myeloid leukemia. Blood 2004;104:4245-4251.
20. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al. Efficacy of STE571, an Abl tyrosine kinase inhibitor, 
in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 2000;96 :3195-
3199.
21. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase 
inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous 
leukemia cells. Leukemia 2001;15:342-347.
22. Fang G, Kim CN, Perkens CL, et al. CGP57148B (STI-571) induces differentiation and apoptosis 
and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. 
Blood 2000;96:2246-2253.
23. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with 
tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for 
detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 
2006;108:28-37.
24. Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing 
current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukemia. 
Leukemia 2006;20:1925-1930.
25. Ross DM, Branford S, Moore S, et al. Limited clinical value of regular bone marrow cytogenetic 
analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. 
Leukemia 2006;20:664-670.
26. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the 
adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or 
Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 
2002;99:3472-3475.
27. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 
1958;53:457-481.
28. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
29. Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia 
in the imatinib era. Biol Blood Marrow Transplant 2006;12:795-807.
30. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in 
the front-line treatment of patients with high-risk, Philadelphia-positive, chronic myeloid leukemioa. 
A European LeukemiaNet Study. Blood 2009;7;113:4497-504.
31. Zonder JA, Pemberton P, Brandt H, et al. The effect of dose increase of imatinib mesylate in 
patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate 
hematologic or cytogenetic response to initial treatment. Clin Cancer Re. 2003;9:2092-2097.
32. Kantarjian HM, Talpaz M, O’Brien S, et al. Dose escalation of imatinib mesylate can overcome 
resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 
2003;101:473-475.
33. Cortes J, Giles F, O’Brien S, et al. Result of high-dose imatinib mesylate in patients with 
152
Jps Chapter 9 en 10 DEF  19-10-2009  12:13  Pagina 152
Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. 
Blood 2003;102:83-86.
34. Castagnetti F, Palandri F, Amabile M, et al. Results of high-dose imatinib mesylate in intermediate 
Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase II trial of the GIMEMA 
CML WP. Blood 2009;113:3428-34.
35. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response 
and safety in chronis-phase chronic myeloid leukemia: a subanalysis of the IRIS study. 
Blood 2008;111:4022-4028.
36. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both 
cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. 
Blood 2007;109:3496-3499.
37. Terragna C, Durante S, Stolfi A, et al. Gene expression profile (GEP) of chronic myeloid leukemia 
(CML) patients at diagnosis: Two distinguished subgroups of CML patients identified, based on a 
molecular signature, irrespective of their Sokal risk score. Blood 2008:112:(abstract 3190).
38. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are 
associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. 
Blood 2008;112:2024-2027.
39. Cortes J, Talpaz M, O’Brien S, et al. Molecular responses in patients with chronic myelogenous 
leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-3432.
40. Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a 
complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated 
chronic myeloid leukemia patients. Clin Cancer Res 2006;12:3037-3042.
41. Palandri F, Iacobucci I, Soverini S, et al. Treatment of Philadelphia-positive chronic myeloid 
leukemia with imatinib: importance of stable molecular response. Clin Cancer Res 2009;15:1059-
1063.
42. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic 
myelogenous leukemia in complete molecular remission for more than 2-years. Blood 
2007;109:58-60.
43. Mahon FX, Huguet F, Guilhot F, et al. Is it possible to stop imatinib in patients with chronic myeloid 
leukemia? An update from a French pilot study and first results from the multicentre << Stop 
Imatinib >> (STIM) study. Blood 2008;112:(abstract 187). 
44. Ross DDM, Grigg A, Schwarer A, et al. The majority of chronic myeloid leukaemia patients who 
cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR, 
and any relapses occur early. Blood 2008;112:(abstract 1102)
153
Jps Chapter 9 en 10 DEF  19-10-2009  12:13  Pagina 153
154
Jps Chapter 9 en 10 DEF  19-10-2009  12:13  Pagina 154
Jps Chapter 9 en 10 DEF  19-10-2009  12:13  Pagina 155
156
Jps Chapter 9 en 10 DEF  19-10-2009  12:13  Pagina 156
157
Imatinib induces major cytogenetic responses in the vast majority of newly diagnosed CML
patients. Most of these responses are durable, but a minority of patients progress to accelerated
phase and eventually to blast crisis. Mechanisms causing this resistance have been described
and include mutations in the ATP binding site of ABL and amplification of genomic BCR-ABL.1
Here, we describe a CML patient who showed a remarkable clinical course on imatinib,
developing blast crisis after having been in a complete cytogenetic response for more than two
years. The BCR-ABL transcript was aberrant, showing an insert of a “kringle” domain of the
KREMEN-1 gene, which, to the best of our knowledge, has not been reported before.
A 27-year-old male with a previous history of gout was diagnosed with CML in July 2000. He
had no siblings. There was no hepatosplenomegaly upon physical examination. The leukocyte
count at diagnosis was 63 600/ul with 4% blasts and platelets of 455 000/ul. Cytogenetic
examination revealed a t(9;22)(q34;q11) and a del9q+ in 100% of metaphases. Spleen diameter
was 18 cm on ultrasound. The Hasford Euro-score was 2763, which classified the CML as high
risk. Hydroxyurea treatment was started. After three weeks, he was recruited into the IRIS
protocol, a randomized trial comparing interferon-alpha plus low-dose cytarabine with imatinib.
He was randomized to imatinib 400 mg daily, which led to a rapid hematological response with
a partial cytogenetic response at three months (46XY, t(9;22)(q34;q11) [1]/46XY [28]) and a
complete cytogenetic response at six months. On quantitative PCR, the maximal reduction of
BCR-ABL transcripts in the peripheral blood was 2.77-log as measured 22 months after start of
imatinib therapy (BCR-ABL/PBGD ratio of 1.6 x 10-3). Good molecular response continued until
July 2002. In January 2003 blood counts dropped with Hb 12.6 g/dl, platelets 182 000/µl and
leukocytes 2 500/µl with 3% blasts with vacuolated cytoplasm. A bone marrow aspirate was
hypocellular, cytogenetic examination was however possible and showed, remarkably, normal
karyotype in 28 metaphases, but both an additional Philadelphia chromosome and an extra
chromosome 8 in two cells. Also, upon metaphase FISH, the ABL signal was apparent both on
the long and on the short arm of chromosome 9, implicating a duplication of the residual ABL
sequences on chromosome 9. BCR-ABL/PBGD ratio had increased with 5.8 x 10-2 in the
peripheral blood and 3.5 x 10-1 in the bone marrow. Bone marrow histology showed a
monotonous population of blast cells, positive for TdT, CD20, CD79a, CD10 and CD45, negative
for CD34, CD117, MPO, lysozyme and CD15, compatible with lymphoid blast crisis. Imatinib
was stopped and he was consecutively treated with chemotherapy according to the ALL-84
protocol, consisting of induction with daunorubicin, vincristine, L-asparaginase and prednisone
plus intrathecal methotrexate, two consolidation cycles with cytarabine plus intrathecal
methotrexate and vincristine, cyclophosphamide and prednisone respectively, followed by
maintenance chemotherapy with mercaptopurine, methotrexate, daunorubicin, prednisone,
vincristine and cyclophosphamide leading to a complete hematological remission.
Unfortunately, a search for an unrelated stem cell donor was not successful. Eight months after
starting the induction chemotherapy, he receives maintenance treatment and is in continuous
complete hematological remission. The latest PCR results showed a very low BCR-ABL
transcript level (BCR-ABL/PBGD ratio of 2.2 x 10-5 in the peripheral blood and 4.1 x 10-5 in the
bone marrow). The size of the BCR-ABL transcript on conventional PCR is unchanged
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compared to that at diagnosis. Imatinib was restarted at a dose of 800 mg daily.
At diagnosis, multiplex PCR, performed according to the protocol of Cross2 showed an
abnormally large product of around 550 bp (see Figure 1). Automated sequencing and restriction
enzyme analysis of the PCR-product at the time of blast crisis did not show any mutation in the
tyrosine kinase catalytic domain of the BCR-ABL gene which is encoded by ABL exons 4-9,1 but
both diagnosis and blast crisis PCR products revealed an insert of 261 bp which was interposed
between the BCR exon 2 and the ABL exon 2. The sequence of the insertion is identical to a
small part of the KREMEN-1 gene that is normally located on chromosome 22q12.1. The
KREMEN-1 gene (Genbank accession no. gi: 24041013) encodes a transmembrane receptor
that, after binding of dickkopf homolog-1 (DKK1), blocks wingless (WNT)/beta-catenin
signaling.3 The insertion encodes a kringle domain which is an extracellular domain of the
KREMEN-1 protein. Kringle domains are autonomous structural domains found in blood clotting
and fibrinolytic proteins, some serine proteases and plasma proteins and play a role in binding
mediators, (e.g. peptides), other proteins, membranes, or phospholipids.4 This kringle insert was
already present at diagnosis, meaning that the recombination event in chromosome 22 that had
resulted in the insertion had taken place at an early phase of the disease. The second
Philadelphia chromosome and trisomy 8 at blast crisis were however acquired during imatinib
treatment. This implicates clonal evolution, which is frequently seen in the advanced phases of
the disease, but is rarely encountered during imatinib treatment as well.5
Although the patient attained complete cytogenetic remission rapidly and his molecular
response was not different from many other patients receiving imatinib,6 he suddenly developed
blast crisis. Deletion of the derivative chromosome 9q has been reported to confer a bad
prognosis in patients treated with interferon-alpha7 and this probably also holds true for imatinib
treated patients as was recently shown.8 However, we can speculate on mechanisms, by which
the kringle domain influenced BCR-ABL function or the activity of imatinib. Firstly, it may be
hypothesized that the binding capacity of the kringle domain to substrates influences the
signaling properties of BCR-ABL. Alternatively, the insertion may cause changes in the three-
dimensional structure of the BCR-ABL protein that could result in a decreased binding of
imatinib into the ATP-binding pocket of ABL. The unfavorable course of the disease in this CML
patient may be related to these mechanisms.
Figure 1. Gel electrophoresis of multiplex PCR-
products. Lane 1: marker, lane 2: patient; lane 3: control
patient with b2a2 fusion, lane 4: b3a2 (K562 cell line).
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ABSTRACT
A 51-year old male with CML who was in major molecular response to imatinib developed an
isolated central nervous system lymphoid blast crisis, first presenting as cerebral edema. This is
a very rare event. The patient was treated with intrathecal liposomal cytarabine injections,
followed by myeloablative allogeneic stem cell transplantation and remains, at eighteen months
after transplant, in complete remission. A review of the literature is presented.
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INTRODUCTION
Since the introduction of imatinib for treatment of chronic myeloid leukemia (CML), blast crisis
has become a rare occurrence. The vast majority of patients respond with complete cytogenetic
remission and up to 80% of patients even attain a major molecular remission.1 In patients who
do not respond as favourably, a switch to a second generation tyrosine kinase inhibitor or to
allogeneic stem cell transplantation can be made, depending, amongst others, on the
mechanism of imatinib resistance. When blast crisis has already occurred before imatinib had
been started, the drug has only very limited efficacy, although long term survivors have been
described.2 If blast crisis develops in the central nervous system it is in general in the course of
an accompanying systemic blast crisis. In these cases outcome is particularly dismal as imatinib
has no significant activity in the CNS.3 Here we report a patient who was in a major molecular
response on imatinib when he developed an isolated CNS localisation of a CML blast crisis.
CASE PRESENTATION
A 51-year old male was diagnosed with chronic phase CML in May 2005. His Sokal score at
diagnosis was 0.95, his Euro score 1363 (both intermediate risk). Cytogenetic examination
showed 46XY, t(9;22)(q34;q11.2) in all of 30 metaphases. BCR-ABL PCR was positive for an
e14a2 transcript. He was included in the HOVON-51 study (www.hovon.nl) where he received
two cycles of cytarabine 200 mg/m2 for seven days and imatinib 800 mg q.d. continuously.
Swiftly, he attained a complete and durable cytogenetic response (at three months after start of
Figure 1. BCR-ABL/GUS ratio as measured by quantitative PCR over time. 
A ratio below 0.1% represents major molecular response.
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treatment) and a major molecular response (0.05% compared to diagnosis) already at three
months after start of treatment that was maintained at further follow-up (see Figure 1). At 12
months after start of treatment he complained of progressive hearing problems. There was a
perceptive as well as a conductive loss. MRI of the brain did not show any abnormality in the
cerebral parenchyma, meninges or cranial nerves. He was given a hearing aid and middle ear
drainage tubes. However, his hearing loss deteriorated so much that he became unable to do
his work as a general practitioner. Six months after his hearing loss had started he developed
progressive confusion, ataxia and word finding disturbances. A CT scan of the brain showed
signs of edema in the posterior fossa with narrowing of the fourth ventricle and obliteration of
the ambient cistern. There were no abnormalities on CT-angiography. MRI of the brain confirmed
the presence of posterior fossa edema without focal lesions and did not show meningeal
enhancement. However, there was bilateral enhanced signal intensity at the inferior cerebellar
peduncle. Because of fear for brain herniation, a lumbar puncture was not performed. As cerebral
edema has been described before as an adverse effect of imatinib, imatinib was stopped and
dexamethasone 10 mg was given.4 He fully recovered within 24 hours. A lumbar puncture was
performed which revealed 1091 leukocytes per mm3 and a protein level of 2.9 g/l in the
cerebrospinal fluid. Cytological examination showed blasts that stained strongly for TdT, CD19,
CD20, CD79a and weakly for CD34. Cytogenetic examination of these blasts showed a single
Philadelphia-chromosome in all metaphases, with a quantitative PCR BCR-ABL level of 944%
(diagnosis=100% in peripheral blood). Sequencing showed no mutations in any part of the ABL-
gene of these cells. At the same time, the BCR-ABL/GUS ratio in the peripheral blood was
0.13%, which was slightly higher than before. Bone marrow examination was normal and still
showed a complete cytogenetic response. The BCR-ABL/GUS ratio had however risen to
0.38%.
We treated the patient with six intrathecal liposomal cytarabine injections and dexamethasone
40 mg q.d. for four days each month. His leukocyte count in the cerebrospinal fluid normalized
after three injections of intrathecal cytarabine. In parallel, the BCR-ABL/GUS ratio on qPCR also
decreased to values below 0.1% (see Figure 1). He was given an HLA-matched unrelated
allogeneic stem cell transplant in December 2007, two and a half years after initial diagnosis.
Myeloablative conditioning consisted of cyclophosphamide and total body irradiation of 12 Gy.
He is now eighteen months after transplant, has limited chronic GVHD and continuous to be in
complete cytogenetic and molecular response without any sign of meningeal relapse up to now.
DISCUSSION
Since the introduction of imatinib for the treatment of chronic myeloid leukemia (CML), blast
crisis has become a rare occurrence. The vast majority of patients responds with complete
cytogenetic remission and up to 80% of patients even attain a major molecular remission.5 In
patients who do not respond as favourably, a switch to a second generation tyrosine kinase
inhibitor or to allogeneic stem cell transplantation can be made, depending, amongst others, on
the mechanism of imatinib resistance. When blast crisis has already occurred before imatinib
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has been started, the drug has only very limited efficacy, although long term survivors have been
described.6 If blast crisis develops in the central nervous system, most often it is in the course
of an accompanying systemic blast crisis. In these cases outcome is particularly dismal as
imatinib has no significant activity in the CNS.7 The sudden occurrence of an isolated CNS blast
crisis is a very rare event in patients on imatinib treatment who have reached a complete
cytogenetic response. To the best of our knowledge Matsuda et al described the only other
patient that had an isolated meningeal localisation of CML blast crisis after having attained a
complete cytogenetic response to imatinib.8 Our patient even attained a major molecular
response. Others have also described the occurrence of isolated CNS blast crisis in several
patients, however all of these patients had either lost their previous responses in the peripheral
blood or bone marrow or never obtained complete cytogenetic response to imatinib at the time
of the isolated blast crisis.9-12 Remarkably, there was no meningeal enhancement on the MRI
scan in our patient. In two patients, described by Aichberger and Petzer, respectively,11,13 this was
also the case, while in the other reports, meningeal enhancement was seen.
Development of sudden systemic blast crisis in patients who are in complete cytogenetic
remission with imatinib has been described more frequently. In fact, previously we reported a
patient with sudden blast crisis (SBC) who had an aberrant BCR-ABL fusion gene.14 Jabbour
found four patients developing SBC amongst more than 500 imatinib treated CML chronic phase
patients.15 In three of these, a rise in the BCR-ABL signal on quantitative PCR preceded the
occurrence of the blast crisis. This contrasts with the patients with solitary CNS blast crisis,
where we and others did not see a rise of the quantitative PCR BCR-ABL signal before the blast
crisis presented.16
These data point to several imperfections of CML treatment with imatinib and other tyrosine
kinase inhibitors (TKI’s). Firstly, currently available TKI’s do not eradicate CML stem cells, which
may then eventually develop secondary mutations leading to blast crisis.17 In general, this seems
an infrequent event, as patients who have attained a major molecular response almost never
progress towards blast crisis.5 Mutations may however develop in the time interval before
molecular response is reached. Secondly, imatinib penetrates very poorly into the cerebrospinal
fluid.18 Several reports show that levels of imatinib or its major active metabolite in the CSF were
10-250-fold lower than plasma levels.7,13,19-22 Apparently, in rare patients, a CML clone, unaffected
by subtherapeutic imatinib levels, hides in the CNS and develops secondary mutations
ultimately leading to CNS blast crisis. Delivery of imatinib into the brain parenchyma could be
improved up five-fold by ABCB1 (P-glycoprotein) and ABCG2 inhibitors, however the effect on
CSF levels was not reported. This five-fold increase may be too low to be clinically relevant.23
Dasatinib, a second generation TKI which is, like imatinib, a ABCB1 substrate24,25 has better
penetration into the CSF and is clinically active against CNS disease, although the levels that
were attained were still quite low both in a preclinical model and in patients.26 P-glycoprotein
inhibitors could increase its CSF levels in mouse models.27,28 Furthermore, Inno-406, a dual ABL
and LYN TKI and also a ABCB1 substrate,29 was shown to penetrate the CSF to such extent that
it was able to inhibit the growth of leukemic cells in the CSF in a mouse model with levels
Jps Chapter 11 + slot DEF  19-10-2009  12:02  Pagina 165
166
reaching approximately 10% of those in plasma. Inhibition of P-glycoprotein by cyclosporine
increased entrance of Inno-406 into the CNS. Next to dasatinib, this compound may therefore
also have a role in patients who have CML blast crisis or Philadelphia positive ALL and who
should receive intrathecal prophylaxis against meningeal invasion by blast cells. Data on CNS
penetration of the other available TKI’s, nilotinib and bosutinib, are lacking.
Initially we mistook our patient’s clinical picture for cerebral edema caused by imatinib as this
had previously been described as a potential adverse effect in two other patients. These
patients, however, took imatinib for blast crisis (one lymphoid, the other myeloid), while our
patient was in a major molecular response of chronic phase CML until just before the event. In
the first patient, development of cerebral edema preceded a leptomeningeal localization of blast
crisis for several weeks. After intrathecal chemotherapy and craniospinal irradiation she attained
complete remission. Restarting imatinib did not provoke a relapse of the cerebral edema. The
other patient died of cerebral edema without evidence of leptomeningeal spread of the blast
crisis. 
We chose to treat our patient with liposomal cytarabine and dexamethasone as dasatinib at that
time was unavailable in the Netherlands. He responded very well and was eventually
successfully transplanted with unrelated donor stem cells. The optimal strategy to proceed in
isolated CNS blast crisis is uncertain as comparative trials are not available due to its rarity. In
the 12 cases described in literature most patients were treated with intrathecal chemotherapy
with or without craniospinal irradiation, in four of them followed by allogeneic stem cell
transplantation.8,19 After a short follow-up period, eight of the reported patients remained in
complete remission at the time of writing the manuscripts. Possibly, this rather favorable
outcome is the result of publication bias.
In conclusion, this case shows that isolated CNS blast crisis of CML can develop while patients
are in (near) major molecular response and which cannot be predicted by rising BCR-ABL levels
on quantitative PCR. CML patients with unexplained neurological signs and symptoms should
therefore always be evaluated for isolated CNS blast crisis. Their complaints and/or signs should
not too easily be ascribed to side effects of imatinib. 
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Until only a decade ago, treatment of CML was very unsatisfactory. The only curative treatment
option was allogeneic stem cell transplantation, however, due to donor availability or age
restrictions, only around a third of patients was eligible for this procedure that was associated
with considerable mortality and morbidity. The alternative, interferon alpha with or without
cytosine-arabinoside, was moderately active in only a subset of patients, and was poorly
tolerated by almost all patients. In the majority of patients, acceptable treatment results were
therefore not attained. It is against this background that we started the studies that are
described in this thesis. In view of the large number of patients that were ineligible for allogeneic
stem cell transplantation, we first set out a study that tried to assess the feasibility and efficacy
of autologous stem cell transplants. Although cure of the disease was not what we expected by
performing this procedure, we aimed at slowing progression of this otherwise fatal disease.
Remarkably, we detected less contaminating malignant cells after one induction chemotherapy
cycle than after the second, a finding that is interesting, but cannot easily be explained (Chapter
8). Due to the advent of the very effective tyrosine kinase inhibitor imatinib, treatment results
have improved dramatically since then. Still, a substantial number of patients shows an
unsatisfactory response and even after the introduction of the second generation tyrosine kinase
inhibitors, like dasatinib, nilotinib and bosutinib, blast crisis of CML remains a problem, as is
illustrated by the two case reports that are presented in this thesis (Chapter 10 and 11).
In a preliminary effort to unravel the genetic background of disease progression in CML, we
identified differentially expressed genes during the course of the disease in a large number of
patients by suppression subtractive hybridization (Chapter 2). Several candidate genes that
potentially play a role in development of blast crisis were found. Unfortunately, one of the genes
that was expected to be quite promising in this respect, interleukin-8, seemed to be irrelevant
after closer examination (Chapter 3). Other candidate genes like GAS2 are currently being
investigated, with the hope of finding new therapeutic targets.
In the meantime, new treatment strategies for blast crisis are urgently needed. Demethylating
agents like decitabine and 5-azacytidine have recently become available in clinical practice. We
investigated their potential value in blast crisis CML by performing methylation specific multiplex
ligation dependent amplification in order to assess methylation patterns of tumor suppressor
genes (Chapter 7). Indeed we could demonstrate extensive methylation in blast crisis CD34+
progenitor cells, which makes demethylating treatment a promising therapeutic option that
deserves further clinical and preclinical investigations.
Even better than improving outcome of blast crisis is preventing its development. This can only
be achieved after optimizing chronic phase treatment results. As we show in Chapter 9, the
addition of cytarabine to imatinib seems to have enhanced antileukemic activity over imatinib
alone. The current randomized HOVON-78 study comparing imatinib with imatinib plus two
courses of intermediate dose cytarabine will assess the value of combination therapy in a
prospective way. 
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An important barrier in attaining cure is the inherent resistance of CML stem cells against a
multitude of agents, including tyrosine kinase inhibitors. Moreover, these persistent stem cells
are a potential source of blast crisis initiating cells. Leukemic stem cells make use of several
mechanisms to defy antileukemic agents, as reviewed in Chapter 1. Unfortunately, many of
these mechanisms are shared by normal hematopoietic stem cells, which leaves pharmacologic
manipulation of these mechanisms non-leukemia specific and thereby possibly too toxic.
Immunotherapeutic approaches may be able to specifically kill CML stem cells without addition
of toxicity, most probably in concert with tyrosine kinase inhibitors. In Chapter 4, we
demonstrate that imatinib does not reduce the T-cell stimulating properties of CML derived
dendritic cells, implicating that concomitant tyrosine kinase inhibition and immunotherapy is
indeed possible. However, vaccination strategies have thus far demonstrated only limited clinical
efficacy. Therefore, identification of new leukemia and stem cell specific targets is still needed.
With that aim, we developed a new flow cytometric strategy that enabled us to distinguish
malignant from normal stem cells in chronic phase CML with high fidelity (Chapter 5). Moreover,
we could demonstrate that CD90 is a leukemia specific stem cell marker at diagnosis (Chapter
6), possibly pointing at CD90 as a future leukemia target.
Never before, it has been possible to select malignant and benign stem cells within single
patients in such a reliable and prospective way. Currently, by exploiting this technique, we are
collecting benign and malignant stem cells from newly diagnosed CML patients to perform
comparative assays. In this way, we anticipate to identify new CML stem cell specific therapeutic
targets which will hopefully pave the way to new specific signal transduction inhibitor strategies
or innovative immunologic treatments.
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Dit proefschrift gaat over een bijzondere, zeldzame bloedziekte, chronische myeloide leukemie
(CML) genaamd. In de afgelopen jaren heb ik samen met anderen, naast mijn ‘gewone’ werk als
internist-hematoloog, onderzoek gedaan naar diverse aspecten van deze ziekte. De resultaten
van dit onderzoek worden in dit proefschrift beschreven. Voor mensen die niet medisch of
biologisch zijn opgeleid, zijn de voorgaande hoofdstukken veelal volstrekt onbegrijpelijk en
onleesbaar. Daarom vertel ik in dit hoofdstuk, in het Nederlands, met uitleg van het vakjargon en
daarmee hopelijk beter begrijpelijk, over dit onderzoek, waarom we het hebben gedaan en wat
het heeft opgeleverd. Voordat ik het onderzoek zelf beschrijf, geef ik eerst uitleg over een paar
in het onderzoek veelvoorkomende onderwerpen: het bloed, bloedcellen en het beenmerg,
eiwitten, chromosomen, DNA en het ziektebeeld CML.
BLOED, BLOEDCELLEN EN BEENMERG
Bloed zorgt voor het transport van allerlei stoffen door het lichaam (zoals zuurstof,
voedingsstoffen, afvalstoffen en hormonen) en speelt tevens een belangrijke rol bij de
bescherming tegen indringers van buitenaf (zoals bacteriën, virussen, schimmels en parasieten).
Bloed bestaat voor meer dan de helft uit plasma, een waterige oplossing van zouten en eiwitten,
en voor het overige uit bloedcellen. Er zijn rode bloedcellen, bloedplaatjes en witte bloedcellen.
Het grootste deel van de bloedcellen is rode bloedcel (medische term: erytrocyt). Elke liter bloed
bevat 3000 tot 4000 miljard van deze cellen. Bloed heeft een rode kleur door het eiwit
‘hemoglobine’ in de rode bloedcellen. Via dat hemoglobine vervoeren rode bloedcellen
ingeademde zuurstof van de longen naar de rest van het lichaam. Bij het verbruik van zuurstof
door het lichaam ontstaat de afvalstof koolstofdioxide, die vervolgens onder andere via het
hemoglobine teruggevoerd wordt naar de longen, waarna het uitgeademd wordt. De tweede
groep bloedcellen zijn de bloedplaatjes (trombocyten). Daarvan zitten er in elke liter bloed 150
tot 400 miljard. Zij zorgen er samen met de stollingseiwitten in het plasma voor dat bloed stelpt
en bloedingen zo gestopt worden. Witte bloedcellen (leukocyten) spelen een belangrijke rol bij
de bestrijding van indringers van buitenaf, zoals bacteriën, virussen, schimmels en parasieten.
Elke liter bloed bevat 4 tot 10 miljard witte bloedcellen. 
Bloedcellen gaan slechts een beperkte tijd mee. De meeste witte bloedcellen leven maar één tot
twee dagen, bloedplaatjes leven ongeveer 10 dagen en rode bloedcellen 120 dagen. Er moeten
dus continu nieuwe gemaakt worden. Dat gebeurt in het beenmerg. Beenmerg bevindt zich
vooral in de ruggenwervels en het bekken. Elke seconde van een mensenleven produceren
bloedvormende stamcellen hier door middel van celdeling ongeveer twee miljoen rode
bloedcellen, twee miljoen bloedplaatjes en bijna een miljoen witte bloedcellen. 
EIWITTEN, CHROMOSOMEN EN DNA
Het is heel erg belangrijk dat er precies genoeg cellen worden geproduceerd. Te veel of te weinig
productie leidt namelijk tot ziekteverschijnselen. De deling, groei en uitrijping van cellen is
daarom een nauwkeurig geregeld proces. Eiwitten spelen hierbij een essentiële rol. Eiwitten zijn
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hele grote moleculen, bestaande uit lange ketens van aminozuren, die op een bepaalde manier
in elkaar gevouwen zijn. Het aantal en de volgorde van de aminozuren en hun ruimtelijke
vouwing bepalen de functie van een eiwit. Alle eiwitten worden in cellen gemaakt. Hoe een cel
een eiwit moet bouwen is opgeslagen in de erfelijke informatie. Die informatie is vastgelegd in
een code in het DNA. Een apart stukje DNA, dat de code voor precies één eiwit bevat, wordt een
gen genoemd. Het DNA is gewikkeld om grote ronde eiwitten. DNA en eiwitten samen vormen
de chromosomen. Elke cel van een mens heeft 23 paar (dus 46) chromosomen. De ene helft is
een exacte kopie van de chromosomen in de eicel van de moeder en de andere helft een exacte
kopie van de chromosomen in de zaadcel van de vader. De chromosomen hebben allemaal een
nummer gekregen. Het grootste paar heeft nummer 1, chromosoompaar 22 is het kleinst.
Chromosoompaar 23 bestaat bij de vrouw uit twee X-chromosomen en bij de man uit een 
X-chromosoom en een veel kleiner Y-chromosoom.
DE CELDELING GAAT MIS
Voor elke celdeling moeten de chromosomen eerst verdubbeld worden. Elke nieuw ontstane cel
moet namelijk een complete set erfelijke informatie hebben, anders kan hij niet goed
functioneren. Nadat de chromosomen verdubbeld zijn moeten ze vervolgens precies verdeeld
worden over de twee nieuwe cellen. Hoewel dit proces van verdubbeling en verdeling extreem
nauwgezet verloopt, gaat het wel eens mis. Dat is geen wonder, gezien het duizelingwekkend
hoge aantal celdelingen dat in een mensenleven plaatsvindt. Het kan dan gebeuren dat een cel
teveel of te weinig chromosomen meekrijgt bij de celdeling. Of er ontstaan breuken in de
chromosomen, waardoor een deel van het erfelijke materiaal zal ontbreken. Ook kan het
gebeuren dat er een breuk ontstaat in meerdere chromosomen tegelijk. Cellen kunnen dit soort
breuken vaak weer herstellen, maar het gebeurt wel eens dat stukjes verkeerd aan elkaar geplakt
worden. Meestal zal een cel na een celdeling waarbij afwijkingen in de chromosomen zijn
ontstaan niet levensvatbaar zijn en sterven. Heel soms echter zal de verandering niet tot de dood
van de cel leiden en zal deze kunnen blijven bestaan. De kans is echter groot dat hij, door het
afwijkende erfelijke materiaal, zich vreemd zal gaan gedragen. Een beetje langzamer groeien is
niet erg en een heel klein beetje abnormaal eiwit produceren kan meestal ook geen kwaad.
Vervelender wordt het echter als de cel zich door de verandering sneller dan normaal gaat delen
en vooral als hij zich niets aantrekt van groeiremmende signalen. De basis voor het ontstaan van
kanker is dan namelijk gelegd! 
LEUKEMIE
Gelukkig kan ons immuunsysteem afwijkende cellen vaak herkennen en opruimen. Soms gaat
dat echter niet goed: de cel gedraagt zich wel vreemd, maar wordt niet als vreemd herkend en
dus niet opgeruimd. Of de cel heeft een slim trucje waarmee hij die immuuncellen om de tuin
leidt. Als een dergelijke cel zich onbeperkt gaat vermeerderen en normale cellen gaat
overwoekeren spreken we van een kwaadaardige aandoening. Leukemie, in de volksmond ook
wel beenmerg- of bloedkanker genoemd, is de verzamelnaam voor verschillende vormen van
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kanker van witte bloedcellen. Er bestaan acute vormen van leukemie, waarbij de kwaadaardige
cellen in het geheel niet meer uitrijpen en chronische vormen, waarbij de cellen dat nog wel
kunnen. Die acute vormen zijn direct levensbedreigend omdat door de woekering van de onrijpe
cellen er geen normale cellen meer gevormd kunnen worden en er dus een tekort aan uitgerijpte
rode en witte bloedcellen en bloedplaatjes ontstaat. Daarnaast gaan de onrijpe cellen vanuit het
beenmerg vaak naar het bloed. Als het er zeer veel worden kan het bloed hierdoor stroperig
worden waardoor de doorbloeding van organen, zoals hersenen, nieren en darmen, verstoord
kan raken. Dit laatste kan ook optreden bij de chronische vormen van leukemie, maar daarbij is
er nog wel uitrijping mogelijk van de kwaadaardige cellen, waardoor bloedarmoede (te weinig
hemoglobine), infecties en bloedingen minder of niet voorkomen. Als er zich zeer veel rijpe of
onrijpe witte bloedcellen in het bloed bevinden, dan kan bloed dat onstolbaar is gemaakt en dat
een tijdje is blijven staan een wittige waas krijgen. Hier komt de naam leukemie vandaan. Dat
betekent namelijk wit bloed. Acute en chronische leukemieën worden nog onderscheiden in
myeloide en lymfatische vormen. Dit onderscheid zit hem in de plaats waar de woekerende
cellen eigenlijk hadden moeten uitrijpen. Bij de lymfatische vormen zou dat in de lymfeklieren
moeten zijn, bij de myeloide vormen in het beenmerg (myelum betekent merg). 
CHRONISCHE MYELOIDE LEUKEMIE (CML)
Deze uitgebreide inleiding was nodig om iets meer te begrijpen van wat ik hierna vertel over
CML. Deze ziekte wordt namelijk veroorzaakt door een chromosoomafwijking, die is ontstaan
door een foute celdeling. In 1960 is dat ontdekt door Amerikaanse onderzoekers in Philadelphia,
Peter Nowell en David Hungerford. Zij vonden in de bloed en beenmergcellen van mensen met
deze aandoening dat één van de chromosomen 22 abnormaal klein was. Dat chromosoom
wordt sindsdien het Philadelphia-chromosoom genoemd. Pas 13 jaar later werd ontdekt dat dit
abnormale chromosoom 22 het resultaat was van een verwisseling van een vrij groot stuk van
chromosoom 22 met een relatief klein stukje van chromosoom 9. Deze oneerlijke ruil leidt ertoe
dat een groot deel van het ABL-gen dat normaliter op chromosoom 9 ligt, vastgeplakt is aan
chromosoom 22, precies op een plek waar het BCR-gen zit. Het BCR-gen en het ABL-gen zijn
daardoor aan elkaar vast komen te zitten. Het bijzondere is nu, dat door deze koppeling van
genen een nieuw, in normale cellen niet bestaand, eiwit wordt gevormd, dat BCR-ABL wordt
genoemd. Dit is een overactief eiwit dat in staat is zeer veel andere eiwitten in de cel te activeren.
De cel gaat hierdoor abnormaal gedrag vertonen: verhoogde delingssnelheid, verminderde
gevoeligheid voor groeiremmende signalen en langere levensduur dan normale cellen.
Bovendien blijven de cellen onvoldoende plakken in het beenmerg en gaan dan, terwijl ze nog
heel onrijp zijn, te vroeg naar het bloed.
Zoals gezegd is de ziekte zeldzaam. In Nederland zijn er ongeveer 100-150 nieuwe gevallen per
jaar. Veel patiënten hebben geen klachten ten tijde van het stellen van de diagnose. De ziekte
wordt dan bij toeval ontdekt, bijvoorbeeld door abnormale bloedwaarden bij een keuring. Als er
wel klachten zijn, dan is het meestal vermoeidheid, gebrek aan eetlust, een vol gevoel in de buik,
afvallen, heftig transpireren (vooral ’s nachts) en soms aanvallen van jicht (een heftige ontsteking
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aan de gewrichten). Anders dan patiënten met acute leukemie zijn deze mensen niet abnormaal
bevattelijk voor infecties en hebben ze ook geen bloedingen. Bij het onderzoek van de buik
wordt meestal een grote milt gevoeld. Het beenmerg en het bloed van CML patiënten bevat een
enorme hoeveelheid witte bloedcellen, soms wel honderd keer zoveel als normaal. Het zijn 
cellen in allerlei rijpingsstadia, van heel onrijpe tot aan volledig uitgerijpte. Al deze cellen hebben
het Philadelphia-chromosoom. 
BEHANDELING VAN CML
Als er niets aan de hiervoor beschreven situatie gedaan zou worden, dan zou de patiënt
uiteindelijk overlijden aan een steeds verder oplopend aantal witte bloedcellen, waardoor het
bloed te dik wordt. Echter, met behulp van simpele, milde chemotherapie, die als capsules kan
worden ingenomen, kunnen de klachten, de vergrote milt en de bloedafwijkingen geheel
verdwijnen. Eigenlijk is er dan niets bijzonders meer te vinden aan de patiënt of het bloed. Het
probleem is echter dat de cellen die het Philadelphia-chromosoom bevatten, niet weggaan. Na
een paar jaar verandert de ziekte dan, meestal geleidelijk, maar soms heel acuut: onrijpe cellen
(blasten) verschijnen in beenmerg en bloed en verdringen de uitgerijpte cellen. De ziekte lijkt dan
precies op een acute leukemie. Er ontstaat dan ernstige bloedarmoede en een grote kans op
dodelijke infecties en levensbedreigende bloedingen. Zo’n situatie wordt een blastencrisis
genoemd. Deze fase van de ziekte is heel moeilijk te behandelen en vaak overlijden patiënten
binnen enkele maanden.
Die milde chemotherapie is dus geen goede optie. Tot ongeveer tien jaar geleden werd daarom
bij voorkeur een zware behandeling gegeven waarbij patiënten eerst werden behandeld met
chemotherapie en bestraling van het gehele lichaam. Daarmee werden alle cellen van het
beenmerg gedood. Hierna werden dan stamcellen van een gezonde donor (een broer of zus, of
een onverwant iemand; gewonnen uit het beenmerg of uit het bloed) in de bloedbaan van de
patiënt ingespoten. Na enige weken herstelde het beenmerg dan weer met de nieuwe
stamcellen en met enig geluk kwam de ziekte daarna niet meer terug. Zo’n behandeling (met
stamcellen van iemand anders) heet een allogene stamceltransplantatie. Er kleefden hier
verschillende nadelen aan. Zo had een deel van de patiënten geen geschikte donor en was de
behandeling voor mensen die ouder waren dan 50-55 jaar te zwaar. Uiteindelijk kwam daardoor
slechts ongeveer een derde van de CML patiënten in aanmerking voor het ondergaan van een
transplantatie. Maar zelfs bij jonge patiënten was de kans op fatale complicaties groot.
Later bleek dat sommige mensen goed reageerden op injecties met het lichaamseigen eiwit
interferon. In een klein deel (ongeveer 20%) van de patiënten bleek hiermee het aantal
Philadelphia-chromosoom bevattende cellen te verminderen. Bij die mensen was de kans op
een blastencrisis veel kleiner. Het middel werd echter zeer slecht verdragen en tenminste een
kwart van de patiënten moest er daardoor zelfs mee stoppen.
Tegen deze achtergrond startten wij ongeveer tien jaar geleden met onderzoek bij mensen die
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geen donor hadden. In plaats van donorstamcellen wilden wij uitzoeken of het mogelijk was om
stamcellen van de patiënt zelf te gebruiken voor stamceltransplantatie. Dat heet dan een
autologe stamceltransplantatie. Bij diverse andere hematologische aandoeningen is dit een
zinvolle behandeling. 
ONDERZOEK EN RESULTATEN
In hoofdstuk 8 is ons onderzoek naar het effect van autologe stamceltransplantatie beschreven.
In dat onderzoek behandelden wij 19 patiënten met recent geconstateerde CML met twee
intensieve chemotherapiekuren die lijken op datgene wat we bij acute leukemie geven. Na elke
chemokuur namen we beenmerg af, verzamelden stamcellen uit het bloed en controleerden of
daarin nog kwaadaardige cellen waren overgebleven. We hadden verwacht dat het beenmerg en
de afgenomen stamcellen schoner zouden zijn na de tweede kuur, maar tot onze verbazing
bleek dat na de eerste kuur er minder leukemiecellen overbleven dan na de tweede kuur. We
kunnen dat eigenlijk niet goed verklaren. Van de 19 patiënten konden we bij negen redelijk
schone stamcellen verkrijgen zodat we die konden gebruiken voor een erop volgende
stamceltransplantatie. Toch was het eindresultaat heel matig: de meeste patiënten die een
transplantatie kregen, hadden na verloop van tijd weer heel veel kwaadaardige cellen in hun
beenmerg. Ook andere onderzoeken in het buitenland leverden matige resultaten op. Erg
enthousiast waren we dus niet over de autologe stamceltransplantatie voor CML. 
Tegen de tijd dat we bovenstaande resultaten publiceerden, kwam er een nieuw revolutionair
middel, imatinib genaamd, beschikbaar voor de behandeling van CML. Imatinib is een remmer
van het abnormale BCR-ABL eiwit. Het bleek, eerst in laboratoriumexperimenten, maar later ook
in grote onderzoeken bij patiënten, dat de cellen met het Philadelphia-chromosoom hierdoor
dood gingen. Bij een groot deel van de mensen die het middel gebruikten, was er, soms al na
enkele maanden nog slechts een spoor van de ziekte over. Daarbij bleek dat er ook geen
blastencrisis meer optrad. Het mooie was bovendien dat het middel heel weinig bijwerkingen
had. Maar helaas werden niet bij alle patiënten zulke mooie resultaten behaald. En in sommige
gevallen werd de diagnose gesteld op het moment dat er al een blastencrisis bestond. In die
situatie werkt imatinib lang niet zo goed. Nog steeds sterven daardoor mensen aan deze ziekte.
De overige hoofdstukken in dit proefschrift beschrijven onderzoeken die uiteindelijk ten doel
hebben de behandelresultaten voor patiënten met CML verder te verbeteren. 
BASAAL ONDERZOEK BESCHREVEN IN HOOFDSTUK 2 T/M 7
Het eerste deel van het proefschrift gaat over de meer basale onderzoeken die we hebben
gedaan met beenmerg en bloed van patiënten met CML. Het doel van het onderzoek dat
beschreven is in hoofdstuk 2 was het identificeren van genetische veranderingen tijdens het
beloop van CML. Ten eerste streefden we daarmee meer inzicht na in het waarom van het
ontstaan van de blastencrisis en ten tweede hoopten we zo een mogelijk aangrijpingspunt voor
therapie te vinden. We gebruikten daarvoor in eerste instantie cellen van een enkele patiënt, nog
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uit het tijdperk van voordat imatinib beschikbaar was, die we hadden afgenomen bij diagnose,
na enkele jaren behandeling en tijdens het bestaan van de blastencrisis. Met behulp van een vrij
ingewikkelde techniek, die suppressie subtractie hybridisatie heet, konden we vaststellen dat
meer dan 25 genen verschillend actief waren in de opeenvolgende fases van de ziekte. Daarna
controleerden we bij een groot aantal andere patiënten of er een gemeenschappelijk patroon
herkenbaar was. Inderdaad konden we dat voor acht van die genen aantonen. Verschillende
hiervan zijn potentieel betrokken in de overgang naar de acute fase. Daarna hebben we veel tijd
gestoken in het onderzoek van één daarvan, interleukine-8, echter, in hoofdstuk 3 beschrijven
we dat juist dat gen waarschijnlijk toch irrelevant is voor het de overgang naar de blastencrisis.
Intussen zijn we nog steeds bezig met het onderzoek naar een ander interessant gen, GAS2
genaamd, maar dat onderzoek is nog niet klaar. 
Ook met de komst van imatinib blijft CML nog voor problemen zorgen. Zelfs bij de mensen die
heel goed reageren op het middel verdwijnt de ziekte niet volledig en wanneer zij zouden
stoppen met de behandeling keert de ziekte snel weer terug. Daarom moet imatinib
waarschijnlijk levenslang voortgezet worden. Helaas is het een kostbaar middel en natuurlijk
heeft een genezende behandeling de voorkeur wanneer de bijwerkingen daarvan tenminste mild
zijn. Daarom wordt ook in ons laboratorium gezocht naar mogelijkheden om de huidige
behandeling verder te verbeteren met aanvullende maatregelen. Zo kan immuuntherapie, 
waarbij we afweercellen uit het lichaam van de patiënt proberen op te zetten tegen de resterende
kwaadaardige cellen, mogelijk van waarde zijn. Centraal in het opwekken van een afweerreactie
staan zogenaamde dendritische cellen. Zij kunnen bepaalde soorten witte bloedcellen activeren,
uiteindelijk leidend tot een immuunreactie tegen indringers, maar potentieel ook tegen
kwaadaardige cellen. Wij onderzochten of dendritische cellen tijdens het gebruik van imatinib
nog wel in staat zouden zijn om hun activerende werk te doen. Inderdaad bleek dat in ons
laboratorium zo te zijn. Dit onderzoek is beschreven in hoofdstuk 4.
Zoals boven vermeld, verdwijnt CML onder invloed van imatinib meestal niet. Met gevoelige
technieken kunnen we nog steeds het DNA van het Philadelphia-chromosoom opsporen.
Waarom blijven die restjes van de ziekte aanwezig, terwijl de overgrote meerderheid van de
kwaadaardige cellen verdwijnt? Dat probleem zit hem in de stamcellen. Die blijken resistent te
zijn tegen imatinib en zelfs tegen de opvolgers van imatinib, die nog sterker werken. Hoewel een
aantal redenen voor die resistentie wel bekend is, heeft dat nog niet geleid tot een behandeling
die de zieke stamcellen aanpakt. Om nieuwe stamcelgerichte therapieën te kunnen ontwikkelen
moeten we hun eigenschappen beter leren kennen. In het kader daarvan hebben we in het
laboratorium een techniek ontwikkeld, beschreven in hoofdstuk 5, die het mogelijk maakt bij
nieuw ontdekte CML patiënten specifiek de kwaadaardige stamcellen te isoleren uit het
beenmerg en bloed. Het blijkt dat er ook een wisselende hoeveelheid normale stamcellen
aanwezig is en die kunnen we er ook uithalen. Zo kunnen we uit een en dezelfde patiënt de
normale en leukemie stamcellen apart in handen krijgen. We verwachten daarmee in staat te zijn
leukemie-stamcel-specifieke kenmerken op en in deze cellen te identificeren. Hopelijk zal dat
leiden tot de ontwikkeling van nieuwe geneesmiddelen die selectief gericht kunnen worden
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tegen de kwaadaardige stamcellen. Overigens bleek bij ons onderzoek al dat in veel gevallen
enkele kenmerken specifiek voorkwamen op de buitenzijde van de kwaadaardige stamcellen,
namelijk de eiwitten CD7, CD11b en CD56. Deze eiwitten komen normaal alleen voor op
uitrijpende witte bloedcellen. 
In hoofdstuk 6 beschrijven we in vervolg daarop, dat CD90 ook specifiek voorkomt op veel
kwaadaardige stamcellen. Op de resterende normale stamcellen werd dit niet aangetroffen.
CD90 kan daarmee gebruikt worden om kwaadaardige stamcellen te identificeren en misschien
wordt het in de toekomst mogelijk om CD90-gerichte therapie toe te passen. Het probleem bij
zowel CD7, CD11b, CD56 als CD90 is wel dat deze eiwitten deels ook op rijpere cellen
voorkomen en dat therapie die cellen met dit eiwit aanpakt zou kunnen leiden tot een sterke
daling van de bloedwaarden van deze cellen. Verder onderzoek op dit terrein is zeker nodig.
Hoewel dit onderzoek ons hoopvol over de toekomst doet zijn, hebben we nú effectievere
therapie nodig voor patiënten die in blastencrisis terecht gekomen zijn. Imatinib en de opvolgers
daarvan zijn namelijk slechts in een deel van de gevallen effectief en dan nog vaak kortdurend.
Recent is er een nieuwe klasse medicijnen, die van de demethylerende middelen, beschikbaar
gekomen. Deze middelen werken mogelijk doordat zij tumorsuppressorgenen kunnen activeren.
Dit zijn genen die normaliter abnormale celgroei tegenhouden of ervoor zorgen dat cellen met
beschadigd DNA dood gaan. Wanneer zij niet functioneren kunnen cellen dus abnormaal gaan
delen of, terwijl hun DNA beschadigd is, blijven leven. Zulke cellen zijn in potentie kankercellen
(zie boven). Het blijkt dat in veel kankersoorten tumorsuppressorgenen niet actief zijn. Voor een
deel wordt dit veroorzaakt door abnormale methylering van het DNA. Daardoor kan het DNA niet
goed vertaald worden in eiwit. Demethylerende middelen kunnen deze abnormale methylering
verminderen en daarmee de tumorsuppressorgenen weer aan zetten. Er was tot nu toe beperkte
informatie beschikbaar over de methylering van tumorsuppressorgenen bij CML die in
blastencrisis was veranderd. In hoofdstuk 7 tonen wij aan dat dat heel vaak het geval is. Bij veel
patiënten zijn er meerdere tumorsuppressorgenen tegelijkertijd gemethyleerd. Dat opent
mogelijkheden om de demethylerende middelen effectief in te zetten bij patiënten met een
blastencrisis. Het verdient aanbeveling dat hiernaar verder onderzoek verricht wordt.
KLINISCH ONDERZOEK BESCHREVEN IN HOOFDSTUK 8 T/M 11
In het tweede deel van het proefschrift zijn de klinische onderzoeken beschreven. Daarvan is
hoofdstuk 8 al eerder samengevat. In het onderzoek dat gerapporteerd is in hoofdstuk 9 
hebben we in een vruchtbaar samenwerkingsverband tussen Nederlandse en Belgische
ziekenhuizen meer dan 160 patiënten behandeld met een combinatie van imatinib en cytarabine,
een middel dat we normaliter vaak bij de behandeling van acute myeloide leukemie gebruiken.
Wij testten van beide middelen verschillende doses om te zien hoe patiënten dit verdroegen en
of hiermee de behandelresultaten zoals die behaald worden met alleen imatinib, verbeterd
konden worden. De combinatie bleek in het algemeen goed te verdragen en inderdaad zagen
wij een heel goede effectiviteit, waarbij na verloop van tijd bij meer dan de helft van de 
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patiënten in het geheel geen zieke cellen meer aantoonbaar waren. Vergeleken met andere
onderzoeken waarin alleen imatinib werd gebruikt suggereert dit onderzoek dat de
combinatiebehandeling beter is. Formeel bewijs hiervoor kan echter alleen geleverd worden
door het uitvoeren van een rechtstreeks vergelijkend onderzoek waarbij patiënten loten voor
ofwel de behandeling met imatinib alleen dan wel de combinatiebehandeling. Dat onderzoek is
nu bezig en zal nog enige jaren doorlopen.
In hoofdstuk 10 en 11 tenslotte worden twee bijzondere patiënten besproken. Beiden kregen
ondanks schijnbaar effectieve behandeling met imatinib plotseling een blastencrisis. Bij de
eerste patiënt bleek sprake te zijn van een BCR-ABL gen dat anders was dan hetgeen we
normaal aantreffen bij mensen met CML, doordat er een stuk van een ander gen, KREMEN-1
genaamd, precies tussen het BCR en het ABL gedeelte in zat. Een dergelijke bevinding is nog
nooit eerder beschreven en onduidelijk is hoe dat precies veroorzaakt is. Ook weten we niet of
het te maken heeft met het onverwachte beloop van de ziekte, maar daarvoor dragen we
verschillende hypotheses aan. Bij de tweede patiënt ontstond er een blastencrisis die alleen in
het hersenvocht aanwezig was. Ook dat is extreem zeldzaam, zeker bij mensen die goed op
imatinib reageren. Vermoedelijk heeft het deels te maken met het feit dat imatinib slecht
doordringt in het hersenvocht. Gelukkig konden we beide patiënten goed behandelen en lijken
zij genezen. Maar beide gevallen tonen eens te meer aan dat CML een potentieel gevaarlijke
ziekte blijft, zelfs in onze tijd waarin we de beschikking hebben over zeer effectieve en gerichte
therapie als imatinib en soortgelijke middelen. Verder onderzoek blijft daarom dringend nodig.
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Het boek is af! Er zijn veel momenten geweest waarop ik dacht dat het nooit meer zou lukken.
Dat het proefschrift er nu toch ligt is te danken aan de hulp van een groot aantal mensen die ik
hier heel graag wil bedanken, één van de dingen waar ik het meest naar uit heb gekeken.
Als eerste mijn promotor, Prof. Dr. G.J. Ossenkoppele. Gert, wij ontmoetten elkaar voor het eerst
tijdens mijn coschap interne geneeskunde. Ik als nieuwe co op afdeling 4 oost. Dat was een
bijzondere ervaring, die ik nooit zal vergeten. Jaren later kwam ik weer terug als arts-assistent
op onze afdeling, op dat moment nog met de gedachte dat ik alles wilde worden, behalve
hematoloog! Dat het toch zo gelopen is, is voor een groot deel te danken aan jou. In een tijd dat
ik nog nooit gehoord had van BCR-ABL, enthousiasmeerde jij me voor het CML onderzoek.
Maar belangrijker misschien nog was dat ik niet eerder in mijn opleiding iemand tegen was
gekomen die zo een voorbeeld voor me was. Ik wilde precies zo’n dokter als jij worden, en
eigenlijk is dat altijd zo gebleven. Jouw scherpe klinische blik, jouw grandioze kennis over de
gehele breedte van ons vak inclusief de morfologie en je enorme leesvermogen, daar kan ik
alleen maar met volle bewondering naar kijken. Je niet aflatende stroom aan ideeën en je
overtuiging dat het me uiteindelijk toch zou lukken om dit proefschrift te schrijven, hebben me
op de been gehouden op de momenten dat ik wat minder optimistisch was. Ik hoop dat we nog
heel lang mooie dingen samen kunnen doen, ik zal er keihard aan blijven werken.
Mijn co-promotor, Dr. G.J. Schuurhuis. Gerrit-Jan, GJ, het heeft vrij lang geduurd voordat ik
merkte dat je het CML onderzoek echt leuk vond. Vooral de laatste jaren is dat gelukkig heel
duidelijk gekomen. Toen ik dacht hoe moet ik nu verder had je nieuwe ideeën die er mede toe
hebben geleid dat dit proefschrift er toch is gekomen. Regelmatig maakte je me een beetje
moedeloos als ik je correcties op mijn stukken terug kreeg en er niet heel veel meer van de
oorspronkelijke tekst over was, maar dat zorgde er wel voor dat het steeds beter werd. Mede
door jou heb ik het stamcelonderzoek in mijn hart gesloten.
Prof. Dr. G.E.G. Verhoef, Prof. Dr. J.J. Cornelissen, Prof. Dr. J.C. Kluin-Nelemans, Dr. A.V.M.B.
Schattenberg en Dr. J.H. Jansen wil ik hartelijk bedanken voor de aandacht die zij als lid van de
promotiecommissie hebben besteed aan mijn proefschrift. Jan, jou dank ik speciaal voor de
voortreffelijke samenwerking in de afgelopen jaren. Ik zie uit naar een succesvolle voortzetting
ervan. 
Prof. Dr. P.C. Huijgens, Peter, ook jou dank ik voor je rol als lid van de promotiecommissie. Nog
veel meer bedank ik je voor je vertrouwen in mij. Ondanks dat alles zo ontzettend lang duurde,
deed je daar nooit moeilijk over. Je zorgde ervoor dat ik extra analytische ondersteuning kreeg
toen dat nodig was. En je stelde me herhaaldelijk gerust als ik me zorgen maakte over hoe het
nu verder moest. Je bent een uniek mens die in staat en bereid is anderen te laten groeien en
bloeien, daarbij jezelf wegcijferend. Een fantastische dokter, topmanager, en altijd even scherp
waar het de wetenschappelijke kant van ons vak betreft. Dat is een zeldzame combinatie. Onze
mooie afdeling vaart er wel bij.
Mijn paranimfen.
Sonja, lieve vriendin, zoals jij is er geen één! Extreem en multipel begaafd op vrijwel elk gebied.
Een buitengewoon goede hematoloog over de volle breedte van ons vak. Ik geniet van de fijne
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gesprekken waarin we praten over alles wat ons bezighoudt en zó veel delen. Wat ben ik 
vereerd dat je naast me staat op deze dag! 
Gerard, mijn goede vriend met een formidabel wetenschappelijk talent. Als ik met je sprak over
het onderzoek gaf dat me altijd weer nieuwe ideeën en nieuwe energie om verder te gaan. Zo
hebben we een deel van het onderzoek in dit proefschrift op jouw afdeling kunnen uitvoeren.
Geweldig dat je aan mijn zijde staat! Wanneer gaan we weer eens samen skiën?
‘Mijn’ analisten. Peter Theijsmeijer, al weer lang weg uit het lab, wijdde mij in in het hematologie
laboratorium en had de zware taak een dokter labwerk te leren. Marjolein Klaver, in al die jaren
niet één dag slechte zin en met grote zorgvuldigheid onze vele experimenten uitvoerend. Heel
erg jammer dat het laboratoriumwerk je lichamelijk te zwaar werd. Een groot gemis voor het CML
onderzoek en onze afdeling! Karlijn Smolders, mijn grote kleine plaaggeest, maar bovenal een
voortreffelijk analist. Je kwam op precies het juiste moment. Deze dag dank ik ook voor een flink
deel aan jou! Fantastisch dat 2010 voor jou en Ronald een heel bijzonder jaar zal worden. Walter
Pouwels, sinds kort ben je het CML-team komen versterken, maar ik ben al erg onder de indruk
van je vakmanschap. Bo van Kuijk, heel erg vers, het wordt nu echt een groep! 
Guus Westra, als ik in de avond eindelijk eens aan zo’n enorm ingewikkelde FACS machine zat,
wist ik regelmatig niet meer op welke knopjes ik moest drukken. Gelukkig kon ik je dan thuis
bellen en kwamen we er zo wel uit. Ik dank je ook voor al je hulp bij het sorten. Dat geldt ook
voor Sander Snel. Altijd goedgemutst, zeker als AZ weer gewonnen had (wat gelukkig vaak zo
was!). Je hulp was onmisbaar, zeker bij de voor mij ondoorgrondelijke Aria.
Fedor Denkers, jouw methyleringswerk heeft geresulteerd in een mooi artikel in dit proefschrift.
Je nauwgezetheid, kennis en kunde op veel terreinen doen veel goeds op onze afdeling. Pauline
Merle, altijd hard aan het werk voor de diagnostiek, maar nooit te beroerd me te helpen met het
uitzoeken van researchmonsters en een grote steun bij het onderwijs.
Marisa Westers, wat een accuratesse, wat een vakvrouw! Wat moest onze afdeling zonder jou?
Ik ben je heel erg dankbaar.
Quinten Waisfisz, dank voor je goede opmerkingen en hulp bij de verschillende stukken. Je hebt
me veel geleerd over de moleculaire biologie.
Wendy Deenik, onze samenwerking was fijn en vruchtbaar. Eerst bij ons, later in Rotterdam en
nu sinds kort ook in het Gooi. Ik ben heel blij dat ook jij bijna zo ver bent. Heel veel succes op
je nieuwe plek! 
Peter Valk, bedankt voor belangrijk researchmateriaal en je kritische blik.
Angelika Dräger, jouw steun heeft me heel erg goed gedaan. Extra hulp in het laboratorium kon
ik heel goed gebruiken en jij regelde het zo dat dat kon. Ik bewonder je werklust en je inzicht in
dingen waar ik helemaal niets van snap.
Monique Terwijn, jouw research raakt heel dicht aan de mijne. Dank voor je hulp en adviezen. Ik
hoop dat we gauw samen verder kunnen gaan met de in-vivo experimenten.
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Angele Kelder, door jouw oplettendheid legde je de basis voor de stamcelidentificatie. Dat dat
ook bij CML van toepassing was, kwam mij heel erg goed uit. 
Floortje Kessler en Willemijn Scholten, ik weet dat het niet makkelijk was mij al die jaren te
verdragen, dank dat jullie het toch volgehouden hebben.
Lot de Witte, Michael de Korte, Wouter Overbeek, Floor de Lijster, Mirjam Nauta en Helen Tanger
hebben als toenmalige stagiair(e)s veel goed werk verricht. Lot, erfelijk belast met een
hematologie-gen ben jij wetenschappelijk ver boven mij uitgestegen. Ik hoop je gauw weer te
zien.
Mijn fantastische collega-hematologen: Arjan, jouw enthousiasme laat AIO’s en anderen bloeien.
Van jouw wetenschappelijke vernuft en inzicht profiteren wij allen. Martine, lieve kamergenote,
hoe goed jij je staand houdt in alle drukte vind ik verbluffend. Het antwoord op jouw vraag is niet
eenvoudig, maar wel belangrijk. Daar praten we nog over. Dank voor je steun en praktische
adviezen, vooral zo op het eind. Josee, volop bezig met belangrijke lymfoomstudies. Zo
betrokken bij je patiënten en anderen. Otto, mijn maatje in de transplantatie-organisatie. Heel
verschillende invalshoeken, maar elkaar mooi aanvullend. We gaan het in de nabije toekomst
nog veel mooier maken! Mariëlle, altijd hard aan het werk en grappig. Nooit te beroerd om een
poli van me over te nemen omdat er weer iets af moest. Ik gun je van harte succes met jouw
onderzoek en help je graag. Djamila, je ontwikkelt je goed tot een volwaardig hematoloog.
Zonder problemen nam je poli’s van me over of bewaakte je de 248. Fijn dat je nog een tijd bij
ons blijft. Josien, dat geldt ook voor jou! Noortje, al bijna klaar en steeds beter. Een aanwinst
voor het CML team!
Jacqueline Cloos en Linda Smit, dank voor jullie kritische opmerkingen en nieuwe ideeën. Ik
verheug me op onze verdere samenwerking.
Shama Bhola, Aggie Nieuwint, Yvonne Heins, Hans Wessels en analisten van het
chromosomenlab, jullie gastvrijheid, behulpzaamheid en interesse in mijn onderzoek heb ik heel
erg gewaardeerd. 
Dominique de Kleijn, moleculair bioloog in Utrecht, samen met Gerard heb je ervoor gezorgd dat
het subtractie experiment tot een goed einde is gekomen. Heel erg veel dank voor je hulp.
Onze poliassistentes Irma Stoffels, Ria de Kruif, Lizelotte Verkerk, Karin van Kessel, Geerte Punt,
Ryonda Stoutenburg en Pia Frieling zochten met grote snelheid en met altijd goede zin 
statussen voor me op om klinische gegevens uit te halen. Jullie zijn een supergoed stel!
De analisten van het routine hematologielab, de bloedbank en het hemostaselab bedank ik voor
de interesse in mijn vorderingen en de vriendschappelijke sfeer die maakt dat het leuk is op het
lab.
Onze voortreffelijke mensen van het trialbureau, Cinthy van Roessel, Maaike Leijdekker, Marjan
Leisink, Ines Versteegden, Tanja Roosma en Joke van Wegen (en sinds kort ook Saida Absalah)
en onze fantastische researchverpleegkundigen Yvonne den Hartog, Astrid Vervoort en Corinne
Tillier, jullie steun en interesse in mijn onderzoek deden me goed! Door jullie voortgaande
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inspanningen om klinische studies succesvol uit te voeren, leggen jullie een essentiële basis
voor het preklinische onderzoek van mij en dat van anderen.
Onze secretaresses Maartje Ens, Annette Brederoo en Marjan Jalink, dank voor jullie 
secretariële ondersteuning en interesse. 
De verpleegkundigen op de afdeling en de dagbehandelingsunit en onze transplantatie-
coordinatoren, Ans Nijntjes, Marieke Schoordijk, Trudy Bollen en Susan van den Brink ben ik
dank verschuldigd voor hun geduld als ik weer eens te laat was omdat ik op het lab iets moest
doen en vooral ook om hun begrip dat ik de laatste tijd minder tijd dan nodig was heb kunnen
steken in het updaten van protocollen en dergelijke. Onze hoofdverpleegkundigen Ingrid
Kampman en Ineke van der Jagt, ook jullie heel erg bedankt voor jullie steun!
Jan van der Meer, mijn opleider in het VU ziekenhuis, jij maakte dat ik internist wilde worden, al
vanaf de eerste klinische demonstratie die ik in 1983 bijwoonde. Ik ben heel blij en vereerd dat
ik onder jouw hoede de opleiding heb mogen doen.
Ernst Nauta, mijn opleider in het Andreas Ziekenhuis, dank ik voor zijn wijze lessen in de eerste,
cruciale fase van mijn opleiding tot internist. De kennis over infectieziekten die ik van jou heb
geleerd komt mij nog dagelijks goed van pas. Ook Hans Beukhof, Ed Monasch, Eldert van der
Zwaan, Dick Buitelaar, Paul Albert, Pascal Sahoury, Eric Wesdorp, Wilco Lesterhuis, Annekatrien
Depla, Teun Deves, Michel van Hengstum, Auke Hillebrand en Aart Vermeulen hebben een
onuitwisbare indruk gemaakt en een solide basis voor mijn opleiding gelegd. De tijd in het
Andreas Ziekenhuis zal ik mede door jullie nooit vergeten.
Mijn collega’s uit andere ziekenhuizen, Gertjan Timmers, Cees Schaar, Stanley Madretsma, Aart
van Dobbenburgh, Geesje Semplonius, Klaas van der Hem, Hein Visser, Danielle van Lammeren,
Tanja van Maanen, Aart van Bochove en Johan Berends dank ik voor het verwijzen van CML
patiënten voor mijn onderzoek of het toezenden van researchmateriaal. Daarnaast bedank ik alle
collega’s die al of niet binnen HOVON verband hebben bijgedragen aan de klinische studies die
in dit proefschrift staan beschreven.
Veel dank ben ik natuurlijk ook verschuldigd aan alle patiënten die hun bloed en beenmerg ter
beschikking stelden voor het onderzoek.
Lieve Karin en Loe, veel dank voor alle steun en de gezelligheid als we samen zijn. Loe, je hebt
samen met Bart een prachtig ontwerp gemaakt. Fantastisch dat je dat hebt willen doen!
Mariecke, Nico, Olga, Rob, Annelous, Eric, Sanne, Michael. Lieve vrienden, superleuke mensen!
Jullie maken dat ik me geweldig thuis voel in Hilversum. Wat kan ik enorm genieten van onze
heerlijke avonden samen! Eric, ik hoop dat we samen ook op professioneel gebied binnenkort
leuke dingen kunnen gaan doen.
Sabine, Arjen, Astrid, Marcel, Lisette, Ronald, Ed, Marianne, Wabe, Elly, Hanneke, Lex, Renee,
Agnes, Robbert-Marc, Suzan, Vincent, Marjan, Margriet, David, Anne, Dirk Jan, Stan, Danielle,
Grant, Pauline. Lieve familie en vrienden, jullie geven het leven extra kleur! Ed, ook heel erg
bedankt voor de mooie lay-out van het boekje.
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Nathalie, mijn lieve zus, zo compleet anders dan ik. Je verwent ons en de kinderen altijd enorm.
Dank voor je steun en gewoon voor dat je er bent. Ik ben zo blij dat jij en Folkert elkaar 
gevonden hebben. Folkert, meevliegen in de cockpit hou ik graag tegoed! 
Lieve papa en mama, niets is jullie teveel als we weer eens hulp of oppas kunnen gebruiken!
Jullie gaven me een liefdevolle opvoeding en onvoorwaardelijke steun bij alles wat ik deed.
Dankzij jullie had ik een onbezorgde studietijd. Volhouden en zo goed mogelijk mijn best doen
leerden jullie me van jongs af aan. Het was onmisbaar bij het afmaken van dit proefschrift. 
Lieve Annelot, Pepijn, Carolien en Ole. Prachtige schatten! Wat maken jullie me altijd blij! Jullie
zijn het mooiste en het liefste dat ik heb. 
Liefste Marieke, vanzelfsprekend eindigt dit dankwoord met jou. Je hebt wel eens gezegd dat
als het proefschrift er kwam, dat meer ondanks dan dankzij jou zou zijn. Niets is minder waar.
Jouw keuze in het leven maakt het me gemakkelijk langer te blijven doorwerken als
experimenten of klinische werkzaamheden daar om vragen. Dat ik weet dat jij er voor me bent
maakt minder goede dagen draaglijk. Je nuchterheid doet me de relativiteit van alles beter
inzien. We delen de mooiste dingen in het leven. Ik hou zo veel van je. Je bent het allerbeste wat
me ooit is overkomen.
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